U.S. patent application number 11/585262 was filed with the patent office on 2007-02-15 for cephem compounds.
This patent application is currently assigned to WAKUNAGA PHARMACEUTICAL CO., LTD.. Invention is credited to Satoshi Inoue, Kenji Itoh, Kohji Kawabata, Keiji Misumi, Masaru Ohgaki, Hidenori Ohki, Shinya Okuda, Kenji Satoh, Ayako Toda, Toshio Yamanaka.
Application Number | 20070037786 11/585262 |
Document ID | / |
Family ID | 32231625 |
Filed Date | 2007-02-15 |
United States Patent
Application |
20070037786 |
Kind Code |
A1 |
Ohki; Hidenori ; et
al. |
February 15, 2007 |
Cephem compounds
Abstract
The present invention relates to a compound of the formula [I]:
##STR1## wherein R.sup.1 is lower alkyl, hydroxy(lower)alkyl or
halo(lower)alkyl, and R.sup.2 is hydrogen or amino protecting
group, or R.sup.1 and R.sup.2 are bonded together and form lower
alkylene or lower alkenylene; R.sup.3 is hydrogen or lower alkyl;
R.sup.4 is ##STR2## R.sup.5 is carboxy or protected carboxy; and
R.sup.6 is amino or protected amino, or a pharmaceutically
acceptable salt thereof, a process for preparing a compound of the
formula [I], and a pharmaceutical composition comprising a compound
of the formula [I] in admixture with a pharmaceutically acceptable
carrier.
Inventors: |
Ohki; Hidenori; (Osaka,
JP) ; Okuda; Shinya; (Osaka, JP) ; Yamanaka;
Toshio; (Osaka, JP) ; Ohgaki; Masaru; (Osaka,
JP) ; Toda; Ayako; (Osaka, JP) ; Kawabata;
Kohji; (Osaka, JP) ; Inoue; Satoshi;
(Takata-gun, JP) ; Misumi; Keiji; (Takata-gun,
JP) ; Itoh; Kenji; (Takata-gun, JP) ; Satoh;
Kenji; (Takata-gun, JP) |
Correspondence
Address: |
C. IRVIN MCCLELLAND;OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
WAKUNAGA PHARMACEUTICAL CO.,
LTD.
Osaka-shi
JP
Astellas Pharma Inc.
Chuo-ku
JP
|
Family ID: |
32231625 |
Appl. No.: |
11/585262 |
Filed: |
October 24, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10695895 |
Oct 30, 2003 |
7129232 |
|
|
11585262 |
Oct 24, 2006 |
|
|
|
Current U.S.
Class: |
514/206 ;
540/222 |
Current CPC
Class: |
Y02P 20/55 20151101;
A61P 31/04 20180101; C07D 501/00 20130101 |
Class at
Publication: |
514/206 ;
540/222 |
International
Class: |
A61K 31/545 20060101
A61K031/545; C07D 501/14 20060101 C07D501/14 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 30, 2002 |
AU |
2002952355 |
Sep 4, 2003 |
AU |
2003904813 |
Claims
1. A compound of the formula [I]: ##STR19## wherein R.sup.1 is
lower alkyl, hydroxy (lower) alkyl or halo (lower) alkyl, and
R.sup.2 is hydrogen or amino protecting group, or R.sup.1 and
R.sup.2 are bonded together and form lower alkylene or lower
alkenylene; R.sup.3 is hydrogen or lower alkyl; R.sup.4 is
##STR20## wherein A is ##STR21## wherein X is O or NH, R.sup.7 is
hydrogen, lower alkyl or amino protecting group, R.sup.8 is
hydrogen or hydroxy, R.sup.9 is amino, mono or di (lower)
alkylamino, protected amino, guanidino, protected guanidino or
saturated 3- to 8-membered heterocyclic group containing 1 to 4
nitrogen atoms optionally substituted by amino or protected amino,
k, m, n and q are independently 0 or 1, and p is 0, 1, 2 or 3;
R.sup.5 is carboxy or protected carboxy; and R.sup.6 is amino or
protected amino, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein R.sup.1 is lower alkyl or
hydroxy(lower)alkyl, and R.sup.2 is hydrogen or amino protecting
group, or R.sup.1 and R.sup.2 are bonded together and form lower
alkylene; R.sup.3 is hydrogen; A is ##STR22## wherein X is O or NH;
R.sup.7 is hydrogen or amino protecting group; R.sup.9 is amino or
protected amino; and p is 0, 1 or 2, or a pharmaceutically
acceptable salt thereof.
3. The compound of claim 2 wherein R.sup.8 is hydrogen, or a
pharmaceutically acceptable salt thereof.
4. The compound of claim 1 wherein R.sup.1 is lower alkyl,
hydroxy(lower)alkyl or halo(lower)alkyl, and R.sup.2 is hydrogen,
aryl(lower)alkyl or acyl, or R.sup.1 and R.sup.2 are bonded
together and form lower alkylene or lower alkenylene; R.sup.5 is
carboxy or esterified carboxy; R.sup.6 is amino or acylamino;
R.sup.7 is hydrogen, lower alkyl or acyl; and R.sup.9 is amino,
mono or di(lower)alkylamino, acylamino, guanidino, acylguanidino or
saturated 3- to 8-membered heterocyclic group containing 1 to 4
nitrogen atoms optionally substituted by amino or acylamino, or a
pharmaceutically acceptable salt thereof.
5. The compound of claim 4 wherein R.sup.1 is lower alkyl or
hydroxy(lower)alkyl, and R.sup.2 is hydrogen, aryl(lower)alkyl or
acyl, or R.sup.1 and R.sup.2 are bonded together and form lower
alkylene; R.sup.5 is carboxy or esterified carboxy; R.sup.6 is
amino or acylamino; R.sup.7 is hydrogen or acyl; and R.sup.9 is
amino or acylamino, or a pharmaceutically acceptable salt
thereof.
6. The compound of claim 5 wherein R.sup.1 is lower alkyl or
hydroxy(lower)alkyl, and R.sup.2 is hydrogen, aryl(lower)alkyl,
lower alkanoyl or lower alkoxycarbonyl, or R.sup.1 and R.sup.2 are
bonded together and form lower alkylene; R.sup.5 is carboxy or
lower alkoxycarbonyl; R.sup.6 is amino, lower alkanoylamino or
lower alkoxycarbonylamino; R.sup.7 is hydrogen, lower alkanoyl or
lower alkoxycarbonyl; and R.sup.9 is amino, lower alkanoylamino or
lower alkoxycarbonylamino, or a pharmaceutically acceptable salt
thereof.
7. The compound of claim 6 wherein R.sup.1 is lower alkyl or
hydroxy(lower)alkyl, and R.sup.2 is hydrogen, or R.sup.1 and
R.sup.2 are bonded together and form lower alkylene; R.sup.5 is
carboxy; R.sup.6 is amino; R.sup.7 is hydrogen or lower alkanoyl;
and R.sup.9 is amino, or a pharmaceutically acceptable salt
thereof.
8. The compound of claim 1 wherein R.sup.4 is selected from the
group consisting of ##STR23## wherein R.sup.7, A, m, p and q are
each as defined in claim 1, R.sup.14 is amino, mono or
di(lower)alkylamino or protected amino, R.sup.15 is guanidino or
protected guanidino, and R.sup.16 is saturated 3- to 8-membered
heterocyclic group containing 1 to 4 nitrogen atoms optionally
substituted by amino or protected amino, or a pharmaceutically
acceptable salt thereof.
9. The compound of claim 1 wherein R.sup.4 is selected from the
group consisting of ##STR24## wherein p is 0, 1 or 2, q is 0 or 1,
R.sup.7 is hydrogen or amino protecting group, and R.sup.9 is amino
or protected amino, or a pharmaceutically acceptable salt
thereof.
10. The compound of claim 9 wherein R.sup.7 is hydrogen, lower
alkanoyl or lower alkoxycarbonyl; and R.sup.9 is amino, lower
alkanoylamino or lower alkoxycarbonylamino, or a pharmaceutically
acceptable salt thereof.
11. The compound of claim 10 wherein R.sup.7 is hydrogen or lower
alkanoyl; and R.sup.9 is amino, or a pharmaceutically acceptable
salt thereof.
12. A process for preparing a compound of the formula [I]:
##STR25## wherein R.sup.1 is lower alkyl, hydroxy(lower)alkyl or
halo(lower)alkyl, and R.sup.2 is hydrogen or amino protecting
group, or R.sup.1 and R.sup.2 are bonded together and form lower
alkylene or lower alkenylene; R.sup.3 is hydrogen or lower alkyl;
R.sup.4 is ##STR26## wherein A is ##STR27## wherein X is O or NH,
R.sup.7 is hydrogen, lower alkyl or amino protecting group, R.sup.8
is hydrogen or hydroxy, R.sup.9 is amino, mono or
di(lower)alkylamino, protected amino, guanidino, protected
guanidino or saturated 3- to 8-membered heterocyclic group
containing 1 to 4 nitrogen atoms optionally substituted by amino or
protected amino, k, m, n and q are independently 0 or 1, and p is
0, 1, 2 or 3; R.sup.5 is carboxy or protected carboxy; and R.sup.6
is amino or protected amino, or a salt thereof, which comprises
(1), reacting a compound of the formula [II]: ##STR28## wherein
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each as defined above, or
its reactive derivative at the amino group, or a salt thereof with
a compound of the formula [III]: ##STR29## wherein R.sup.5 and
R.sup.6 are each as defined above, or its reactive derivative at
the carboxy group, or a salt thereof to give a compound of the
formula [I]: ##STR30## wherein R.sup.1 , R.sup.2, R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are each as defined above, or a salt thereof,
or (2) subjecting a compound of the formula [Ia]: ##STR31## wherein
R.sup.1 , R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A,
k, m, n, p and q are each as defined above, and R.sup.9a is
protected amino, protected guanidino or saturated 3- to 8-membered
heterocyclic group containing 1 to 4 nitrogen atoms substituted by
protected amino, or a salt thereof to elimination reaction of the
amino protecting group to give a compound of the formula [Ib]:
##STR32## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6,
R.sup.7, R.sup.8, A, k, m, n, p and q are each as defined above,
and R.sup.9b is amino, guanidino or saturated 3- to 8-membered
heterocyclic group containing 1 to 4 nitrogen atoms substituted by
amino, or a salt thereof, or (3) reacting a compound of the formula
[VI]: ##STR33## wherein R.sup.5 and R.sup.6 are each as defined
above, R.sup.10, is protected carboxy, and Y is a leaving group, or
a salt thereof with a compound of the formula [VII]: ##STR34##
wherein R.sup.1 , R.sup.2, R.sup.3 and R.sup.4 are each as defined
above, or a salt thereof to give a compound of the formula [VIII]:
##STR35## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6 and R.sup.10 are each as defined above, and Z.sup.{circle
around (-)} is an anion, or a salt thereof, and subjecting the
compound of the formula [VIII] or a salt thereof to elimination
reaction of the carboxy protecting group, to give a compound of the
formula [I]: ##STR36## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are each as defined above, or a salt
thereof.
13. A pharmaceutical composition comprising a compound of claim 1
or a pharmaceutically acceptable salt thereof in admixture with a
pharmaceutically acceptable carrier.
14. A compound of claim 1 or a pharmaceutically acceptable salt
thereof for use as a medicament.
15. A compound of claim 1 or a pharmaceutically acceptable salt
thereof for use as an antimicrobial agent.
16. Use of a compound of claim 1 or a pharmaceutically acceptable
salt thereof for manufacture of a medicament for treating
infectious diseases.
17. A method for the treatment of infectious diseases which
comprising administering a compound of claim 1 or a
pharmaceutically acceptable salt thereof to human or animals.
Description
TECHNICAL FIELD
[0001] The present invention relates to new cephem compounds and
pharmaceutically acceptable salts thereof. More particularly, the
present invention relates to new cephem compounds and
pharmaceutically acceptable salts thereof, which have antimicrobial
activities, to processes for preparation thereof, to pharmaceutical
composition comprising the same, and to a method for treating
infectious diseases in human being and animals.
DISCLOSURE OF INVENTION
[0002] One object of the present invention is to provide novel
cephem compounds and pharmaceutically acceptable salts thereof,
which are highly active against a number of pathogenic
microorganisms.
[0003] Another object of the present invention is to provide
processes for the preparation of said cephem compounds and salts
thereof.
[0004] A further object of the present invention is to provide a
pharmaceutical composition comprising, as an active ingredient,
said cephem compounds or their pharmaceutically acceptable
salts.
[0005] Still further object of the present invention is to provide
a method for treating infectious diseases caused by pathogenic
microorganisms, which comprises administering said cephem compounds
to infected human being or animals.
[0006] The object cephem compounds of the present invention are
novel and can be represented by the following general formula [I]:
##STR3## wherein [0007] R.sup.1 is lower alkyl, hydroxy(lower)alkyl
or halo(lower)alkyl, and [0008] R.sup.2 is hydrogen or amino
protecting group, or [0009] R.sup.1 and R.sup.2 are bonded together
and form lower alkylene or lower alkenylene; [0010] R.sup.3 is
hydrogen or lower alkyl; [0011] R.sup.4 is ##STR4## [0012] wherein
[0013] A is ##STR5## [0014] wherein X is O or NH, [0015] R.sup.7 is
hydrogen, lower alkyl or amino protecting group, [0016] R.sup.8 is
hydrogen or hydroxy, [0017] R.sup.9 is amino, mono or
di(lower)alkylamino, protected amino, guanidino, protected
guanidino or saturated 3- to 8-membered heterocyclic group
containing 1 to 4 nitrogen atoms optionally substituted by amino or
protected amino, [0018] k, m, n and q are independently 0 or 1, and
[0019] p is 0, 1, 2 or 3; [0020] R.sup.5 is carboxy or protected
carboxy; and [0021] R.sup.6 is amino or protected amino.
[0022] As to the object compound [I], the following points are to
be noted.
[0023] That is, the object compound [I] includes syn isomer (Z
form), anti isomer (E form) and a mixture thereof. Syn isomer (Z
form) means one geometrical isomer having the partial structure
represented by the following formula: ##STR6## wherein R.sup.5 and
R.sup.6 are each as defined above, and anti isomer (E form) means
the other geometrical isomer having the partial structure
represented by the following formula: ##STR7## wherein R.sup.5 and
R.sup.6 are each as defined above, and all of such geometrical
isomers and mixture thereof are included within the scope of this
invention.
[0024] In the present specification and claims, the partial
structure of these geometrical isomers and mixture thereof are
represented for convenience sake by the following formula: ##STR8##
wherein R.sup.5 and R.sup.6 are each as defined above.
[0025] Another point to be noted is that the pyrazolio moiety of
the compound [I] can also exist in the tautomeric form, and such
tautomeric equilibrium can be represented by the following formula.
##STR9## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each as
defined above.
[0026] Both of the above tautomeric isomers are included within the
scope of the present invention, and-in the present specification
and claims, however, the object compound [I] is represented for
convenience sake by one expression of the pyrazolio group of the
formula (A).
[0027] The cephem compound [I] of the present invention can be
prepared by the following processes as illustrated in the
following. ##STR10## ##STR11## ##STR12## ##STR13## wherein R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A,
k, m, n, p and [0028] q are each as defined above, [0029] R.sup.10
is protected carboxy, [0030] Y is a leaving group, [0031]
Z.sup.{circle around (-)} is an anion, [0032] R.sup.1a is protected
hydroxy(lower)alkyl, [0033] R.sup.1b is hydroxy(lower)alkyl, [0034]
R.sup.9a is protected amino, protected guanidino or saturated 3- to
8-membered heterocyclic group containing 1 to 4 nitrogen atoms
substituted by protected amino, and [0035] R.sup.9b is amino,
guanidino or saturated 3- to 8-membered heterocyclic group
containing 1 to 4 nitrogen atoms substituted by amino.
[0036] The starting compounds [II] and [VI] can be prepared by the
following processes. ##STR14## ##STR15## wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, .sup.6, R.sup.10, Y and Z.sup.{circle
around (-)} are each as defined above, [0037] R.sup.11 is protected
amino, [0038] R.sup.12 is protected carboxy, and [0039] R.sup.13 is
amino protecting group or lower alkyl.
[0040] The starting compounds [VII] and [XI] or salts thereof can
be prepared by the methods disclosed in the Preparations 3-6, 8-47
and 49-102 described later or similar manners thereto.
[0041] In the above and subsequent descriptions of this
specification, suitable examples of the various definitions are
explained in detail as follows.
[0042] The term "lower" is used to mean a group having 1 to 6,
preferably 1 to 4, carbon atoms, unless otherwise indicated.
[0043] Suitable "lower alkyl", and "lower alkyl" moiety in
"hydroxy(lower)alkyl", "protected hydroxy(lower)alkyl",
"aryl(lower)alkyl", "halo(lower)alkyl" and "mono or
di(lower)alkylamino", include straight or branched alkyl having 1
to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl,
isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in
which more preferred one is C.sub.1-C.sub.4 alkyl.
[0044] Suitable "hydroxy(lower)alkyl" includes
hydroxy(C.sub.3-C.sub.6)alkyl such as hydroxymethyl,
1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl,
3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl and
6-hydroxyhexyl, in which more preferred one is
hydroxy(C.sub.1-C.sub.4)alkyl.
[0045] Suitable "halo(lower)alkyl" includes straight or branched
alkyl having 1 to 6 carbon atoms substituted by 1 to 5 halogen
atoms such as chlorine, bromine, iodine and fluorine. Preferred
examples of "halo(lower)alkyl" include fluoromethyl,
difluoromethyl, trifluoromethyl, chloromethyl, bromomethyl,
2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,
2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl,
3-fluoropropyl and 2,2,3,3,3-pentafluoropropyl, in which more
preferred one is halo(C.sub.1-C.sub.4)alkyl.
[0046] Suitable "mono or di(lower)alkylamino" includes mono or
di(C.sub.1-C.sub.6)alkylamino such as methylamino, dimethylamino,
ethylamino, diethylamino, N-ethyl-N-methylamino, propylamino,
butylamino and N-ethyl-N-propylamino, in which more preferred one
is mono or di (C.sub.1-C.sub.4) alkylamino.
[0047] Suitable "lower alkylene" formed by R.sup.1 and R.sup.2
includes straight alkylene having 1 to 6, preferably 2 to 4 carbon
atoms, such as methylene, ethylene, trimethylene and
tetramethylene, in which more preferred one is straight alkylene
having 2 or 3 carbon atoms.
[0048] Suitable "lower alkenylene" formed by R.sup.1 and R.sup.2
includes straight alkenylene having 2 to 6, preferably 2 to 4
carbon atoms, such as vinylene and propenylene, in which more
preferred one is straight alkenylene having 2 or 3 carbon
atoms.
[0049] Suitable "saturated 3- to 8-membered heterocyclic group
containing 1 to 4 nitrogen atoms" includes azetidinyl (e.g.,
1-azetidinyl and 3-azetidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl
and 3-pyrrolidinyl), imidazolidinyl (e.g., 1-imidazolidinyl and
4-imidazolidinyl), piperidinyl (e.g., 1-piperidinyl and
4-piperidinyl) and piperazinyl (e.g., 1-piperazinyl), in which more
preferred one is saturated 4- to 6-membered heterocyclic group
containing 1 to 4 nitrogen atoms.
[0050] The saturated 3- to 8-membered heterocyclic group containing
1 to 4 nitrogen atoms is optionally substituted by amino or
protected amino. Suitable examples of "saturated 3- to 8-membered
heterocyclic group containing 1 to 4 nitrogen atoms optionally
substituted by amino or protected amino" include 1-azetidinyl,
3-amino-1-azetidinyl, 3-tert-butoxycarbonylamino-1-azetidinyl,
3-azetidinyl, 1-pyrrolidinyl, 3-amino-1-pyrrolidinyl,
3-tert-butoxycarbonylamino-1-pyrrolidinyl, 3-pyrrolidinyl,
1-piperidinyl, 4-piperidinyl and 1-piperazinyl.
[0051] Suitable "aryl" moiety in "aryl(lower)alkyl" includes
C.sub.6-C.sub.12 aryl such as phenyl and naphthyl, in which more
preferred one is phenyl.
[0052] Suitable "aryl(lower)alkyl" includes mono-, di- or
triphenyl(lower)alkyl such as benzyl, phenethyl, benzhydryl and
trityl.
[0053] Suitable "lower alkanoyl" and "lower alkanoyl" moiety in
"lower alkanoylamino" include straight or branched alkanoyl having
1 to 6 carbon atoms, such as formyl, acetyl, propionyl, butyryl,
isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl, in which
more preferred one is C.sub.1-C.sub.4 alkanoyl.
[0054] Suitable "lower alkoxy" moiety in "lower alkoxycarbonyl" and
"lower alkoxycarbonylamino" includes straight or branched alkoxy
having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy,
isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy,
tert-pentyloxy and hexyloxy, in which more preferred one is
C.sub.1-C.sub.4 alkoxy.
[0055] Suitable "amino protecting group" in "protected amino"
includes an acyl group as mentioned below, substituted or
unsubstituted aryl(lower)alkylidene [e.g., benzylidene,
hydroxybenzylidene, etc.], aryl(lower)alkyl such as mono-, di- or
triphenyl(lower)alkyl [e.g., benzyl, phenethyl, benzhydryl, trityl,
etc.], and the like.
[0056] Suitable "acyl" includes lower alkanoyl [e.g., formyl,
acetyl, propionyl, hexanoyl, pivaloyl, etc.], mono(or di or
tri)halo(lower)alkanoyl [e.g., chloroacetyl, trifluoroacetyl,
etc.], lower alkoxycarbonyl [e.g., methoxycarbonyl, ethoxycarbonyl,
tert-butoxycarbonyl, tert-pentyloxycarbonyl, hexyloxycarbonyl,
etc.], carbamoyl, aroyl [e.g., benzoyl, toluoyl, naphthoyl, etc.],
aryl(lower)alkanoyl [e.g., phenylacetyl, phenylpropionyl, etc.],
aryloxycarbonyl [e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.],
aryloxy(lower)alkanoyl [e.g., phenoxyacetyl, phenoxypropionyl,
etc.], arylglyoxyloyl [e.g., phenylglyoxyloyl, naphthylglyoxyloyl,
etc.], aryl(lower)alkoxycarbonyl which optionally substituted by
suitable substituent(s) [e.g., benzyloxycarbonyl,
phenethyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], and the
like.
[0057] Preferable examples of "amino protecting group" include
aryl(lower)alkyl and acyl, in which more preferred ones are
aryl(lower)alkyl, lower alkanoyl and lower alkoxycarbonyl, and
particularly preferred ones are mono-, di- or
triphenyl(C.sub.1-C.sub.6)alkyl, C.sub.1-C.sub.6 alkanoyl and
(C.sub.1-C.sub.6)alkoxycarbonyl.
[0058] Preferable examples of "protected amino" include
aryl(lower)alkylamino and acylamino, in which more preferred ones
are aryl(lower)alkylamino, lower alkanoylamino and lower
alkoxycarbonylamino, and particularly preferred ones are mono-, di-
or triphenyl(C.sub.1-C.sub.6)alkylamino, C.sub.1-C.sub.6
alkanoylamino and (C.sub.1-C.sub.6) alkoxycarbonylamino.
[0059] Preferable examples of "protected guanidino" include
acylguanidino (monoacylguanidino and diacylguanidino) such as
2,3-bis[(lower)alkoxycarbonyl]guanidino [e.g.,
2,3-bis(tert-butoxycarbonyl)guanidino], in which more preferred one
is 2,3-bis [(C.sub.1-C.sub.6)alkoxycarbonyl]guanidino.
[0060] Suitable "protected hydroxy" in the "protected
hydroxy(lower)alkyl" includes acyloxy group, aryl(lower)alkyloxy
group, and the like. Suitable "acyl" moiety in the "acyloxy"
includes lower alkanoyl [e.g., formyl, acetyl, propionyl, hexanoyl,
pivaloyl, etc.], mono(or di or tri)halo(lower)alkanoyl, [e.g.,
chloroacetyl, trifluoroacetyl, etc.], lower alkoxycarbonyl, [e.g.,
methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl,
tert-pentyloxycarbonyl, hexyloxycarbonyl, etc.], carbamoyl, and the
like. Suitable "aryl(lower)alkyl" moiety in the
"aryl(lower)alkyloxy" includes mono-, di- or triphenyl(lower)alkyl
[e.g., benzyl, phenethyl, benzhydryl, trityl, etc.], and the
like.
[0061] Suitable "protected carboxy" includes esterified carboxy and
the like, and concrete examples of esterified carboxy include lower
alkoxycarbonyl [e.g., methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl,
isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl-,
hexyloxycarbonyl, l-cyclopropylethoxycarbonyl, etc.] which may have
suitable substituent(s), for example, lower
alkanoyloxy(lower)alkoxycarbonyl [e.g., acetoxymethoxycarbonyl,
propionyloxymethoxycarbonyl, butyryloxymethoxycarbonyl,
valeryloxymethoxycarbonyl, pivaloyloxymethoxycarbonyl,
1-acetoxyethoxycarbonyl, 1-propionyloxyethoxycarbonyl,
2-propionyloxyethoxycarbonyl, hexanoyloxymethoxycarbonyl, etc.],
lower alkanesulfonyl(lower)alkoxycarbonyl, [e.g.,
2-mesylethoxycarbonyl, etc.] or mono(or di or
tri)halo(lower)alkoxycarbonyl [e.g., 2-iodoethoxycarbonyl,
2,2,2-trichloroethoxycarbonyl, etc.]; lower alkenyloxycarbonyl
[e.g., vinyloxycarbonyl, allyloxycarbonyl, etc.]; lower
alkynyloxycarbonyl [e.g., ethynyloxycarbonyl, propynyloxycarbonyl,
etc.]; aryl(lower)alkoxycarbonyl which may have suitable
substituent(s) [e.g., benzyloxycarbonyl,
4-methoxybenzyloxycarbonyl, 4-nitrobezyloxycarbonyl,
phenethyloxycarbonyl, trityloxycarbonyl, benzhydryloxycarbonyl,
bis(methoxyphenyl)methoxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl,
4-hydroxy-3,5-di-tert-butylbenzyloxycarbonyl, etc.];
aryloxycarbonyl which may have suitable substituent(s) [e.g.,
phenoxycarbonyl, 4-chlorophenoxycarbonyl, tolyloxycarbonyl,
4-tert-butylphenoxycarbonyl, xylyloxycarbonyl, mesityloxycarbonyl,
cumenyloxycarbonyl, etc.]; and the like.
[0062] Preferable examples of "protected carboxy" include lower
alkoxycarbonyl and aryl(lower)alkoxycarbonyl which may have
suitable substituent(s), in which more preferred one is
(C.sub.1-C.sub.6)alkoxycarbonyl.
[0063] Suitable "leaving group" includes halogen [e.g., chlorine,
bromine, iodine, etc.] or acyloxy such as arylsulfonyloxy [e.g.,
benzenesulfonyloxy, tosyloxy, etc.], lower alkylsulfonyloxy [e.g.,
mesyloxy, etc.], lower alkanoyloxy [e.g., acetyloxy, propionyloxy,
etc.], and the like.
[0064] Suitable "anion" includes formate, acetate,
trifluoroacetate, maleate, tartrate, methanesulfonate,
benzenesulfonate, toluenesulfonate, chloride, bromide, iodide,
sulfate, hydrogen sulfate, phosphate, and the like.
[0065] Suitable pharmaceutically acceptable salts of the object
compound [I] are conventional non-toxic salts and include, for
example, a salt with a base or an acid addition salt such as a salt
with an inorganic base, for example, an alkali metal salt [e.g.,
sodium salt, potassium salt, etc.], an alkaline earth metal salt
[e.g., calcium salt, magnesium salt, etc.], an ammonium salt; a
salt with an organic base, for example, an organic amine salt
[e.g., trimethylamine salt, triethylamine salt, pyridine salt,
picoline salt, ethanolamine salt, triethanolamine salt,
dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.];
an inorganic acid addition salt [e.g., hydrochloride, hydrobromide,
sulfate, hydrogen sulfate, phosphate, etc.]; an organic carboxylic
or sulfonic acid addition salt [e.g., formate, acetate,
trifluoroacetate, maleate, tartrate, citrate, fumarate,
methanesulfonate, benzenesulfonate, toluenesulfonate, etc.]; and a
salt with a basic or acidic amino acid [e.g., arginine, aspartic
acid, glutamic acid, etc.].
[0066] The preferred embodiments of the cephem compound of the
present invention represented by the general formula [I] are as
follows.
[0067] (1) The compound of the formula [I] wherein [0068] R.sup.1
is lower alkyl or hydroxy(lower)alkyl, and [0069] R.sup.2 is
hydrogen or amino protecting group, or [0070] R.sup.1 and R.sup.2
are bonded together and form lower alkylene; [0071] R.sup.3 is
hydrogen; [0072] A is ##STR16##
[0073] wherein X is O or NH; [0074] R.sup.7 is hydrogen or amino
protecting group; [0075] R.sup.9 is amino or protected amino; and
[0076] p is 0, 1 or 2, [0077] or a pharmaceutically acceptable salt
thereof.
[0078] (2) The compound of (1) above wherein R.sup.8 is hydrogen,
or a pharmaceutically acceptable salt thereof.
[0079] (3) The compound of the formula [I] wherein [0080] R.sup.1
is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and [0081]
R.sup.2 is hydrogen, aryl(lower)alkyl or acyl, or [0082] R.sup.1
and R.sup.2 are bonded together and form lower alkylene or lower
alkenylene; [0083] R.sup.5 is carboxy or esterified carboxy; [0084]
R.sup.6 is amino or acylamino; [0085] R.sup.7 is hydrogen, lower
alkyl or acyl; and [0086] R.sup.9 is amino, mono or
di(lower)alkylamino, acylamino, guanidino, acylguanidino or
saturated 3- to 8-membered heterocyclic group containing 1 to 4
nitrogen atoms optionally substituted by amino or acylamino, [0087]
or a pharmaceutically acceptable salt thereof.
[0088] (4) The compound of (3) above wherein [0089] R.sup.1 is
lower alkyl or hydroxy(lower)alkyl, and [0090] R.sup.2 is hydrogen,
aryl(lower)alkyl or acyl, or [0091] R.sup.1 and R.sup.2 are bonded
together and form lower alkylene; [0092] R.sup.5 is carboxy or
esterified carboxy; [0093] R.sup.6 is amino or acylamino; [0094]
R.sup.7 is hydrogen or acyl; and [0095] R.sup.9 is amino or
acylamino, [0096] or a pharmaceutically acceptable salt
thereof.
[0097] (5) The compound of (4) above wherein [0098] R.sup.1 is
lower alkyl or hydroxy(lower)alkyl, and [0099] R.sup.2 is hydrogen,
aryl(lower)alkyl, lower alkanoyl or lower alkoxycarbonyl, or [0100]
R.sup.1 and R.sup.2 are bonded together and form lower alkylene;
[0101] R.sup.5 is carboxy or lower alkoxycarbonyl; [0102] R.sup.6
is amino, lower alkanoylamino or lower alkoxycarbonylamino; [0103]
R.sup.7 is hydrogen, lower alkanoyl or lower alkoxycarbonyl; and
[0104] R.sup.9 is amino, lower alkanoylamino or lower
alkoxycarbonylamino, [0105] or a pharmaceutically acceptable salt
thereof.
[0106] (6) The compound of (5) above wherein [0107] R.sup.1 is
C.sub.1-C.sub.6 alkyl or hydroxy(C.sub.1-C.sub.6)alkyl, and [0108]
R.sup.2 is hydrogen, mono-, di- or triphenyl(C.sub.1-C.sub.6)alkyl,
C.sub.1-C.sub.6 alkanoyl or (C.sub.1-C.sub.6)alkoxycarbonyl, or
[0109] R.sup.1 and R.sup.2 are bonded together and form
C.sub.1-C.sub.6 alkylene; [0110] R.sup.5 is carboxy or
(C.sub.1-C.sub.6) alkoxycarbonyl; [0111] R.sup.6 is amino,
C.sub.1-C.sub.6 alkanoylamino or (C.sub.1-C.sub.6)
alkoxycarbonylamino; [0112] R.sup.7 is hydrogen, C.sub.1-C.sub.6
alkanoyl or (C.sub.1-C.sub.6) alkoxycarbonyl; and [0113] R.sup.9 is
amino, C.sub.1-C.sub.6 alkanoylamino or (C.sub.1-C.sub.6)
alkoxycarbonylamino, [0114] or a pharmaceutically acceptable salt
thereof.
[0115] (7) The compound of (5) above wherein [0116] R.sup.1 is
lower alkyl or hydroxy(lower)alkyl, and [0117] R.sup.2 is hydrogen,
or [0118] R.sup.1 and R.sup.2 are bonded together and form lower
alkylene; [0119] R.sup.5 is carboxy; [0120] R.sup.6 is amino;
[0121] R.sup.7 is hydrogen or lower alkanoyl; and [0122] R.sup.9 is
amino, [0123] or a pharmaceutically acceptable salt thereof.
[0124] (8) The compound of (7) above wherein [0125] R.sup.1 is
C.sub.1-C.sub.6 alkyl or hydroxy(C.sub.1-C.sub.6)alkyl, and [0126]
R.sup.2 is hydrogen, or [0127] R.sup.1 and R.sup.2 are bonded
together and form C.sub.1-C.sub.6 alkylene; [0128] R.sup.5 is
carboxy; [0129] R.sup.6 is amino; [0130] R.sup.7 is hydrogen or
C.sub.1-C.sub.6 alkanoyl; and [0131] R.sup.9 is amino, [0132] or a
pharmaceutically acceptable salt thereof.
[0133] (9) The compound of the formula [I] wherein [0134] R.sup.4
is selected from the group consisting of ##STR17## wherein R.sup.7,
A, m, p and q are each as defined above in the formula [I], [0135]
R.sup.14 is amino, mono or di(lower)alkylamino or protected amino,
[0136] R.sup.15 is guanidino or protected guanidino, and [0137]
R.sup.16 is saturated 3- to 8-membered heterocyclic group
containing 1 to 4 nitrogen atoms optionally substituted by amino or
protected amino, [0138] or a pharmaceutically acceptable salt
thereof.
[0139] (10) The compound of the formula [I] wherein [0140] R.sup.4
is selected from the group consisting of ##STR18## wherein [0141] p
is 0, 1 or 2, [0142] q is 0 or 1, [0143] R.sup.7 is hydrogen or
amino protecting group, and [0144] R.sup.9 is amino or protected
amino, [0145] or a pharmaceutically acceptable salt thereof.
[0146] (11) The compound of (10) above wherein [0147] R.sup.7 is
hydrogen, lower alkanoyl or lower alkoxycarbonyl; and [0148]
R.sup.9 is amino, lower alkanoylamino or lower alkoxycarbonylamino,
[0149] or a pharmaceutically acceptable salt thereof.
[0150] (12) The compound of (11) above wherein [0151] R.sup.7 is
hydrogen, C.sub.1-C.sub.6 alkanoyl or
(C.sub.1-C.sub.6)alkoxycarbonyl; and [0152] R.sup.9 is amino,
C.sub.1-C.sub.6 alkanoylamino or (C.sub.1-C.sub.6)
alkoxycarbonylamino, [0153] or a pharmaceutically acceptable salt
thereof.
[0154] (13) The compound of (11) above wherein [0155] R.sup.7 is
hydrogen or lower alkanoyl; and [0156] R.sup.9 is amino, [0157] or
a pharmaceutically acceptable salt thereof.
[0158] (14) The compound of (13) above wherein [0159] R.sup.7 is
hydrogen or C.sub.1-C.sub.6 alkanoyl; and [0160] R.sup.9 is amino,
[0161] or a pharmaceutically acceptable salt thereof.
[0162] The processes for preparing the object compound of the
present invention are explained in detail in the following.
Process 1
[0163] The compound [I] or a salt thereof can be prepared by
reacting the compound [II] or its reactive derivative at the amino
group, or a salt thereof with the compound [III] or its reactive
derivative at the carboxy group, or a salt thereof.
[0164] Suitable reactive derivative at the amino group of the
compound [II] includes Schiff's base type imino or its tautomeric
enamine type isomer formed by the reaction of the compound [II]
with a carbonyl compound such as aldehyde, ketone and the like; a
silyl derivative formed by the reaction of the compound [II] with a
silyl compound such as bis(trimethylsilyl)acetamide,
mono(trimethylsilyl)acetamide [e.g., N-(trimethylsilyl)acetamide],
bis(trimethylsilyl)urea and the like; a derivative formed by the
reaction of the compound [II] with phosphorus trichloride or
phosgene.
[0165] Suitable salts of the compound [II] and its reactive
derivative can be referred to the ones as exemplified for the
compound [I].
[0166] Suitable reactive derivative at the carboxy group of the
compound [III] includes an acid halide, an acid anhydride, an
activated amide, and an activated ester. A suitable example of the
reactive derivatives may be an acid chloride; an acid azide; a
mixed acid anhydride with an acid such as substituted phosphoric
acid [e.g., dialkylphosphoric acid, phenylphosphoric acid,
diphenylphosphoric acid, dibenzylphosphoric acid, halogenated
phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid,
thiosulfuric acid, sulfuric acid, alkanesulfonic acid [e.g.,
methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g.,
acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic
acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid,
trichloroacetic acid, etc.] and aromatic carboxylic acid [e.g.,
benzoic acid, etc.]; a symmetrical acid anhydride; an activated
amide with imidazole, 4-substituted imidazole, dimethylpyrazole,
triazole or tetrazole; an activated ester [e.g., cyanomethyl ester,
methoxymethyl ester, dimethyliminomethyl
[(CH.sub.3).sub.2N.sup.+.dbd.CH--] ester, vinyl ester, propargyl
ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester,
trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester,
phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester,
p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl
ester, piperidyl ester, 8-quinolyl thioester, etc.]; or an ester
with an N-hydroxy compound [e.g., N,N-dimethylhydroxylamine,
1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,
N-hydroxyphthalimide, N-hydroxy-1H-benzotriazole, etc.]. These
reactive derivatives can optionally be selected from them according
to the kind of the compound [III] to be used.
[0167] Suitable salts of the compound [III] and its reactive
derivative can be referred to the ones as exemplified for the
compound [I].
[0168] The reaction is usually carried out in a conventional
solvent such as water, alcohol [e.g., methanol, ethanol, etc.],
acetone, dioxane, acetonitrile, chloroform, methylene chloride,
ethylene chloride, tetrahydrofuran, ethyl acetate,
N,N-dimethylformamide, pyridine or any other organic solvent which
does not adversely affect the reaction. These conventional solvents
may also be used in a mixture with water.
[0169] In this reaction, when the compound [III] is used in free
acid form or its salt form, the reaction is preferably carried out
in the presence of a conventional condensing agent such as
N,N'-dicyclohexylcarbodiimide;
N-cyclohexyl-N'-morpholinoethylcarbodiimide;
N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide;
N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide;
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide;
N,N'-carbonyl-bis-(2-methylimidazole);
pentamethyleneketene-N-cyclohexylimine;
diphenylketene-N-cyclohexylimine; ethoxyacetylene;
1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate;
isopropyl polyphosphate; phosphorus oxychloride(phosphoryl
chloride); phosphorus trichloride; thionyl chloride; oxalyl
chloride; lower alkyl haloformate [e.g., ethyl chloroformate,
isopropyl chloroformate, etc.], triphenylphosphine;
2-ethyl-7-hydroxybenzisoxazolium salt;
2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt;
1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called
Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide
with thionyl chloride, phosgene, trichloromethyl chloroformate,
phosphorus oxychloride, etc.; and the like.
[0170] The reaction may also be carried out in the presence of an
inorganic or organic base such as an alkali metal bicarbonate,
tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine,
N,N-di(lower)alkylbenzylamine, and the like.
[0171] The reaction temperature is not critical, and the reaction
is usually carried out under cooling to warming.
Process 2
[0172] The compound [Ib] or a salt thereof can be prepared by
subjecting the compound [Ia] or a salt thereof to elimination
reaction of the amino protecting group.
[0173] Elimination reaction is carried out in accordance with a
conventional method such as hydrolysis and the like.
[0174] The hydrolysis is preferably carried out in the presence of
a base or an acid including Lewis acid.
[0175] Suitable base includes an inorganic base and an organic base
such as an alkali metal [e.g., sodium, potassium, etc.], an
alkaline earth metal [e.g., magnesium, calcium, etc.], the
hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine
[e.g., trimethylamine, triethylamine, etc.], picoline,
1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane,
1,8-diazabicyclo[5.4.0]undec-7-ene, and the like.
[0176] Suitable acid includes an organic acid [e.g., formic acid,
acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic
acid, etc.], and an inorganic acid [e.g., hydrochloric acid,
hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen
bromide, etc.].
[0177] The elimination using Lewis acid such as trihaloacetic acid
[e.g., trichloroacetic acid, trifluoroacetic acid, etc.], and the
like is preferably carried out in the presence of cation trapping
agents [e.g., anisole, phenol, etc.].
[0178] The reaction is usually carried out in a solvent such as
water, alcohol [e.g., methanol, ethanol, etc.], methylene chloride,
tetrahydrofuran, a mixture thereof or any other solvent which does
not adversely influence the reaction. A liquid base or acid can be
also used as a solvent.
[0179] The reaction temperature is not critical and the reaction is
usually carried out under cooling to warming.
Process 3-(i)
[0180] The compound [VIII] or a salt thereof can be prepared by
reacting the compound [VI] or a salt thereof with the compound
[VII] or a salt thereof.
[0181] Suitable salt of the compounds [VI], [VII] and [VIII] can be
referred to the ones as exemplified for the compound [I].
[0182] The present reaction may be carried out in a solvent such as
water, phosphate buffer, acetone, chloroform, acetonitrile
nitrobenzene, methylene chloride, ethylene chloride, formamide,
N,N-dimethylformamide, methanol, ethanol, diethyl ether,
tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent
which does not adversely affect the reaction, preferably in ones
having strong polarities. Among the solvents, hydrophilic solvents
may be used in a mixture with water. When the compound [VII] is
liquid, it can also be used as a solvent.
[0183] The reaction is preferably conducted in the presence of a
base, for example, an inorganic base such as alkali metal
hydroxide, alkali metal carbonate, alkali metal hydrogencarbonate,
an organic base such as trialkylamine, and the like.
[0184] The reaction temperature is not critical, and the reaction
is usually carried out at ambient temperature, under warming or
under heating. The present reaction is preferably carried out in
the presence of alkali metal halide [e.g., sodium iodide, potassium
iodide, etc.], alkali metal thiocyanate [e.g., sodium thiocyanate,
potassium thiocyanate, etc.], and the like.
[0185] Anion Z.sup.{circle around (-)} may be one derived from a
leaving group Y, and it may be converted to other anion by a
conventional method.
Process 3-(ii)
[0186] The compound [I] or a salt thereof can be prepared by
subjecting the compound [VIII] or a salt thereof to elimination
reaction of the carboxy protecting group.
[0187] Elimination reaction is carried out in similar manner to the
reaction in the aforementioned Process 2, and therefore the
reagents to be used and reaction conditions (e.g., solvent,
reaction temperature, etc.) can be referred to those of Process
2.
Process 4
[0188] The compound [Id] or a salt thereof can be prepared by
subjecting the compound [Ic] or a salt thereof to elimination
reaction of the hydroxy protecting group.
[0189] Suitable method of this elimination reaction includes
conventional one such as hydrolysis, reduction and the like.
(i) For hydrolysis:
[0190] The hydrolysis is preferably carried out in the presence of
a base or an acid including Lewis acid.
[0191] Suitable base includes an inorganic base and an organic base
such as an alkali metal [e.g., sodium, potassium, etc.], an
alkaline earth metal [e.g., magnesium, calcium, etc.], the
hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine
[e.g., trimethylamine, triethylamine, etc.], picoline,
1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane,
1,8-diazabicyclo[5.4.0]undec-7-ene, and the like.
[0192] Suitable acid includes an organic acid [e.g., formic acid,
acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic
acid, etc.], and an inorganic acid [e.g., hydrochloric acid,
hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen
bromide, etc.].
[0193] The elimination using Lewis acid such as trihaloacetic acid
[e.g., trichloroacetic acid, trifluoroacetic acid, etc.] and the
like is preferably carried out in the presence of cation trapping
agents [e.g., anisole, phenol, etc.].
[0194] The reaction is usually carried out in a solvent such as
water, alcohol [e.g., methanol, ethanol, etc.], methylene chloride,
tetrahydrofuran, a mixture thereof or any other solvent which does
not adversely influence the reaction. A liquid base or acid can be
also used as a solvent.
[0195] The reaction temperature is not critical and the reaction is
usually carried out under cooling to warming. (ii) For
reduction:
[0196] Reduction is carried out in a conventional manner, including
chemical reduction and catalytic reduction.
[0197] Suitable reducing reagents to be used in chemical reduction
are a combination of a metal [e.g., tin, zinc, iron, etc.] or
metallic compound [e.g., chromium chloride, chromium acetate, etc.]
and an organic acid or inorganic acid [e.g., formic acid, acetic
acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid,
hydrochloric acid, hydrobromic acid, etc.].
[0198] Suitable catalysts to be used in catalytic reduction are
conventional ones such as platinum catalysts [e.g., platinum plate,
spongy platinum, platinum black, colloidal platinum, platinum
oxide, platinum wire, etc.], palladium catalysts [e.g., spongy
palladium, palladium black, palladium oxide, palladium on carbon,
colloidal palladium, palladium on barium sulfate, palladium on
barium carbonate, etc.], nickel catalysts [e.g., reduced nickel,
nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g., reduced
cobalt, Raney cobalt, etc.], iron catalysts [e.g., reduced iron,
Raney iron, etc.], copper catalysts [e.g., reduced copper, Raney
copper, Ullman copper, etc.] and the like.
[0199] The reduction is usually carried out in a conventional
solvent which does not adversely influence the reaction such as
water, methanol, ethanol, propanol, N,N-dimethylformamide or a
mixture thereof.
[0200] Additionally, in case that the above-mentioned acids to be
used in chemical reduction are liquid, they can also be used as a
solvent.
[0201] Further, a suitable solvent to be used in catalytic
reduction may be the above-mentioned solvent, and other
conventional solvent such as diethyl ether, dioxane,
tetrahydrofuran, etc., or a mixture thereof.
[0202] The reaction temperature of this reduction is not critical
and the reaction is usually carried out under cooling to
warming.
[0203] When R.sup.6 is protected amino, the amino protecting group
in R.sup.6 can be eliminated by a conventional method such as
hydrolysis.
[0204] Processes A and B for the preparation of the starting
compounds are explained in detail in the following.
Process A-(i)
[0205] The compound [XII] or a salt thereof can be prepared by
reacting the compound [X] or a salt thereof with the compound [XI]
or a salt thereof.
[0206] This reaction can be carried out in a similar manner to the
reaction in the aforementioned Process 3-(i), and therefore the
reagents to be used and reaction conditions (e.g., solvent,
reaction temperature, etc.) can be referred to those of Process
3-(i).
Process A-(ii)
[0207] The compound [II] or a salt thereof can be prepared by
subjecting the compound [XII] or a salt thereof to elimination
reaction of the amino protecting groups in R.sup.11 and R.sup.13
and the carboxy protecting group in R.sup.12.
[0208] This reaction can be carried out in a similar manner to the
reaction in the aforementioned Process 2, and therefore the
reagents to be used and reaction conditions (e.g., solvent,
reaction temperature, etc.) can be referred to those of Process
2.
Process B
[0209] The compound [VI] or a salt thereof can be prepared by
reacting the compound [XIII] or its reactive derivative at the
amino group, or a salt thereof with the compound [XIV] or its
reactive derivative at the carboxy group, or a salt thereof.
[0210] This reaction can be carried out in a similar manner to the
reaction in the aforementioned Process 1, and therefore the
reagents to be used and reaction conditions (e.g., solvent,
reaction temperature, etc.) can be referred to those of Process
1.
[0211] The compounds obtained by the above processes can be
isolated and purified by a conventional method such as
pulverization, recrystallization, column chromatography,
reprecipitation, and the like.
[0212] It is to be noted that the compound [I] and other compounds
may include one or more stereoisomer(s) such as optical isomer(s)
and geometrical isomer(s) due to asymmetric carbon atom(s) and
double bond(s), and all of such isomers and mixtures thereof are
included within the scope of this invention.
[0213] The object compounds [I] and pharmaceutically acceptable
salts thereof include solvates [e.g., enclosure compounds (e.g.,
hydrate, etc.)].
[0214] The object compound [I] and pharmaceutically acceptable
salts thereof are novel and exhibit high antimicrobial activity,
inhibiting the growth of a wide variety of pathogenic
microorganisms including Gram-positive and Gram-negative
microorganisms and are useful as antimicrobial agents.
[0215] Now in order to show the utility of the object compound [I],
the test data on MIC (minimal inhibitory concentration) of a
representative compound of this invention are shown in the
following.
Test Method
[0216] In vitro antibacterial activity was determined by the
two-fold agar-plate dilution method as described below.
[0217] One loopful of an overnight culture of each test strain in
Trypticase-soy broth (10.sup.6 viable cells per ml) was streaked on
heart infusion agar (HI-agar) containing graded concentrations of
representative test compound, and the minimal inhibitory
concentration (MIC) was expressed in .mu.g/ml after incubation at
37.degree. C. for 20 hours.
Test Compound
[0218] Compound (a):
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-[7-(3-aminopropionamido)-2,3-dihydro-5-(1H-imidazo[1,2-
-b]pyrazolio)]methyl-3-cephem-4-carboxylate (Example 3) [0219]
Compound (b):
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-methyl-1-pyraz-
olio]methyl-3-cephem-4-carboxylate (Example 4) [0220] Compound (c):
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-methyl-1-pyrazolio]met-
hyl-3-cephem-4-carboxylic acid hydrogen sulfate (Example 6) [0221]
Compound (d):
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido)-3-(3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazol-
io)methyl-3-cephem-4-carboxylic acid hydrogen sulfate (Example 7)
[0222] Compound (e):
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)methyl-3-cep-
hem-4-carboxylic acid hydrogen sulfate (Example 11)
[0223] Ceftazidime TABLE-US-00001 TABLE 1 Test results Test strain
Test compound MIC (.mu.g/ml) Pseudomonas (a) 2 aeruginosa (b) 1 FP
1380 (c) 2 (d) 2 (e) 1 Ceftazidime 128
[0224] For therapeutic administration, the object compound [I] and
pharmaceutically acceptable salts thereof of the present invention
are used in the form of a conventional pharmaceutical preparation
which contains said compound as an active ingredient, in admixture
with pharmaceutically acceptable carriers such as an organic or
inorganic solid or liquid excipient which is suitable for oral,
parenteral or external administration. The pharmaceutical
preparations may be in a solid form such as tablet, granule,
powder, capsule, or in a liquid form such as solution, suspension,
syrup, emulsion, lemonade and the like.
[0225] If needed, there may be included in the above -preparations
auxiliary substances, stabilizing agents, wetting agents and other
commonly used additives such as lactose, citric acid, tartaric
acid, stearic acid, magnesium stearate, terra alba, sucrose, corn
starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao
butter, ethylene glycol, and the like.
[0226] While the dosage of the compound [I] may vary from and also
depend upon the age, conditions of the patient, a kind of diseases,
a kind of the compound [I] to be applied, etc. In general amounts
between 1 mg and 4,000 mg or even more per day may be administered
to a patient. An average single dose of about 50 mg, 100 mg, 250
mg, 500 mg, 1000 mg or 2000 mg of the object compounds [I] of the
present invention may be used in treating diseases infected by
pathogenic microorganisms.
[0227] The following Preparations and Examples are given for the
purpose of illustrating the present invention in more detail.
Preparation 1
[0228] To a solution of
(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)[(2-tert-butoxy-1,1-dimethyl-2-oxoet-
hoxy)imino]ethanoic acid (5 g) in a mixture of tetrahydrofuran (80
ml) and N,N-dimethylformamide (20 ml) was added a solution of
sodium bis(trimethylsilyl)amide (8.33 g) in tetrahydrofuran (12
ml), and the mixture was stirred for 15 minutes. To the reaction
mixture was added a solution of di-tert-butyl dicarbonate (3.3 g)
in tetrahydrofuran (20 ml) under ice-cooling, and the mixture was
stirred under ice-cooling for 3 hours. To the reaction mixture was
added ethyl acetate, and the mixture was washed with 10% aqueous
potassium hydrogen sulfate solution, and then washed with a
phosphate buffer (pH 6.86). The organic layer was separated, dried
over anhydrous magnesium sulfate, filtered and concentrated in
vacuo. The residue was triturated with diisopropyl ether and dried
in vacuo to give
(Z)-2-(5-[(tert-butoxycarbonyl)amino]-1,2,4-thiadiazol-3-yl)[(2-tert-buto-
xy-1,1-dimethyl-2-oxoethoxy)imino]ethanoic acid (3.10 g).
[0229] IR (KBr) 3191.6, 2981.4, 1714.4, 1550.5, 1153.2, 1000.9
cm.sup.-1
[0230] .sup.1H-NMR(DMSO-d.sub.6) .delta. 1.37 (9H, s), 1.45 (6H,
s), 1.50 (9H, s), 12.7 (1H, s)
[0231] ESI-MS: m/z=429(M-H)
Preparation 2
[0232] A mixture of N,N-dimethylformamide (0.648 ml) and phosphoryl
chloride (0.781 ml) was stirred at room temperature for 30 minutes.
To the mixture were added tetrahydrofuran (4 ml) and
(Z)-2-{5-[(tert-butoxycarbonyl)amino]-1,2,4-thiadiazol-3-yl)[(2-tert-buto-
xy-1,1-dimethyl-2-oxoethoxy)imino]ethanoic acid (3 g) at 4.degree.
C., and the reaction mixture was stirred at room temperature for 1
hour. Meanwhile, a mixture of benzhydryl
7.beta.-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride
(3 g) and N-(trimethylsilyl)acetamide (8.72 g) in tetrahydrofuran
(15 ml) was warmed to make a clear solution. The solution was then
cooled to -20.degree. C. and added to the activated acid solution
obtained above. The reaction mixture was stirred at a temperature
of -10.degree. C. to 0.degree. C. for 1 hour and poured into a
mixture of ethyl acetate and water. The aqueous layer was
separated, and the organic layer was washed with brine, dried over
anhydrous magnesium sulfate and filtered. The filtrate was
concentrated in vacuo and purified by column chromatography on
silica gel eluting with hexane/ethyl acetate (3:2) to give
benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-
-carboxylate (4.79 g).
[0233] IR (KBr) 2981.4, 1793.5, 1720.2, 1524.8, 1371.1, 1247.7,
1151.3 cm.sup.-1
[0234] .sup.1H-NMR(DMSO-d.sub.6) .delta. 1.39 (6H, s), 1.48 (3H,
s), 1.50 (6H, s), 3.58 (1H, d, J=18.3 Hz), 3.76 (1H, d, J=18.3 Hz),
4.44 (2H, s), 5.29 (1H, d, J=5.0 Hz), 6.01 (1H, dd, J=8.6, 5.0 Hz),
6.97 (1H, s), 7.2-7.6 (1H, m), 9.65 (1H, d, J=5.0 Hz), 12.7 (1H,
s)
[0235] ESI-MS: m/z=849(M+Na)
Preparation 3
[0236] To a solution of 5-amino-1-methylpyrazole (5 g) in ethanol
(50 ml) was added isoamyl nitrite (6.92 ml), and then 20%
hydrochloric acid (drops) was added at 4.degree. C. The reaction
mixture was refluxed for 2 hours and cooled to room temperature. To
the reaction mixture was added diisopropyl ether (50 ml), and the
mixture was stirred for 0.5 hour. The resulting precipitate was
collected by filtration and dried in vacuo to give
5-amino-1-methyl-4-nitrosopyrazole (3.53 g).
[0237] .sup.1H-NMR(DMSO-d.sub.6) .delta. 3.51 (3H, s), 8.07 (2H,
brs), 8.51 (1H, s)
[0238] APCI-MS: m/z=127(M+H)
Preparation 4
[0239] To a solution of 5-amino-1-methyl-4-nitrosopyrazole (1 g) in
water (40 ml) were added concentrated sulfuric acid (0.423 ml) and
palladium on carbon (0.3 g) under a hydrogen atmosphere. The
mixture was stirred overnight. The reaction mixture was filtered,
and the filtrate was evaporated in vacuo. To the residue was added
isopropyl alcohol, and the resulting precipitate was collected by
filtration to give 4,5-diamino-1-methylpyrazole sulfuric acid salt
(1.71 g).
[0240] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.54 (3H, s), 7.19 (1H,
s)
[0241] ESI-MS: m/z=113(M+H)
Preparation 5
[0242] To a suspension of 1,1'-carbonyldiimidazole (9.73 g) in
dehydrated chloroform (72 ml) was added tert-butyl
N-(2-aminoethyl)carbamate (9.61 g) under ice-cooling, and the
mixture was stirred at room temperature for 1 hour. To the reaction
mixture were added N-ethyldiisopropylamine (14.22 g) and
4,5-diamino-1-methylpyrazole sulfuric acid salt (10.51 g), and the
mixture was stirred at 50.degree. C. for 15 hours. The insoluble
materials were removed by filtration. To the filtrate were added
chloroform (200 ml) and 5% aqueous sodium hydrogen carbonate
solution (10.0 ml). The organic layer was separated, and the
aqueous layer was extracted with a mixed solvent of chloroform and
methanol (4:1). The organic layers were combined, dried over
anhydrous magnesium sulfate, filtered and concentrated in vacuo.
The residue was triturated with ethyl acetate and dried in vacuo to
give
5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazol-
e (14.0 g) as a solid.
[0243] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.96-2.98
(2H, m), 3.03-3.07 (2H, m), 3.50 (3H, s), 4.81 (2H, br), 5.92 (1H,
br), 6.80 (1H, br), 6.96 (1H, s), 7.18 (1H, br)
EXAMPLE 1
[0244] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-
-carboxylate (500 mg) in N,N-dimethylformamide (1.0 ml) was added
sodium iodide (100 mg), and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture was added a
solution of
5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazol-
e (216 mg) in N,N-dimethylformamide (1.0 ml). The whole mixture was
stirred at 32.degree. C. for 4 hours. To the resulting reaction
mixture were added ethyl acetate (50 ml) and water (50 ml). The
aqueous layer was separated, and the organic layer was washed with
10% aqueous sodium trifluoroacetate solution and brine, dried over
anhydrous sodium sulfate and filtered. The filtrate was
concentrated to about 5 ml in vacuo. The concentrate was poured
into diusopropyl ether (75 ml), and the resulting precipitate was
collected by filtration and dried in vacuo. To a solution of the
resulting solid in methylene chloride (1.8 ml) were added anisole
(0.6 ml) and trifluoroacetic acid (1.2 ml). The resulting solution
was stirred at room temperature for 4 hours and poured into
diisopropyl ether (80 ml). The resulting precipitate was collected
by filtration and dried in vacuo to give a crude product (380 mg),
which was purified by preparative high-performance liquid
chromatography (HPLC) utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-py-
razolio}methyl-3-cephem-4-carboxylate (21 mg) as an amorphous
solid.
[0245] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
3.12 (2H, t, J=5.7 Hz), 3.22 (1H, d, J=17.9 Hz), 3.49 (1H, d,
J=17.9 Hz) 3.46 (2H, t, J=5.7 Hz), 3.71 (3H, s), 4.95 (1H, d,
J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d, J=4.6 Hz) 5.84
(1H, d, J=4.6 Hz), 7.89 (1H, s)
Preparation 6
[0246] To absolution of
5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazol-
e (597 mg) and triethylamine (243 mg) in methylene chloride (10 ml)
was added triphenylmethyl chloride (669 mg), and the mixture was
stirred at room temperature for 19 hours. The reaction mixture was
washed successively with 10% aqueous citric acid solution, brine
and saturated aqueous sodium hydrogen carbonate solution. The
organic layer was dried over anhydrous magnesium sulfate, filtered
and concentrated in vacuo. The residue was triturated with ethyl
acetate to give
4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methyl-5-triphenylmet-
hylaminopyrazole (640 mg) as a solid.
[0247] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.70 (3H,
s), 2.94-2.96 (2H, m), 2.99-3.01 (2H, m), 5.68 (1H, brs), 5.96 (1H,
br), 6.78 (1H, br), 6.85 (1H, br), 7.00 (1H, s), 7.13-7.15 (6H, m),
7.24-7.28 (9H, m)
Preparation 7
[0248] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(60 g) in toluene (600 ml) were added a solution of sodium iodide
(61.8 g) in 0.05 mol phosphate buffer (pH 7, 500 ml) and
tricaprylylmethylammonium chloride (6.67 g). The mixture was
stirred at room temperature for 15 hours. The reaction mixture was
added to a mixture of ethyl acetate and water. The organic layer
was washed with water and brine, and then dried over magnesium
sulfate. The magnesium sulfate was filtered off, and the filtrate
was evaporated to 255 g under reduced pressure. The concentrate was
poured into diisopropyl ether (2 L). The resulting precipitate was
collected by filtration and dried to give benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(59.4 g).
[0249] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 1.46 (6H,
s), 3.57 and 3.87 (2H, ABq, J=18.0 Hz), 3.76 (3H, s), 4.30 (2H,
bs), 5.25 (1H, d, J=4.9 Hz), 5.94 (1H, dd, J=4.9, 8.7 Hz), 6.95
(1H, bs), 7.15-7.60 (1H, m), 8.17 (2H, bs), 9.53 (1H, d, J=8.7
Hz)
EXAMPLE 2
[0250] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(810 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added a solution of
4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methyl-5-triphenylmet-
hylaminopyrazole (640 mg) in methylene chloride (10 ml). The whole
mixture was stirred at room temperature for 26 hours. To the
resulting reaction mixture were added ethyl acetate (50 ml) and
water (50 ml). The aqueous layer was separated, and the organic
layer was washed with 10% aqueous sodium trifluoroacetate solution
and brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was concentrated to about 5 ml in vacuo. The concentrate
was poured into diisopropyl ether (80 ml), and the resulting
precipitate was collected by filtration and dried in vacuo. To a
solution of the resulting solid in methylene chloride (2.38 ml)
were added anisole (0.79 ml) and trifluoroacetic acid (1.58 ml).
The resulting solution was stirred at room temperature for 4 hours
and poured into diisopropyl ether (80 ml). The resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (635 mg), which was purified by preparative HPLC
utilizing ODS column. The eluate containing a desired product was
concentrated to about 30 ml in vacuo. The concentrate was adjusted
to about pH 3 with concentrated hydrochloric acid and
chromatographed on Diaion.RTM. HP-20 (Mitsubishi Chemical
Corporation) eluting with 30% aqueous 2-propanol. The eluate was
concentrated to about 30 ml in vacuo and lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazol-
io}methyl-3-cephem-4-carboxylate (54 mg) as an amorphous solid.
[0251] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
3.12 (2H, t, J=5.7 Hz), 3.22 (1H, d, J=17.9 Hz), 3.49 (1H, d,
J=17.9 Hz) 3.46 (2H, t, J=5.7 Hz), 3.71 (3H, s), 4.95 (1H, d,
J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d, J=4.6 Hz), 5.84
(1H, d, J=4.6 Hz), 7.89 (1H, s)
Preparation 8
[0252] To a solution of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (120
g) in sulfuric acid (500 ml) was added potassium nitrate (111 g)
under ice-cooling. The mixture was stirred at room temperature for
48 hours. The reaction mixture was added to ice (2.0 kg). The
crystalline residue was collected by filtration and dried in vacuo
to give 7-nitro-2,3-dihydro-1H-imidazo[1,2-b]pyrazole (132 g) as a
solid.
[0253] .sup.1H-NMR (DMSO-d.sub.6) .delta. 4.05-4.09 (2H, m),
4.17-4.20 (2H, m), 7.82 (1H, s), 7.97 (1H, br)
Preparation 9
[0254] A suspension of
7-nitro-2,3-dihydro-1H-imidazo[1,2-b]pyrazole (97 g) in a mixed
solvent of sulfuric acid (34 ml) and water (2000 ml) was treated
with 10% palladium on carbon (10 g) under a hydrogen atmosphere at
room temperature for 4 days. After the catalyst was filtered off,
the filtrate was concentrated in vacuo. The residue was triturated
with methanol and dried in vacuo to give
7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt
(90.2 g) as a solid.
[0255] .sup.1H-NMR (DMSO-d.sub.6) 8 3.87-3.90 (2H, m), 4.07-4.10
(2H, m), 7.28 (1H, s)
Preparation 10
[0256] To a solution of
7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt
(2.22 g) and N-ethyldiisopropylamine (2.84 g) in methylene chloride
(70 ml) was added
N-[3-(tert-butoxycarbonylamino)-propionyloxy]succinimide (3.15 g).
The mixture was stirred at room temperature for 4 hours. The
reaction mixture was washed with saturated aqueous sodium hydrogen
carbonate solution, and the organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The oily
residue was purified by column chromatography on silica gel eluting
with 5% methanol/chloroform to give
7-[3-(tert-butoxycarbonylamino)propionyl]amino-2,3-dihydro-1H-imidazo[1,2-
-b]pyrazole (2.2 g) as a solid.
[0257] .sup.1H-NMR (CDCl.sub.3) .delta. 1.44 (9H, s), 2.52 (2H, t,
J=6.0 Hz), 3.36-3.47 (2H, m), 3.96 (2H, t, J=8.2 Hz), 4.18 (2H, t,
J=8.2 Hz), 5.16 (1H, br), 7.16 (1H, s), 7.90 (1H, br)
EXAMPLE 3
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[7-(3-aminopropionamido)-2,3-dihydro-5-(1H-imidazo[1,2--
b]pyrazolio)]methyl-3-cephem-4-carboxylate
[0258] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
7-[3-(tert-butoxycarbonylamino)propionyl]amino-2,3-dihydro-1H-imidazo[1,2-
-b]pyrazole in the same manner as in Example 1 as an amorphous
solid.
[0259] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (3H, s), 1.52 (3H, s),
2.83 (2H, t, J=6.4 Hz), 3.26 (1H, d, J=17.9 Hz), 3.53 (1H, d,
J=17.9 Hz), 3.31 (2H, t, J=6.4 Hz), 4.15 (2H, t, J=8.7 Hz), 4.33
(1H, q, J=8.7 Hz), 4.42 (1H, q, J=8.7 Hz), 4.95 (1H, d, J=15.1 Hz),
5.03 (1H, d, J=15.1 Hz), 5.25 (1H, d, J=5.0 Hz), 5.84 (1H, d, J=5.0
Hz), 8.06 (1H, s)
Preparation 11
tert-Butyl
[2-(5-amino-1-methyl-1H-pyrazol-4-ylcarbamoyl)ethyl]carbamate
[0260] The title compound was obtained from
4,5-diamino-1-methylpyrazole sulfuric acid salt and
N-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide in the same
manner as in Preparation 10.
[0261] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.35 (2H,
t, J=7.1 Hz) 3.18 (2H, q, J=7.1 Hz), 3.50 (3H, s), 4.90 (2H, s),
6.83 (1H, t, J=7.1 Hz), 7.14 (1H, s), 9.06 (1H, s)
[0262] AP-MS: m/z=283
Preparation 12
tert-Butyl
(2-[1-methyl-5-(tritylamino)-1H-pyrazol-4-ylcarbamoyl]ethyl}car-
bamate
[0263] The title compound was obtained from tert-butyl
[2-(5-amino-1-methyl-1H-pyrazol-4-ylcarbamoyl)ethyl]-carbamate in
the same manner as in Preparation 6.
[0264] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 2.08 (2H,
t, J=7.1 Hz) 2.71 (3H, s), 3.04 (2H, q, J=7.1 Hz), 5.57 (1H, s),
6.72 (1H, t, J=7.1 Hz), 7.1-7.4 (16H, m), 8.25 (1H, s)
EXAMPLE 4
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-methyl-1-pyrazolio]m-
ethyl-3-cephem-4-carboxylate
[0265] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and tert-butyl
{2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-ylcarbamoyl]ethyl}carbamate
in the same manner as in Example 1.
[0266] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 2.89 (2H, t,
J=6.5 Hz), 3.20 and 3.47 (2H, ABq, J=18 Hz), 3.34 (2H, t, J=6.5
Hz), 3.75 (3H, s), 4.99 and 5.21 (2H, ABq, J=16 Hz), 5.25 (1H, d,
J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.02 (1H, s)
[0267] ESI-MS: m/z=674(M+Na)
Preparation 13
[0268] To a solution of
1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine
(22.3 g) in dichioromethane (100 ml) were added
4,5-diamino-1-methylpyrazole sulfuric acid salt (10 g) and
triethylamine (33. 2 ml) at 4.degree. C., and the mixture was
stirred at room temperature overnight. The reaction mixture was
poured into a mixture of ethyl acetate and water. The aqueous layer
was separated, and the organic layer was washed with brine, dried
over anhydrous magnesium sulfate and filtered. The filtrate was
concentrated in vacuo. The concentrate was poured into
acetonitrile, and the resulting precipitate was collected by
filtration and dried in vacuo to give 5-amino-4-[2',3'-bis
(tert-butoxycarbonyl)guanidino]-1-methylpyrazole (11.62 g).
[0269] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 (9H, s), 1.50 (9H,
s), 3.52 (3H, s), 5.14 (2H, s), 7.11 (1H, s), 9.14 (1H, s), 11.5
(1H, s)
[0270] ESI-MS: m/z=353 (M-H)
Preparation 14
4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-methyl-5-(tritylamino)pyrazo-
le
[0271] The title compound was obtained from
5-amino-4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-methylpyrazole
in the same manner -as in Preparation 6.
[0272] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 (9H, s), 1.50 (9H,
s), 2.85 (3H, s), 5.88 (1H, s), 7.17 (1H, s), 7.21 (15H, m), 8.85
(1H, s), 11.2 (1H, s)
[0273] ESI-MS: m/z=597 (M+H)
EXAMPLE 5
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)
methyl-3-cephem-4-carboxylate
[0274] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino) acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and
4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-methyl-S-(tritylamino)pyraz-
ole in the same manner as in Example 1.
[0275] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.53 (6H, s), 3.25 and
3.57 (2H, ABq, J=18 Hz), 3.75 (3H, s), 5.00 and 5.18 (2H, ABq, J=15
Hz), 5.27 (1H, d, J=4.9 Hz), 5.85 (1H, d, J=4.9 Hz), 8.05 (1H,
s)
Preparation 15
[0276] To a suspension of 4,5-diamino-1-methylpyrazole sulfuric
acid salt (305 g) in tetrahydrofuran (3.05 L) was added tert-butyl
2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethylcarbamate (415 g) under
ice-cooling. To the mixture was added diisopropylethylamine (556
ml) dropwise at a temperature below 10.degree. C. The mixture was
stirred at room temperature overnight. To the resulting solution
were added brine and saturated aqueous sodium hydrogen carbonate
solution, and the mixture was extracted with ethyl acetate (3.0 L).
The aqueous layer was extracted with tetrahydrofuran/ethyl
acetate=1/1 (3.0 L) twice. The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated in vacuo.
The residue was triturated with diisopropyl ether (1.0 L).and dried
in vacuo to give tert-butyl
2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate
(307 g).
[0277] IR (KBr) 3440, 3349, 1670, 1631, 1525, 1276, 1163, 1074,
1014, 860, 791 cm.sup.-1
[0278] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 3.44 (3H,
s), 3.64 (2H, d, J=5.9 Hz), 4.91 (2H, brs), 6.97 (1H, t, J=5.9 Hz),
7.15 (1H, s), 9.09 (1H, brs)
Preparation 16
[0279] To a solution of tert-butyl
2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate
(307 g) in N,N-dimethylformamide (1.5 L) was added triphenylmethyl
chloride (334 g). To the mixture was added triethylamine (318 ml)
dropwise. The mixture was stirred at room temperature for 1 hour.
The reaction mixture was dissolved in ethyl acetate. The solution
was washed successively with water, 10% aqueous citric acid
solution, water and brine. The extract was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The residue
was triturated with acetonitrile (1.5 L) and dried in vacuo to give
tert-butyl
2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoethylcarbamate
(468 g).
[0280] IR (KBr) 3336, 3280, 1724, 1683, 1599, 1234, 939, 704
cm.sup.-1
[0281] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.73 (3H,
s), 3.38 (2H, d, J=5.8 Hz), 5.58 (1H, s), 6.94 (1H, t, J=5.8 Hz),
7.11-7.35 (15H, m), 7.21 (1H, s), 8.31 (1H, s)
[0282] ESI-MS: m/z=512.3(M+H.sup.+)
EXAMPLE 6
[0283] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(489 g) in N,N-dimethylformamide (1.4 L) was added sodium iodide
(102 g). After stirring at room temperature for 1 hour, tert-butyl
2-([l-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoethylcarbamate
(383 g) was added to the mixture. Stirring was continued at
37.degree. C. for 24 hours. The resulting mixture was poured into
water and extracted with ethyl acetate. The organic layer was
washed successively with water, 10% aqueous sodium thiosulfate
solution, brine and 10% aqueous sodium trifluoroacetate solution,
dried over magnesium sulfate, filtered and evaporated in vacuo. The
residue was dissolved in ethyl acetate (3.5 L), and the solution
was dropwise added to diisopropyl ether (36 L). The precipitate was
collected by filtration. The filter cake was washed with
diisopropyl ether and dried in vacuo.
[0284] The obtained solid (700 g) was dissolved in dichloromethane
(1.4 L), and to the solution were added anisole (700 ml) and
trifluoroacetic acid (2.1 L) successively. After stirring at room
temperature for 4 hours, the reaction mixture was poured into
diisopropyl ether (30 L). The precipitate was collected by
filtration. The obtained solid was washed with diisopropyl ether
and dried in vacuo. The crude product was dissolved in water (3.5
L), and the pH of the solution was adjusted to -7.0 with 28%
aqueous ammonia solution. The insoluble material was filtered off,
and the pH of the filtrate was adjusted to 1 with concentrated
hydrochloric acid. The insoluble material was filtered off again.
The filtrate was chromatographed on Diaion.RTM. HP-20 eluting with
20% aqueous 2-propanol. The eluate was concentrated to about 3.0 L
in vacuo, and 2.0M sulfuric acid (102 ml) was added to the
concentrate. The mixture was lyophilized to give the crude
product.
[0285] The crude product was purified by preparative HPLC (pH 7.0
phosphate buffer and acetonitrile), and the eluate containing a
desired product was concentrated to about 6 L in vacuo. The
concentrate was adjusted to about pH 1 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20 eluting
with 20% aqueous 2-propanol. The eluate was concentrated to about
550 ml in vacuo, and 2.0M sulfuric acid (54.5 ml) was added to the
concentrate. To the mixture was added dropwise acetonitrile (880
ml), and the mixture was stirred at room temperature overnight. To
the mixture was added acetonitrile (200 ml), and the mixture was
stirred at room temperature for 2 hours. The resulting white
crystals were collected by filtration, washed with 25% aqueous
acetonitrile and dried under reduced pressure to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-methyl-1-pyrazolio]met-
hyl-3-cephem-4-carboxylic acid hydrogen sulfate (72.5 g).
[0286] IR (KBr) 1778, 1700, 1653, 1525, 1149, 1111, 617
cm.sup.-1
[0287] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 3.22 and 3.45
(2H, ABq, J=17.8 Hz), 3.73 (3H, s), 4.03 (2H, s), 5.05 and 5.27
(2H, ABq, J=15.8 Hz), 5.25 (1H, d, J=4.8 Hz), 5.87 (1H, d, J=4.8
Hz), 8.09 (1H, s)
[0288] ESI-MS: m/z=638.2(M+H.sup.+)
EXAMPLE 7
[0289] A solution of
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazol-
io)methyl-3-cephem-4-carboxylate (36 g) in water was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 1.5 L in vacuo. The
concentrate was adjusted to about pH 1 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20 (6 L)
eluting with 20% aqueous 2-propanol. The eluate was concentrated to
about 800 ml in vacuo, and 2M sulfuric acid (17 ml) was added. The
resulting solution was lyophilized to give a sulfuric acid salt as
an amorphous powder (23.6 g).
[0290] The powder was dissolved in water (71 ml) and ethanol (57
ml). After addition of seed crystals (310 mg), which resulted in
the precipitation of white solid, the mixture was stirred for 1
hour. A mixture of ethanol (47 ml) and water (37 ml) was added over
30 minutes, and ethanol (33 ml) was added over 20 minutes. Then the
slurry was stirred for an additional 1.5 hour. The precipitate was
collected by filtration, washed with ethanol/water (60 ml/20 ml)
and ethanol (60 ml) and dried to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazol-
io)methyl-3-cephem-4-carboxylic acid hydrogen sulfate as crystals
(17.3 g).
[0291] IR (KBr) 3353, 3183, 1778, 1652, 1558, 1403, 1321, 1143,
1118, 997, 619. cm.sup.-1
[0292] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 3.10-3.55 (6H,
m), 3.71 (3H, s), 5.02 and 5.23 (2H, ABq, J=16.7 Hz), 5.25 (1H, d,
J=4.9 Hz), 5.87 (1H, d, J=4.9 Hz), 7.91 (1H, s)
[0293] ESI-MS: m/z=667(M+H.sup.+)
[0294] X-ray powder diffraction analysis (by Rigaku X-ray
Diffraction system MultiFlex) TABLE-US-00002 2.theta. intensity 8.0
1286 12.7 586 13.8 423 16.1 618 18.9 520 20.4 748 21.5 667 22.4
1058 23.3 944 24.0 618 25.5 813 26.7 472 27.9 537 28.5 455 31.3 390
X-ray: Cu/40 kV/30 mA
Preparation 17
5-Amino-1-ethyl-4-nitrosopyrazole
[0295] The title compound was obtained from 5-amino-1-ethylpyrazole
in the same manner as in Preparation 3.
[0296] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.21 (3H, t, J=7.1 Hz),
3.93 (2H, q, J=7.1 Hz), 7.04 and 8.53 (1H, s), 8.10 and 8.15 (1H,
brs)
[0297] APCI-MS: m/z=141(M+H).sup.+
Preparation 18
4,5-Diamino-1-ethylpyrazole sulfuric acid salt
[0298] The title compound was obtained from
5-amino-1-ethyl-4-nitrosopyrazole in the same manner as in
Preparation 4.
[0299] .sup.1H-NMR (D.sub.2O) .delta. 1.36 (3H, t, J=7.3 Hz), 4.10
(2H, q, J=7.3 Hz), 7.77 (1H, s)
[0300] ESI-MS: m/z=127(M+H).sup.+
Preparation 19
5-Amino-4-[3-(tert-butoxycarbonylamino)-propionylamino]-1-ethylpyrazole
[0301] The title compound was obtained from
4,5-diamino-1-ethylpyrazole sulfuric acid salt in the same manner
as in Preparation 15.
[0302] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.24 (3H, t, J=7.2 Hz),
1.37 (9H, s) 2.35 (2H, t, J=7.1 Hz), 3.18 (2H, dt, J=7.1, 7.1 Hz),
3.85 (q, J=7.2 Hz), 4.88 (2H, brs), 6.75-6.90 (1H, m), 7.17 (1H,
s), 9.05 (1H, brs)
[0303] APCI-MS: m/z=298(M+H).sup.+
Preparation 20
4-[3-(tert-Butoxycarbonylamino)propionylamino]-1-ethyl-5-triphenylmethylam-
inopyrazole
[0304] The title compound was obtained from
5-amino-4-[3-(tert-butoxycarbonylamino)propionylamino]-1-ethylpyrazole
in the same manner as in Preparation 16.
[0305] .sup.1H-NMR (DMSO-d.sub.6) .delta. 0.88 (3H, t, J=7.2 Hz),
1.39 (9H, s) 2.02 (2H, t, J=7.1 Hz), 2.95-3.20 (4H, m), 5.59 (1H,
brs), 6.60-6.75 (1H, m), 7.10-7.35 (16H, m), 8.04 (1H, brs)
[0306] ESI-MS: m/z=540(M+H).sup.+, 562(M+Na).sup.+
EXAMPLE 8
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-(3-aminopropionylamino)-2-ethyl-1-pyrazoliol-
methyl-3-cephem-4-carboxylate
[0307] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and
4-[3-(tert-butoxycarbonylamino)propionylamino]-1-ethyl-5-triphenylmethyla-
minopyrazole in the same manner as in Example 1.
[0308] IR (KBr) 3415, 1763, 1658, 1598, 1529, 1402, 1361
cm.sup.-1
[0309] .sup.1H-NMR (D.sub.2O) .delta. 1.33 (3H, t, J=7.2 Hz), 1.53
(6H, s), 2.89 (2H, t, J=6.5 Hz), 3.17 and 3.49 (2H, ABq, J=17.7
Hz), 3.34 (2H, t, J=6.5 Hz), 4.28 (2H, q, J=7.2 Hz), 5.05 and 5.16
(2H, ABq, J=15.4 Hz), 5.26 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8
Hz), 8.03 (1H, s)
Preparation 21
tert-Butyl
2-[(5-amino-1-ethyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate
[0310] The title compound was obtained from
4,5-diamino-1-ethylpyrazole sulfuric acid salt in the same manner
as in Preparation 15.
[0311] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.21 (3H, t, J=7.2 Hz),
1.39 (9H, s), 3.64 (2H, d, J=6.0 Hz), 3.86 (2H, d, J=7.2 Hz), 4.88
(2H, brs), 6.90-7.00 (1H, m), 7.17 (1H, s), 9.06 (1H, brs)
[0312] ESI-MS: m/z=284(M+H).sup.+, 306(M+Na).sup.+
Preparation 22
tert-Butyl
2-{[1-ethyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethylca-
rbamate
[0313] The title compound was obtained from tert-butyl
2-[(5-amino-1-ethyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate in
the same manner as in Preparation 16.
[0314] .sup.1H-NMR (DMSO-d.sub.6) .delta. 0.88 (3H, t, J=7.2 Hz),
1.38 (9H, s) 3.16 (2H, q, J=7.2 Hz), 3.31 (2H, d), 5.59 (1H, brs),
6.80-6.95 (1H, m), 7.10-7.40 (16H, m), 8.03 (1H, brs)
[0315] ESI-MS: m/z=526(M+H).sup.+, 548(M+Na).sup.+
EXAMPLE 9
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-ethyl-1-pyrazolio]methy-
l-3-cephem-4-carboxylate
[0316] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and tert-butyl
2-{[1-ethyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethylcarbamate
in the same manner as in Example 1.
[0317] IR (KBr) 3444, 1761, 1635, 1626, 1446, 1406 cm.sup.-1
[0318] .sup.1H-NMR (D.sub.2O) .delta. 1.33 (3H, t, J=7.2 Hz), 1.53
(6H, s), 2.89 (2H, t, J=6.5 Hz), 3.17 and 3.49 (2H, ABq, J=17.7
Hz), 4.00 (2H, s), 4.28 (2H, q, J=7.2 Hz), 5.06 and 5.17 (2H, ABq,
J=15.4 Hz), 5.27 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.07
(1H, s)
Preparation 23
5-Amino-4-[2',3'-bis(tert-butoxycarbonyl)-guanidino]-1-ethylpyrazole
[0319] The title compound was obtained from
1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine
and 4,5-diamino-1-ethylpyrazole sulfuric acid salt in the same
manner as in Preparation 13.
[0320] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.22 (3H, t, J=7.1 Hz),
1.37 (9H, s), 1.50 (9H, s), 3.88 (2H, d, J=7.1 Hz), 5.12 (2H, brs),
7.14 (1H, s), 9.16 (1H, brs), 11.51 (1H, brs)
[0321] ESI-MS: m/z=369(M+H).sup.+
Preparation 24
4-[2',3'-Bis(tert-butoxycarbonyl)guanidino]-1-ethyl-5-triphenylmethylamino-
pyrazole
[0322] The title compound was obtained from
5-amino-4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-ethylpyrazole
in the same manner as in Preparation 16.
[0323] .sup.1H-NMR (DMSO-d.sub.6) .delta. 0.86 (3H, t, J=7.1 Hz),
1.38 (9H, s) 1.49 (9H,s), 5.85 (1H, brs), 7.10-7.30 (16H, m), 8.80
(1H, brs), 11.14 (1H, brs)
[0324] ESI-MS: m/z=611(M+H).sup.+, 633(M+Na).sup.+
EXAMPLE 10
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-2-ethyl-4-guanidino-1-pyrazolio]methyl-3-cephe-
m-4-carboxylate
[0325] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and
4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-ethyl-5-triphenylmethylamin-
opyrazole in the same manner as in Example 1.
[0326] IR (KBr) 3437, 1760, 1658, 1625, 1406, 1065 cm.sup.-1
[0327] .sup.1H-NMR (D.sub.2O) .delta. 1.35 (3H, t, J=7.3 Hz), 1.53
(6H, s), 3.26 and 3.61 (2H, ABq, J=17.8 Hz), 4.29 (2H, q, J=7.3
Hz), 5.06 and 5.17 (2H, ABq, J=15.7 Hz), 5.29 (1H, d, J=4.8 Hz),
5.85 (1H, d, J=4.8 Hz), 8.06 (1H, s)
EXAMPLE 11
[0328] To a suspension of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(500 g) in N,N-dimethylformamide (2.5 L) was added
4-[2',3'-bis(tert-butoxycarbonyl)guanidino]-1-methyl-5-triphenylmethylami-
nopyrazole (419 g) and the mixture was stirred at room temperature
for 16 hours. The reaction mixture was added to a mixture of ethyl
acetate and water. The organic layer was washed with water, brine
and 10% aqueous sodium trifluoroacetate solution and then dried
over magnesium sulfate. The magnesium sulfate was filtered off, and
the-filtrate was evaporated to 3.3 kg under reduced pressure. The
concentrate was poured into diisopropyl ether (33 L), and the
resulting precipitate was collected by filtration and dried in
vacuo.
[0329] To a solution of the resulting solid in methylene chloride
(1500 ml) were added anisole (500 ml) and trifluoroacetic acid
(1500 ml). The resulting solution was stirred at room temperature
for 4 hours and poured into diisopropyl ether. The resulting
precipitate was collected by filtration and dried in vacuo. The
crude product was dissolved in water (3.5 L), and the pH of the
solution was adjusted to 7.0 with 28% aqueous ammonia solution. The
insoluble material was filtered off, and the pH of the filtrate was
adjusted to 1 with concentrated hydrochloric acid. The insoluble
material was filtered off, again. The filtrate was chromatographed
on Diaion.RTM. HP-20 eluting with 20% aqueous 2-propanol. The
eluate was concentrated to about 3.0 L in vacuo. To the concentrate
was added 2.0M sulfuric acid (150 ml), and the mixture was
lyophilized to give the crude product. The crude product was
purified with preparative HPLC utilizing ODS column (pH. 7.0
phosphate buffer and acetonitrile). The eluate containing a desired
product was concentrated to about 6 L in vacuo. The concentrate was
adjusted to about pH 1 with concentrated hydrochloric acid and
chromatographed on Diaion.RTM. HP-20 eluting with 20% aqueous
2-propanol. The eluate was concentrated to about 1.5 L in vacuo. To
the concentrate was added 2.0M sulfuric acid (60 ml), and the
mixture was lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)methyl-3-cep-
hem-4-carboxylic acid hydrogen sulfate (48.5 g).
[0330] IR (KBr) 1776, 1714, 1677, 1651, 1402, 1112 cm.sup.-1
[0331] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 3.28 and 3.58
(2H, ABq, J=17.8 Hz), 3.74 (3H, s), 5.15 and 5.23 (2H, ABq, J=15.7
Hz), 5.27 (1H, d, J=4.8 Hz), 5.88 (1H, d, J=4.8 Hz), 8.07 (1H,
s)
[0332] ESI-MS: m/z=623.2(M+H.sup.+)
Preparation 25
[0333] To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole
sulfuric acid salt (2.4 g) in methylene chloride (40 ml) were added
N-ethyldiisopropylamine (2.1 ml) and
N-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide (2.3 g)
under ice-cooling, and the mixture was stirred at room temperature
for 6 hours. To the reaction mixture were added brine (40 ml) and
saturated aqueous sodium hydrogen carbonate solution (20 ml), and
the mixture was extracted with a mixture of ethyl acetate and
2-propanol (3:1, 60 ml). The organic layer was dried over anhydrous
sodium sulfate, filtered and concentrated in vacuo. The residue was
triturated with diethyl ether to give
5-amino-4-[3-(tert-butoxycarbonylamino)propionyl]-amino-1-(2-hydroxyethyl-
)pyrazole (1.65 g) as a solid.
[0334] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.35 (2H,
t, J=7.3 Hz) 3.16-3.20 (2H, m), 3.62-3.65 (2H, m), 3.90 (2H, t,
J=6.0 Hz), 4.85 (2H, brs), 4.92 (1H, t, J=5.0 Hz), 6.84 (1H, t,
J=5.5 Hz), 7.20 (1H, s), 9.09 (1H, brs)
EXAMPLE 12
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-(2-hydroxyethyl)-1-p-
yrazoliolmethyl-3-cephem-4-carboxylate
[0335] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
5-amino-4-[3-(tert-butoxycarbonylamino)propionyl]amino-1-(2-hydroxyethyl)-
pyrazole in the same manner as in Example 1 as an amorphous
solid.
[0336] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (6H, s), 2.88 (2H, t,
J=6.4 Hz), 3.15 (1H, d, J=17.9 Hz), 3.48 (1H, d, J=17.9 Hz), 3.32
(2H, t, J=6.4 Hz), 3.88 (2H, t, J=4.8 Hz), 4.39 (1H, dt, J=16.5 Hz,
4.8 Hz), 4.42 (1H, dt, J=16.5, 4.8 Hz), 5.06 (1H, d, J=15.1 Hz),
5.11 (1H, d, J=15.1 Hz), 5.25 (1H, d, J=5.0 Hz), 5.83 (1H, d, J=5.0
Hz), 8.05 (1H, s)
Preparation 26
[0337] To a solution of
4-formyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (1.51 g) in
sulfuric acid (7.5 ml) was added potassium nitrate (111 g) under
ice-cooling. The mixture was stirred at room temperature for 17
hours. The reaction mixture was added to ice (100 g). The
crystalline residue was collected by filtration and dried in vacuo
to give 3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (0.63
g) as a solid.
[0338] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.00-2.05 (2H, m),
3.30-3.36 (2H, m) 3.99 (2H, t, J=6.0 Hz), 7.85 (1H, s), 7.89 (1H,
s)
Preparation 27
[0339] A solution of
3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (1.68 g) in a
mixture of sulfuric acid (0.6 ml), acetic acid (100 ml) and water
(10 ml) was treated with 10% palladium on carbon (0.5 g) under a
hydrogen atmosphere at room temperature for 6 days. After the
catalyst was filtered off, the filtrate was concentrated in vacuo.
The residue was triturated with ethanol and dried in vacuo to give
3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid
salt (2.3 g) as a solid.
[0340] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.97-2.01 (2H, m), 3.22
(2H, t, J=5.0 Hz), 3.98 (2H, t, J=6.0 Hz), 7.22 (1H, s)
Preparation 28
[0341] To a solution of
3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid
salt (2.96 g) and N-ethyldiisopropylamine (3.88 g) in methylene
chloride (70 ml) was added
1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine
(3.91 g). The mixture was stirred at room temperature for 150
minutes. The reaction mixture was washed with saturated aqueous
sodium hydrogen carbonate solution. The organic layer was dried
over anhydrous magnesium sulfate, filtered and concentrated in
vacuo. The residue was purified by column chromatography on silica
gel eluting with 2% methanol/chloroform to give
3-[2,3-bis(tert-butoxycarbonyl)guanidino]-4,5,6,7-tetrahydropyraz-
olo[1,5-a]pyrimidine (3.4 g) as a solid.
[0342] .sup.1H-NMR (CDCl.sub.3) .delta. 1.48 (9H, s), 1.52 (9H, s),
2.12-2.14 (2H, m), 3.33-3.37 (2H, m), 4.08 (2H, t, J=6.0 Hz), 6.17
(1H, brs), 7.16 (1H, s), 9.87 (1H, brs), 11.39 (1H, brs)
EXAMPLE 13
[0343] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-
-carboxylate (1.0 g) in N,N-dimethylformamide (2.0 ml) was added
sodium iodide (181 mg), and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture were added
3-[2,3-bis(tert-butoxycarbonyl)guanidino]-4,5,6,7-tetrahydropyrazolo[1,5--
a]pyrimidine (571 mg) and methylene chloride (2.0 ml). The whole
mixture was stirred at room temperature for 7 hours. To the
reaction mixture were added ethyl acetate (100 ml) and water (50
ml). The aqueous layer was separated, and the organic layer was
washed with 10% aqueous sodium trifluoroacetate solution and brine,
dried over sodium sulfate and filtered. The filtrate was
concentrated to about 5 ml in vacuo. The concentrate was poured
into diisopropyl ether (150 ml), and the resulting precipitate was
collected by filtration and dried in vacuo.
[0344] To a solution of the resulting solid in methylene chloride
(3.0 ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0
ml), and the mixture was stirred at room temperature for 4 hours.
The reaction mixture was poured into diisopropyl ether (150 ml),
and the resulting precipitate was collected by filtration and dried
in vacuo to give a crude product (570 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-[3-guanidino-4,5,6,7-tetrahydro-1-pyrazolo[1,5-a]-
pyrimidinio]methyl-3-cephem-4-carboxylate (51 mg) as an amorphous
solid.
[0345] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
2.05-2.25 (2H, m), 3.26 (1H, d, J=17.4 Hz), 3.56 (1H, d, J=17.4
Hz), 3.30-3.45 (2H, m), 4.15 (2H, t, J=6.0 Hz), 4.93 (1H, d, J=15.6
Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d, J=4.8 Hz), 5.84 (1H, d,
J=4.8 Hz), 7.99 (1H, s)
Preparation 29
[0346] To a solution of
7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt
(4.4 g), 4-(dimethylamino)pyridine (244 mg) and triethylamine (8.10
g) in chloroform (45 ml) was added
1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine
(10.18 g). The mixture was stirred at room temperature for 2 hours.
The reaction mixture was washed successively with 10% aqueous
citric acid solution, brine and saturated aqueous sodium hydrogen
carbonate solution. The organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The residue
was triturated with diisopropyl ether to give
7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[-
1,2-b]pyrazole (4.6 g) as a solid.
[0347] .sup.1H-NMR (CDCl.sub.3) .delta. 1.49 (9H, s), 1.52 (9H, s),
3.97-4.01 (2H, m), 4.21 (2H, t, J=7.8 Hz), 5.30 (1H, brs), 7.19
(1H, s), 9.86 (1H, brs), 11.32 (1H, brs)
EXAMPLE 14
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3.-[7-guanidino-2,3-dihydro-5-(1H-imidazo[1,2-blpyrazolio-
)]methyl-3-cephem-4-carboxylate
[0348] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[1,2-b]py-
razole in the same manner as in Example 13 as an amorphous
solid.
[0349] 1H-NMR (D.sub.2O) .delta. 1.51 (3H, s), 1.52 (3H, s), 3.35
(1H, d, J=17.9 Hz), 3.61 (1H, d, J=17.9 Hz), 4.19 (2H, t, J=8.7
Hz), 4.37 (1H, q, J=8.7 Hz), 4.47 (1H, q, J=8.7 Hz), 5.00 (1H, d,
J=15.1 Hz), 5.04 (1H, d, J=15.1 Hz), 5.26 (1H, d, J=4.8 Hz), 5.84
(1H, d, J=4.8 Hz), 8.13 (1H, s)
Preparation 30
[0350] To a solution of 5-amino-1-(2-hydroxyethyl)pyrazole (6.35 g)
in a mixed solvent of ethanol (25 ml) and concentrated hydrochloric
acid (0.035 ml) was added dropwise isoamyl nitrite (7.03 g). The
mixture was stirred at room temperature for 17 hours. The
crystalline residue was collected by filtration and dried in vacuo
to give 5-amino-1-(2-hydroxyethyl)-4-nitrosopyrazole (4.0 g) as a
solid.
[0351] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.68 (2H, t, J=5.5 Hz),
3.94 (2H, t, J=5.5 Hz), 4.89 (1H, br), 8.06(2H, br), 8.53 (1H,
s)
Preparation 31
[0352] A solution of 5-amino-1-(2-hydroxyethyl)-4-nitrosopyrazole
(97 g) in a mixed solvent of sulfuric acid (34 ml) and water (2000
ml) was treated with 10% palladium on carbon (10 g) under a
hydrogen atmosphere at room temperature for 4 days. After the
catalyst was filtered off, the filtrate was concentrated in vacuo.
The residue was triturated with methanol and dried in vacuo to give
4,5-diamino-1-(2-hydroxyethyl)pyrazole sulfuric acid salt (90.2 g)
as a solid.
[0353] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.66 (2H, t, J=5.5 Hz),
3.95 (2H, t, J=5.5 Hz), 7.25 (1H, s)
Preparation 32
[0354] To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole
sulfuric acid salt (50.0 g) in chloroform (500 ml) were added
4-(dimethylamino)pyridine (2.54 g), triethylamine (116 ml) and
1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine
(106 g). The mixture was stirred under reflux for 2 hours. After
cooling on an ice bath, the reaction mixture was washed
successively with water, 4% aqueous citric acid solution, water and
aqueous sodium hydrogen carbonate solution. The organic layer was
dried over sodium sulfate, filtered and concentrated in vacuo. The
residue was triturated with a mixed solvent of ethyl acetate (50
ml) and diethyl ether (200 ml) to give
5-amino-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-(2-hydroxyethyl)pyraz-
ole (50 g) as a solid.
[0355] .sup.1H-NMR (CDCl.sub.3) .delta. 1.47 (9H, s), 1.53 (9H, s),
3.28 (1H, br) 4.02-4.05 (4H, m), 4.65 (2H, br), 7.22 (1H, s), 9.85
(1H, br), 11.55 (1H, br)
EXAMPLE 15
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-guanidino-2-(2-hydroxyethyl)-1-pyrazolio]met-
hyl-3-cephem-4-carboxylate
[0356] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
5-amino-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-(2-hydroxyethyl)pyraz-
ole in the same manner as in Example 13 as an amorphous solid.
[0357] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 3.21 (1H, d,
J=17.9 Hz), 3.59 (1H, d, J=17.9 Hz), 3.90 (2H, t, J=4.8 Hz),
4.35-4.50 (2H, m), 5.07 (1H, d, J=14.9 Hz), 5.11 (1H, d, J=14.9
Hz), 5.28 (1H, d, J=5.0 Hz), 5.84 (1H, d, J=5.0 Hz), 8.09 (1H,
s)
Preparation 33
[0358] To a solution of
7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[1,2-b]py-
razole (1.83 g) in pyridine (10 ml) was added triphenylmethyl
chloride (1.67 g). The mixture was stirred at 50.degree. C. for 5
hours. After cooling, chloroform (50 ml) was added to the reaction
mixture, and the mixture was washed successively with 10% aqueous
citric acid solution, brine and saturated aqueous sodium hydrogen
carbonate solution. The organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The residue
was purified by column chromatography on silica gel eluting with 2%
methanol/chloroform to give
7-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-triphenylmethyl-2,3-dihydro-1-
H-imidazo[1,2-b]pyrazole (1.57 g) as a solid.
[0359] .sup.1H-NMR (CDCl.sub.3) .delta. 1.47* (9H, s), 1.48 (9H,
s), 3.50 (2H, t, J=7.8 Hz), 3.92 (2H, t, J=7.8 Hz), 7.07-7.26 (1H,
m) 7.53-7.54 (6H, m), 8.34 (1H, brs), 11.12 (1H, brs)
EXAMPLE 16
[0360] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(819 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added
7-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-triphenylmethyl-2,3-dihydro-1-
H-imidazo[1,2-b]pyrazole (730 mg). The whole mixture was stirred at
room temperature for 6 hours. To the resulting reaction mixture
were added ethyl acetate (100 ml) and water (50 ml). The aqueous
layer was separated, and the organic layer was washed with 10%
aqueous sodium trifluoroacetate solution, 10% aqueous sodium
thiosulfate solution and brine, dried over sodium sulfate and
filtered. The filtrate was concentrated to about 5 ml in vacuo. The
concentrate was poured into diisopropyl ether (120 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo.
[0361] To a solution of the resulting solid in methylene chloride
(2.0 ml) were added anisole (0.67 ml) and trifluoroacetic acid
(1.34 ml), and the mixture was stirred at room temperature for 4
hours. The reaction mixture was poured into diisopropyl ether (120
ml). The resulting precipitate was collected by filtration and
dried in vacuo to give a crude product (430 mg), which was purified
by preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-[7-guanidino-2,3-dihydro-5-(1H-imidazo[1,2-b]pyra-
zolio)]methyl-3-cephem-4-carboxylate (20.4 mg) as an amorphous
solid.
[0362] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (3H, s), 1.52 (3H, s),
3.35 (1H, d, J=17.9 Hz), 3.61 (1H, d, J=17.9 Hz), 4.19 (2H, t,
J=8.7 Hz), 4.37 (1H, q, J=8.7 Hz), 4.47 (1H, q, J=8.7 Hz), 5.00
(1H, d, J=15.1 Hz), 5.04 (1H, d, J=15.1 Hz), 5.26 (1H, d, J=4.8
Hz), 5.84 (1H, d, J=4.8 Hz), 8.13 (1H, s)
Preparation 34
[0363] To a suspension of1,1'-carbonyldiimidazole (1.94 g) in
methylene chloride (20 ml) was added tert-butyl
N-(3-aminopropyl)carbamate (2.30 g), and the mixture was stirred at
room temperature for 1 hour. To the reaction mixture were added
N-ethyldiisopropylamine (2.56 g) and 4,5-diamino-1-methylpyrazole
sulfuric acid salt (2.10 g), and the mixture was stirred at
30.degree. C. for 3 days. The reaction mixture was concentrated in
vacuo. The residue was purified by column chromatography on silica
gel eluting with 6% methanol/chloroform to give
5-amino-4-(3-(3-[(tert-butoxycarbonyl)amino]propyl)ureido)-1-methylpyrazo-
le (1.75 g) as a solid.
[0364] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 (9H, s), 1.43-1.49
(2H, m), 2.89-2.93 (2H, m), 2.98-3.01 (2H, m), 3.50 (3H, s), 4.79
(2H, br), 5.85 (1H, br), 6.77 (1H, br), 6.96 (1H, s), 7.12 (1H,
br)
EXAMPLE 17
[0365] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-
-carboxylate (1.0 g) in N,N-dimethylformamide (2.0 ml) was added
sodium iodide (199 mg), and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture was added
5-amino-4-(3-(3-[(tert-butoxycarbonyl)amino]propyl)ureido)-1-methylpyrazo-
le (415 mg) and the whole mixture was stirred at 32.degree. C. for
24 hours. To the resulting reaction mixture were added ethyl
acetate (50 ml) and water (50 ml). The aqueous layer was separated,
and the organic layer was washed with 10% aqueous sodium
trifluoroacetate solution and brine, dried over anhydrous sodium
sulfate and filtered. The filtrate was concentrated to about 5 ml
in vacuo. The concentrate was poured into diisopropyl ether (100
ml), and the resulting precipitate was collected by filtration and
dried in vacuo. To a solution of the resulting solid in methylene
chloride (3.6 ml) were added anisole (1.2 ml) and trifluoroacetic
acid (2.4 ml). The resulting solution was stirred at room
temperature for 4 hours and poured into diisopropyl ether (100 ml).
The resulting precipitate was collected by filtration and dried in
vacuo to give a crude product (939 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate-was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-(3-amino-4-[3-(3-aminopropyl)ureido]-2-methyl-1-pyrazo-
liomethyl-3-cephem-4-carboxylate (53 mg) as an amorphous solid.
[0366] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
1.85-1.88 (2H, m), 3.03 (2H, t, J=8 Hz), 3.22(2H, t, J=l8 Hz), 3.26
(2H, t, J=7 Hz), 3.49 (1H, d, J=18 Hz), 3.72 (3H, s), 4.96 (1H, d,
J=15 Hz), 5.16 (1H, d, J=15 Hz), 5.25 (1H, d, J=5 Hz), 5.84 (1H, d,
J=5 Hz), 7.88 (1H, s)
Preparation 35
[0367] To a suspension of 1,11-carbonyldiimidazole (973 mg) in
methylene chloride (10 ml) was added tert-butyl
N-(2-aminoethyl)carbamate (1.11 g) under ice-cooling, and the
mixture was stirred at room temperature for 2 hours. To the
reaction mixture were added N-ethyldiisopropylamine (1.28 g) and
3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid
salt (1.18 g), and the mixture was stirred at 50.degree. C. for 6
hours. The reaction mixture was washed with brine. The organic
layer was dried over anhydrous magnesium sulfate, filtered and
concentrated in vacuo. The residue was purified by column
chromatography on silica gel eluting with 5% methanol/chloroform to
give
3-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-4,5,6,7-tetrahydropyraz-
olo[1,5-a]pyrimidine (150 mg) as a solid.
[0368] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 2.-11-2.16
(2H, m), 3.22-3.35 (6H, m), 4.09 (2H, t, J=7 Hz), 4.69 (1H, br),
5.14 (2H, br), 5.69 (1H, br), 7.17 (1H, s)
EXAMPLE 18
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-(3-[3-(2-aminoethyl)ureido]-4,5,6,7-tetrahydro-1-pyrazo-
lo[1,5-a]pyrimidinio)methyl-3-cephem-4-carboxylate
[0369] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
3-(3-(2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-4,5,6,7-tetrahydropyraz-
olo[1,5-a]pyrimidine in the same manner as in Example 17 as an
amorphous solid.
[0370] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
2.09-2.21 (2H, m), 3.13 (2H, t, J=6 Hz), 3.24 (1H, d, J=18 Hz),
3.35-3.52 (5H, m), 4.12-4.15 (2H, m), 4.88 (1H, d, J=16 Hz), 5.13
(1H, d, J=16 Hz), 5.25 (1H, d, J=5 Hz), 5.85 (1H, d, J=5 Hz), 7.83
(1H, s)
Preparation 36
[0371] To a suspension of 1,1'-carbonyldiimidazole (973 mg) in
methylene chloride (10 ml) was added
O-[2-(tert-butoxycarbonylamino)ethyl]hydroxylamine (1.11 g) under
ice-cooling, and the mixture was stirred at room temperature for 2
hours. To the reaction mixture were added N-ethyldiisopropylamine
(1.28 g) and 4,5-diamino-1-methylpyrazole sulfuric acid salt (1.05
g), and the mixture was stirred under reflux for 4 hours. The
reaction mixture was washed with brine. The organic layer was dried
over anhydrous magnesium sulfate, filtered and concentrated in
vacuo. The residue was purified by column chromatography on silica
gel eluting with 10% methanol/chloroform to give
5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethoxy}ureido)-1-methylpyrazo-
le (255 mg) as a solid.
[0372] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 3.19-3.20
(2H, m), 3.51 (3H, s), 3.72 (2H, t, J=6 Hz), 4.86 (2H, br), 6.95
(1H, br), 7.06 (1H, s), 8.02 (1H, brs), 9.15 (1H, brs)
EXAMPLE 19
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-(3-amino-4-[3-(2-aminoethoxy)ureido]-2-methyl-1-pyrazol-
io)methyl-3-cephem-4-carboxylate
[0373] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethoxy)-ureido)-1-methylpyraz-
ole in the same manner as in Example 17 as an amorphous solid.
[0374] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
3.21 (1H, d, J=18 Hz), 3.33 (2H, t, J=5 Hz), 3.47 (1H, d, J=18 Hz),
3.74 (3H, s), 4.17 (2H, t, J=5 Hz), 4.99 (1H, d, J=l5 Hz), 5.17
(1H, d, J=15 Hz), 5.26 (1H, d, J=5 Hz), 5.86 (1H, d, J=5 Hz), 7.93
(1H, s)
Preparation 37
[0375] To a suspension of 1,1'-carbonyldiimidazole (1.95 g) in
methylene chloride (20 ml) was added tert-butyl
N-(2-aminoethyl)carbamate (1.92 g) under ice-cooling, and the
mixture was stirred at room temperature for 2 hours. To the
reaction mixture were added N-ethyldiisopropylamine (2.59 g) and
7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt
(2.22 g), and the mixture was stirred at room temperature for 16
hours. To the reaction mixture were added trityl chloride (9.0 g)
and triethylamine (3.0 g). The mixture was stirred at room
temperature for 24 hours. The reaction mixture was washed with 10%
aqueous citric acid solution, brine and saturated aqueous sodium
hydrogen carbonate solution. The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated in vacuo.
The residue was purified by column chromatography on silica gel
eluting with 3% methanol/chloroform to give
7-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-2,3-dihydro-1-tritylimi-
dazo[1,2-b]pyrazole (800 mg) as a solid.
[0376] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 3.19 (4H,
br), 3.69 (1H, brs), 3.78-3.85 (4H, m), 4.51 (1H, br),. 5.07 (1H,
br), 7.20 (1H, s), 7.26-7.34 (9H, m), 7.46-7.47 (6H, m)
EXAMPLE 20
[0377] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(820 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added
7-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-2,3-dihydro-1-tritylimi-
dazo[1,2-b]pyrazole (700 mg), and the whole mixture was stirred at
room temperature for 6 hours. To the resulting reaction mixture
were added ethyl acetate (50 ml) and water (50 ml). The aqueous
layer was separated, and the organic layer was washed with 10%
aqueous sodium trifluoroacetate solution and brine, dried over
anhydrous sodium sulfate and filtered. The filtrate was
concentrated to about 5 ml in vacuo. The concentrate was poured
into diisopropyl ether (120 ml)., and the resulting precipitate was
collected by filtration and dried in vacuo. To a solution of the
resulting solid in methylene chloride (3.0 ml) were added anisole
(1.0 ml) and trifluoroacetic acid (2.0 ml). The resulting solution
was stirred at room temperature for 4 hours and poured into
diisopropyl ether (120 ml). The resulting precipitate was collected
by filtration and dried in vacuo to give a crude product (830 mg),
which was purified by preparative HPLC utilizing ODS column. The
eluate containing a desired product was concentrated to about 30 ml
in vacuo. The concentrate was adjusted to about pH 3 with
concentrated hydrochloric acid and chromatographed on Diaion.RTM.
HP-20 (Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{7-[3-(2-aminoethyl)ureido]-2,3-dihydro-5-(1H-imidazo[-
1,2-b]pyrazolio))methyl-3-cephem-4-carboxylate (28.5 mg) as an
amorphous solid.
[0378] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (3H, s), 1.54 (3H, s),
3.14 (2H, t, J=6 Hz), 3.29 (1H, d, J=18 Hz), 3.49 (2H, t, J=6 Hz),
3.57 (1H, d, J=18 Hz), 4.16 (2H, t, J=9 Hz), 4.31-4.45 (2H, m),
4.94 (1H, d, J=15 Hz), 5.02 (1H, d, J=15 Hz), 5.27 (1H, d, J=5 Hz),
5.85 (1H, d, J=5 Hz), 7.95 (1H, s)
Preparation 38
[0379] To a suspension of 1,1'-carbonyldiimidazole (2.0 g) in
dehydrated chloroform (30 ml) was added a solution of tert-butyl
N-(2-hydroxyethyl)carbamate (1.92 g) in dehydrated chloroform (10
ml) under ice-cooling, and the mixture was stirred at room
temperature for 1 hour. To the reaction mixture were added
N-ethyldiisopropylamine (2.2 ml) and 4,5-diamino-1-methylpyrazole
sulfuric acid salt (2.58 g), and the mixture was stirred at room
temperature for 17.5 hours. To the reaction mixture were added
trityl chloride (3.42 g) and triethylamine (1.25 g). The mixture
was stirred at room temperature for 2 hours. The reaction mixture
was washed with 10% aqueous citric acid solution, brine and
saturated aqueous sodium hydrogen carbonate solution. The organic
layer was dried over anhydrous magnesium sulfate, filtered and
concentrated in vacuo. The residue was purified by column
chromatography on silica gel eluting with 5% methanol/chloroform to
give
4-{[2-(tert-butoxycarbonylamino)ethoxycarbonyl]amino}-5-(tritylamino)-1-m-
ethylpyrazole (1.91 g) as a solid.
[0380] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 2.89 (3H, s),
3.30-3.36 (2H, m), 4.03-4.07 (2H, m), 4.37 (1H, brs), 4.75 (1H,
br), 5.42 (1H, br), 7.17-7.30 (16H, m)
EXAMPLE 21
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-{3-amino-4-[(2-aminoethoxycarbonyl)amino]-2-methyl-1-py-
razolio)methyl-3-cephem-4-carboxylate
[0381] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and
4-{[2-(tert-butoxycarbonylamino)ethoxycarbonyl]amino}-5-(tritylamino)-1-m-
ethylpyrazole in the same manner as in Example 20 as an amorphous
solid.
[0382] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (3H, s), 1.54 (3H, s),
3.18 (1H, d, J=18 Hz), 3.30-3.38 (2H, m), 3.43 (1H, d, J=18 Hz),
3.71 (3H, s), 4.37-4.40 (2H, m), 4.97 (1H, d, J=15 Hz), 5.18 (1H,
d, J=15 Hz), 5.24 (1H, d, J=5 Hz), 5.83 (1H, d, J=5 Hz), 7.95 (1H,
s)
Preparation 39
[0383] To a solution of
7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt
(1.42 g) and N-ethyldiisopropylamine (2.73 g) in methylene chloride
(50 ml) was added
N-[2-(tert-butoxycarbonylamino)-acetoxy]succinimide (1.90 g). The
mixture was stirred at room temperature for 22 hours. The reaction
mixture was washed with saturated aqueous sodium hydrogen carbonate
solution, and the organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The oily residue was
purified by column chromatography on silica gel eluting with 5%
methanol/chloroform to give
7-[2-(tert-butoxycarbonylamino)acetyl]amino-2,3-dihydro-1H-imidazo[1,2-b]-
pyrazole (1.07 g) as a solid.
[0384] .sup.1H-NMR (CDCl.sub.3) .delta. 1.47 (9H, s), 3.89 (2H, d,
J=5.5 Hz), 3.97 (2H, dt, J=2.7, 7.3 Hz), 4.18 (2H, t, J=7.3 Hz),
4.55 (1H, br), 5.22 (1H, br), 7.16 (1H, s), 7.95 (1H, br)
EXAMPLE 22
[0385] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)acetamido)-3-chloromethyl-3-cephem-4-
-carboxylate (1.0 g) in N,N-dimethylformamide (2.0 ml) was added
sodium iodide (181 mg), and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture was added
7-[2-(tert-butoxycarbonylamino)acetyl]amino-2,3-dihydro-1H-imidazo[1,2-b]-
pyrazole (421 mg). The whole mixture was stirred at 30.degree. C.
for 3 hours. To the resulting reaction mixture were added ethyl
acetate (100 ml) and water (50 ml). The aqueous layer was
separated, and the organic layer was washed with 10% aqueous sodium
trifluoroacetate solution and brine, dried over anhydrous sodium
sulfate and filtered. The filtrate was concentrated to about 5 ml
in vacuo. The concentrate was poured into diisopropyl ether (150
ml), and the resulting precipitate was collected by filtration and
dried in vacuo. To a solution of the resulting solid in methylene
chloride (3.0 ml) were added anisole (1.0 ml) and trifluoroacetic
acid (2.0 ml). The resulting solution was stirred at room
temperature for 4 hours and poured into diisopropyl ether (150 ml).
The resulting precipitate was collected by filtration and dried in
vacuo to give a crude product (830 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-[7-(2-aminoacetamido)-2,3-dihydro-5-(1H-imidazo[1,2-b]-
pyrazolio)]methyl-3-cephem-4-carboxylate (20.8 mg) as an amorphous
solid.
[0386] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (3H, s), 1.52 (3H, s),
3.26 (2H, d, J=18 Hz), 3.54 (2H, d, J=18 Hz), 3.97 (2H, s), 4.16
(2H, t, J=9 Hz), 4.35 (1H, q, J=9 Hz), 4.44 (1H, q, J=9 Hz), 4.97
(2H, d, J=15 Hz), 5.04 (2H, d, J=15 Hz), 5.25 (1H, d, J=4 Hz), 5.84
(1H, d, J=4 Hz), 8.10 (1H, s)
Preparation 40
[0387] To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole
sulfuric acid salt (1.20 g) and
N-[2-(tert-butoxycarbonylamino)acetoxy]succinimide (1.35 g) in
methylene chloride (20 ml) was added N-ethyldiisopropylamine (2.1
ml) under ice-cooling, and the mixture was stirred at room
temperature for 17 hours. The reaction mixture was washed with
water (40 ml), saturated aqueous sodium hydrogen carbonate solution
(40 ml) and brine (40 ml). The organic layer was dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo. The
oily residue was purified by column chromatography on silica gel
eluting with 10% methanol/chloroform to give
5-amino-4-[2-(tert-butoxycarbonylamino)acetyl]amino-1-(2-hydroxye-
thyl)pyrazole (1.20 g) as a solid.
[0388] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 3.89-3.90
(4H, m), 4.00-4.04 (2H, m), 4.26 (2H, br), 5.51 (1H, br), 7.17 1(H,
s), 8.06 (1H, br)
EXAMPLE 23
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-[3-amino-4-(2-aminoacetamido)-2-(2-hydroxyethyl)-1-pyra-
zoliolmethyl-3-cephem-4-carboxylate
[0389] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
5-amino-4-[2-(tert-butoxycarbonylamino)acetyl]amino-1-(2-hydroxyethyl)pyr-
azole in the same manner as in Example 22 as an amorphous
solid.
[0390] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (6H, s), 3.15 (2H, d,
J=l8 Hz), 3.48 (2H, d, J=18 Hz), 3.88 (1H, dt, J=16 Hz), 4.02 (2H,
s), 4.42 (1H, dt, J=16.5 Hz), 5.07 (2H, d, J=15 Hz), 5.13 (2H, d,
J=15 Hz), 5.27 (1H, d, J=5 Hz), 5.84 (1H, d, J=5 Hz), 8.09 (1H,
s)
Preparation 41
[0391] To a solution of
3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid
salt (2.96 g) and N-ethyldiisopropylamine (2.59 g) in methylene
chloride (70 ml) was added
N-[2-(tert-butoxycarbonylamino)acetoxy]succinimide (2.72 g). The
mixture was stirred at room temperature for 14 hours. The reaction
mixture was washed with saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
purified by column chromatography on silica gel eluting with 6%
methanol/chloroform to give
3-[2-(tert-butoxycarbonylamino)acetyl]amino-4,5,6,7-tetrahydropyr-
azolo[1,5-a]pyrimidine (2.4 g) as a solid.
[0392] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 2.08-2.12
(2H, m), 3.29-3.32 (2H, m), 3.90 (2H, br), 4.07 (2H, t, J=6.0 Hz),
5.00 (1H, br), 5.38 (1H, br), 7.12 (1H, s), 8.11 (1H, br)
EXAMPLE 24
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido)-3-[3-(2-aminoacetamido)-4,5,6,7-tetrahydro-1-pyrazolo[1,5-
-a]pyrimidinio]methyl-3-cephem-4-carboxylate
[0393] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
3-[2-(tert-butoxycarbonylamino)acetyl]amino-4,5,6,7-tetrahydropyrazolo[1,-
5-a]pyrimidine in the same manner as in Example 22 as an amorphous
solid.
[0394] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
2.05-2.25 (2H, m), 3.21 (2H, d, J=18 Hz), 3.45 (2H, d, J=18 Hz),
3.30-3.45 (2H, m), 4.00 (2H, s), 4.10-4.25 (2H, m), 4.92 (2H, d,
J=15 Hz), 5.17 (2H, d, J=15 Hz), 5.24 (1H, d, J=5 Hz), 5.84 (1H, d,
J=5 Hz), 7.97 (1H, s)
Preparation 42
[0395] To a solution of
3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid
salt (4.44 g) and N-ethyldiisopropylamine (3.88 g) in methylene
chloride (100 ml) was added
N-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide (4.29 g).
The mixture was stirred at room temperature for 6 hours. The
reaction mixture was washed with saturated aqueous sodium hydrogen
carbonate solution. The organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The residue
was purified by column chromatography on silica gel eluting with 5%
methanol/chloroform to give
3-[3-(tert-butoxycarbonylamino)propionyl]amino-4,5,6,7-tetrahydro-
pyrazolo[1,5-a]pyrimidine (3.67 g) as an oil.
[0396] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 2.08-2.13
(2H, m), 2.52 (2H, t, J=6.0 Hz), 3.32 (2H, t, J=5.0 Hz), 3.43-3.46
(2H, m), 4.07 (2H, t, J=6.0 Hz), 5.12 (1H, br), 5.23 (1H, br), 7.13
(1H, s), 7.97 (1H, br)
EXAMPLE 25
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino.)acetamido]-3-[3-(3-aminopropionamido)-4,5,6,7-tetrahydro-1-pyrazolo-
[1,5-a]pyrimidinio]methyl-3-cephem-4-carboxylate
[0397] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-te-
rt-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem--
4-carboxylate and
3-[3-(tert-butoxycarbonylamino)propionyl]amino-4,5,6,7-tetrahydropyrazolo-
[1,5-a]pyrimidine in the same manner as in Example 22 as an
amorphous solid.
[0398] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (3H, s), 1.52 (3H, s),
2.05-2.25 (2H, m), 2.85 (2H, t, J=7 Hz), 3.20 (2H, d, J=18 Hz),
3.44 (2H, d, J=18 Hz), 3.30-3.45 (2H, m), 3.31 (2H, t, J=7 Hz),
4.05-4.20 (2H, m), 4.91 (2H, d, J=16 Hz), 5.16 (2H, d, J=16 Hz),
5.23 (1H, d, J=5 Hz), 5.84 (1H, d, J=5 Hz), 7.92 (1H, s)
Preparation 43
[0399] To a solution of 5-amino-1-methylpyrazole (100 g) in water
(700 ml) were added concentrated hydrochloric acid (86 ml) and
sodium nitrite (63.9 g) in water (200 ml) at a temperature below
10.degree. C. The reaction mixture was stirred at 5.degree. C. for
30 minutes. The precipitated solid was collected by filtration and
dried to give 5-amino-1-methyl-4-nitrosopyrazole (117 g).
[0400] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.52 and 3.59 (3H, s),
7.22 and 8.51 (1H, s), 8.17 and 8.51 (1H, brs)
Preparation 44
[0401] To a suspension of 5-amino-1-methyl-4-nitrosopyrazole (117
g) were added sulfuric acid (91 g) and 10% palladium on carbon (58
g). The mixture was hydrogenated under balloon pressure for 10
hours. The reaction mixture was filtered, and the filtrate was
concentrated in vacuo. To the concentrate was added isopropyl
alcohol (2.3 L), and the mixture was stirred for 1 hour. The
precipitated solid was collected by filtration and dried to give
4,5-diamino-1-methylpyrazole sulfuric acid salt (158 g).
[0402] .sup.1H-NMR (D.sub.2O) .delta. 3.74 (3H, s), 7.80 (1H,
s)
Preparation 45
[0403] A solution of 4,5-diamino-1-methylpyrazole sulfuric acid
salt (158 g) in water (1.1 L) was neutralized to pH 6.9 with 4N
aqueous sodium hydroxide solution, and dioxane (474 ml) was added
to this solution. To the resulting mixture was added dropwise
phenyl chloroformate (124 g) maintaining pH of the mixture at 6.9
with 4N aqueous sodium hydroxide solution at a temperature below
10.degree. C. The reaction mixture was stirred for 1 hour. The
precipitated solid was collected by filtration and dried to give
5-amino-1-methyl-4-phenoxycarbonylaminopyrazole (155 g).
[0404] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.52 (3H, s), 5.00 (2H,
brs), 7.10-7.50 (6H, m), 8.93 (1H, brs)
Preparation 46
[0405] To a suspension of
5-amino-1-methyl-4-phenoxycarbonylaminopyrazole (153.8 g) in
tetrahydrofuran (1 L) were added triethylamine (67 g) and
triphenylmethyl chloride (185 g) at room temperature. The mixture
was stirred for 6.5 hours. To the reaction mixture was added
heptane (2.6 L), and the mixture was stirred for 1 hour. The
precipitated solid was collected by filtration and washed with
heptane-diisopropyl ether (1:1). The crude solid was suspended in
water (3 L), and the suspension was stirred for 1 hour. The solid
was collected by filtration and dried to give
1-methyl-4-phenoxycarbonylamino-5-triphenylmethylaminopyrazole
(253.6 g).
[0406] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.74 (3H, s), 5.57 (1H,
brs), 7.00-7.50 (21H, m), 8.12 (1H, brs)
Preparation 47
[0407] To a suspension of
1-methyl-4-phenoxycarbonylamino-5-triphenylmethylaminopyrazole
(253.6 g) in N,N-dimethylformamide (1.5 L) were added triethylamine
(59.5 g) and tert-butyl N-(2-aminoethyl)carbamate (94.2 g) in
N,N-dimethylformamide (254 ml). The mixture was stirred for 5 hours
and poured into water (10.6 L). The slurry was stirred for 1 hour.
The precipitated solid was collected by filtration and dried to
give a crude product. The crude product was suspended in
N,N-dimethylformamide, and the suspension was heated under reflux
for 20 minutes. The suspension was cooled to ambient temperature
over 4 hours. The solid was collected by filtration, washed with
acetonitrile and dried to give
4-[N-(2-tert-butoxycarbonylaminoethyl)carbamoylamino]-1-methyl-5-tripheny-
lmethylaminopyrazole (261.2 g).
[0408] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.69 (3H, s), 2.90-3.05
(4H, m), 5.69 (1H, brs), 5.91-6.01 (1H, m), 6.74-6.81 (1H, m), 6.87
(1H, brs), 7.00 (1H, s), 7.10-7.30 (15H, m)
Preparation 48
[0409] To a solution of
(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylet-
hoxyimino)acetic acid (319 g) in N,N-dimethylacetamide (1.5 L) were
added potassium carbonate (113 g) and methanesulfonyl chloride (126
ml) under ice-cooling. The mixture was stirred at 10.degree. C. for
2 hours. The reaction mixture was added to a mixture of ethyl
acetate and water. The organic layer was washed with water and
brine to give an activated acid solution. On the other hand, a
suspension of 4-methoxybenzyl
71-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (300
g) in a mixture of water (1 L) and ethyl acetate (1 L) was adjusted
to pH 6 with triethylamine under ice-cooling. To the resulting
mixture was dropwise added the above obtained activated acid
solution at 10.degree. C. under stirring. Stirring was continued at
5-10.degree. C. for 1.5 hours keeping pH of the reaction mixture at
6 with triethylamine. The organic layer was separated, washed with
water and brine, and evaporated in vacuo. The concentrate was
poured into diisopropyl ether (15 L), and the resulting precipitate
was collected by filtration and dried to give 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(495.7 g).
[0410] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 1.44 (6H,
s), 3.45-3.70 (2H, m), 3.76 (3H, s), 4.46 and 4.54 (1H, ABq, J=16
Hz) 5.10-5.28 (2H+1H, m), 5.90 (1H, dd, J=4.9, 8.5 Hz), 6.94 (2H,
d, J=8.7 Hz), 7.36 (2H, d, J=8.7 Hz), 8.18 (2H, brs), 9.52 (1H, d,
J=8.5 Hz)
EXAMPLE 26
[0411] To a solution of 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(150 g) in N,N-dimethylformamide (400 ml) was added
1,3-bis(trimethylsilyl)urea (225 g) and the mixture was stirred for
30 minutes. Potassium iodide (51.2 g) was added to this solution,
and the mixture was stirred for 30 minutes.
[0412]
4-[N-(2-tert-Butoxycarbonylaminoethyl)-carbamoylamino]-1-methyl-5--
triphenylmethylaminopyrazole (147 g) was dissolved in
N,N-dimethylformamide (650 ml) at 78.degree. C. and the solution
was cooled to 45.degree. C. The solution was added to the solution
of
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
obtained above. The reaction mixture was stirred at 35.degree. C.
for 18.5 hours and poured into a mixture of ethyl acetate (2 L),
water (1.8 L). and 20% aqueous sodium chloride solution (150 ml).
The organic layer was washed with a mixture of 10% aqueous sodium
thiosulfate solution (375 ml) and 20% aqueous sodium chloride
solution (375 ml). The organic layer was washed successively with
10% aqueous sodium trifluoroacetate solution three times (750
ml.times.3) and 20% aqueous sodium chloride solution (750 ml). The
organic layer was concentrated in vacuo, and the precipitated
4-[N-(2-tert-butoxycarbonylaminoethyl)-carbamoylamino]-1-methyl-5-triphen-
ylmethylaminopyrazole was filtered off. The filtrate was further
concentrated in vacuo to a volume of approximately 600 ml. This
solution was added to diisopropyl ether and the suspension was
stirred for 1 hour. The resulting solid was collected by filtration
and dried. The solid was dissolved in dichloromethane (669 ml) To
the solution were added anisole (223 ml) and trifluoroacetic acid
(669 ml). The reaction mixture was stirred for 4 hours and poured
into diisopropyl ether. The resulting solid was collected by
filtration and dried. This solid was suspended in water, and pH of
the suspension was adjusted to 7 with aqueous ammonia solution at a
temperature below 10.degree. C. The resulting precipitate was
filtered off. The filtrate was acidified to pH 1 with concentrated
hydrochloric acid at a temperature below 10.degree. C., and the
resulting precipitate was filtered off. The filtrate was
chromatographed on Diaion.RTM. HP-20 (11 L) eluting with 20%
aqueous 2-propanol. The eluate was concentrated to about 3.5 L in
vacuo, and 2M sulfuric acid (51 ml) was added. The mixture was
lyophilized to give a crude product (72.2 g).
[0413] The crude product (3 g) was purified by preparative HPLC
utilizing ODS column. The eluate containing a desired product was
concentrated in vacuo. The concentrate was adjusted to about pH 1
with concentrated hydrochloric acid and chromatographed on
Diaion.RTM. HP-20 (400 ml) eluting with 20% aqueous 2-propanol. The
eluate was concentrated to about 73 ml in vacuo, and 2M sulfuric
acid (1.5 ml) was added. The mixture was further evaporated to a
volume of approximately 12.5 ml, and water (6 ml) was added. After
addition of seed crystals (10 mg), which resulted in the
precipitation of a white solid, the mixture was stirred at room
temperature for 1 hour. The mixture was further stirred at
5.degree. C. for 13 hours. 2-Propanol (20 ml) was added at
5.degree. C. over 20 minutes, and the slurry was stirred at room
temperature for 4 hours. 2-Propanol (20 ml) was added over 30
minutes, and the slurry was stirred at room temperature for 3
hours. The precipitated crystals were collected by filtration and
dried to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)carbamoylamino]-2-methyl-1-
-pyrazolio)methyl-3-cephem-4-carboxylic acid hydrogen sulfate (1.51
g) as crystals.
[0414] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 3.10-3.55 (6H,
m), 3.71 (3H, s), 5.02 and 5.23 (2H, ABq, J=16.7 Hz), 5.25 (1H, d,
J=4.9 Hz), 5.87 (1H, d, J=4.9 Hz), 7.91 (1H, s)
Preparation 49
[0415] A suspension of 4,5-diamino-1-methylpyrazole sulfuric acid
salt (20 g) in triethylamine (29.2 ml) was stirred at 0.degree. C.
for 10 minutes. A mixture of acetic anhydride (9.87 ml) and formic
acid (7.96 ml) was stirred at 40.degree. C. for 30 minutes, cooled
to 0.degree. C., and added dropwise to the above solution at
0.degree. C. The whole mixture was stirred at 0.degree. C. for 2
hours. To the mixture was added brine, and the whole mixture was
extracted with tetrahydrofuran. The organic layer was dried over
magnesium sulfate and evaporated under reduced pressure to give
crude N-(5-amino-1-methyl-1H-pyrazol-4-yl)formamide, which was used
in the next step without further purification.
Preparation 50
[0416] The crude product of
N-(5-amino-1-methyl-1H-pyrazol-4-yl)formamide (13.33 g) was
dissolved in N,N-dimethylformamide (130 ml). To the solution were
added trityl chloride (29.2 g), triethylamine (66.3 ml) and
4-dimethylaminopyridine (465 mg), and the mixture was stirred at
60.degree. C. for 5 hours. To the reaction mixture was added water,
and the whole mixture was extracted with ethyl acetate. The organic
layer was washed with water and brine, and dried over magnesium
sulfate. The solvent was evaporated under reduced pressure to give
a white solid. The solid was triturated with ethyl
acetate/diisopropyl ether (1:1) to give
N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide (19.18 g).
The NMR spectrum of this compound indicates the existence of its
rotamer.
[0417] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.76 and 2.92 (3H, s),
5.56 and 5.84 (1H, s), 7.0-7.4 (16H, m), 7.66 (1H, d, J=1.7 Hz),
8.3-8.4 (1H, m)
[0418] ESI-MS: m/z=405.2(M+Na).sup.+
Preparation 51
[0419] To a solution of
N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide (3.825 g) in
N,N-dimethylformamide (66 ml) was added sodium hydride (264 mg, 60%
oil suspension) under a nitrogen atmosphere at 0.degree. C. under
stirring. The mixture was stirred at 0.degree. C. for 15 minutes.
To the mixture were added tert-butyl N-(3-bromopropyl)carbamate
(2.62 g) in N,N-dimethylformamide (10 ml) and sodium iodide (1.65
g). The mixture was warmed to room temperature and stirred for 2
hours. 10% Aqueous potassium hydrogen sulfate solution (5 ml) was
added, and the mixture was extracted with ethyl acetate. The
organic layer was washed with water and brine, and dried over
magnesium sulfate. The solvent was evaporated under reduced
pressure, and the residue was chromatographed on silica gel eluting
with methylene chloride/ethyl acetate (4:1) to give tert-butyl
3-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)propylcarba-
mate (2.714 g). The NMR spectrum of this compound indicates the
existence of its rotamer.
[0420] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 and 1.39 (9H, s),
2.6-2.9 (6H, m), 2.89 (3H, s), 5.34 and 6.01 (1H, s), 6.6-6.9 (1H,
m), 7.0-7.4 (15H, m), 7.5-7.6 (1H, m), 7.95 (1H, s)
[0421] ESI-MS: m/z=562.3(M+Na).sup.+
EXAMPLE 27
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-13-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-methyl-1-
-pyrazoliolmethyl-3-cephem-4-carboxylate
[0422] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
and tert-butyl
3-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)propylcarba-
mate in the same manner as in Example 1. The NMR spectrum of this
compound indicates the existence of its rotamer.
[0423] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 1.7-2.1 (2H,
m), 2.9-3.9 (9H, m), 4.97 and 5.20 (2H, ABq, J=15.2 Hz), 5.26 (1H,
d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 8.0-8.3 (2H, m)
EXAMPLE 28
[0424] To a suspension of
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)-acetamido]-3-{3-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-methyl-
-1-pyrazolio)methyl-3-cephem-4-carboxylate (140 mg) in methanol
(2.6 ml) was added concentrated hydrochloric acid (0.176 ml) at
room temperature, and the mixture was stirred for 6.5 hours. To the
reaction mixture was added sodium hydrogen carbonate (177 mg), and
the mixture was purified by preparative HPLC (ODS column,
acetonitrile/phosphate buffer (pH 7)=5:95). The eluate containing a
desired product was evaporated to remove acetonitrile, acidified
with diluted hydrochloric acid and. chromatographed on Diaion.RTM.
HP-20 eluting with 20t aqueous 2-propanol. The eluate was
concentrated under reduced pressure and lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-{3-amino-4-[(3-aminopropyl)amino]-2-methyl-1-pyra-
zolio)methyl-3-cephem-4-carboxylate 439 mg).
[0425] .sup.1H-NMR (D.sub.2O) .delta. 1.52-1.54 (6H, m), 1.95 (2H,
tt, J=7.3 Hz, 7.3 Hz), 3.0-3.2 (4H, m), 3.16 and 3.38 (2H, ABq,
J=17.7 Hz), 3.68 (3H, s), 4.89 and 5.11 (2H, ABq, J=15.6 Hz), 5.22
(1H, d, J=4.8 Hz), 5.83 (1H, d, J=4.8 Hz), 7.59 (1H, s)
[0426] ESI-MS: m/z=636.3(M-H).sup.-
Preparation 52
tert-Butyl
2-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)e-
thylcarbamate
[0427] The title compound was obtained from
N-[l-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide and
tert-butyl N-(2-bromoethyl)carbamate in the same manner as in
Preparation 51.
[0428] IR (KBr) 1709, 1670, 1170, 704 cm.sup.-1
[0429] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.35 and 1.36 (9H, s),
2.65 and 2.75 (3H, s), 2.73-2.90 (4H, m), 5.45 and 6.02 (1H, s),
6.78 and 6.88 (1H, t-like), 7.05-7.30 (15H, m), 7.31 and 7.57 (1H,
s)
[0430] ESI-MS: m/z=426.3(M+H.sup.+), 548.3(M+Na.sup.+)
EXAMPLE 29
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)-N-formylamino]-2-methyl-1--
pyrazolio}methyl-3-cephem-4-carboxylate
[0431] The title compound was obtained from benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
and tert-butyl
2-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)ethylcarbam-
ate in the same manner as in Example 1.
[0432] IR (KBr) 1770, 1675, 1653, 1597 cm.sup.-1
[0433] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.53 (6H, s), 3.12-3.78
(4H, m), 3.77 and 3.78 (3H, s), 3.86-3.96 (2H, m), 5.00 and 5.19
(2H, ABq, J=15.2 Hz), 5.28 (1H, d, J=4.8 Hz), 5.86 (1H, d, J=4.8
Hz), 8.15 and 8.18 (1H, s), 8.19 and 8.33 (1H, s)
[0434] ESI-MS: m/z=652.2(M+H.sup.+)
EXAMPLE 30
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-{3-amino-4-[(2-aminoethyl)amino]-2-methyl-1-pyrazolio)m-
ethyl-3-cephem-4-carboxylate
[0435] The title compound was obtained from
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)-N-formylamino]-2-methyl-1-
-pyrazolio)methyl-3-cephem-4-carboxylate in the same manner as in
Example 28.
[0436] IR (KBr) 1770, 1651, 1593 cm.sup.-1
[0437] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.53 (3H, s), 1.59 (3H,
s), 3.13-3.26 (4H, m), 3.26 and 3.39 (2H, ABq, J=17.8 Hz), 3.68
(3H, s), 4.87 and 5.11 (2H, ABq, J=15.7 Hz), 5.25 (1H, d, J=4.8
Hz), 5.84 (1H, d, J=4.8 Hz), 7.63 (1H, s)
[0438] ESI-MS: m/z=622.2(M-H.sup.-)
Preparation 53
[0439] To a suspension of 1-methyl-1H-pyrazole-4,5-diamine sulfate
(86 g) in tetrahydrofuran (1.3 L) was added triethylamine (117 ml),
and then (2S)-4-[(tert-butoxycarbonyl)amino]-2-hydroxybutanoic acid
(82.5 g) was added to the mixture. To the mixture were added
1-hydroxybenzotriazole (58.3 g) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (82.7
g) under ice-cooling. The reaction mixture was stirred at room
temperature for 8 hours. To the reaction mixture were added ethyl
acetate (1.3 L), saturated aqueous sodium hydrogen carbonate
solution and sodium chloride, and the mixture was stirred for 30
minutes. The organic layer was separated, and the aqueous layer was
extracted with ethyl acetate (1.0 L) six times. The extract was
dried over anhydrous magnesium sulfate, filtered and concentrated
in vacuo. The residue was purified by silica gel column
chromatography eluting with ethyl acetate/tetrahydrofuran (1/1) to
give tert-butyl
{(3S)-4-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-hydroxy-4-oxobutyl)ca-
rbamate (69.5g).
[0440] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 1.6-1.9 (1H,
m), 1.9-2.2 (1H, m), 3.1-3.3 (1H, m), 3.3-3.5 (1H, m), 3.65 (3H,
s), 4.20 (1H, dd, J=3.6, 6.6 Hz), 4.7-5.3 (4H, m), 7.24 (1H, s),
8.58 (1H, s)
[0441] [.alpha.].sup.20.sub.D(c=1.05,
CHCl.sub.3)=-27.06.degree.
Preparation 54
[0442] To a solution of tert-butyl
{(3S)-4-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-hydroxy-4-oxobutyl}ca-
rbamate (68.51 g) in N,N-dimethylformamide (350 ml) was added
chlorotriphenylmethane (67 g). To the mixture was dropwise added
triethylamine (67 ml). The mixture was stirred at room temperature
for 12 hours. The reaction mixture was dissolved in dichloromethane
(2 L). The solution was washed successively with water and brine.
The extract was dried over anhydrous magnesium sulfate, filtered
and concentrated in vacuo. The residue was triturated with
acetonitrile and dried in vacuo to give tert-butyl
((3S)-3-hydroxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxo-
butyl)carbamate (64 g).
[0443] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 1.3-1.6 (1H,
m), 1.8-2.1 (1H, m), 2.95 (3H, s), 2.9-3.2 (1H, m), 3.3-3.6 (1H,
m), 3.95 (1H, m), 4.53 (1H, d, J=4.5 Hz), 4.74 (1H, s), 4.92 (1H,
brs), 7.1-7.3 (15H, m), 7.39 (1H, s), 7.73 (1H, s)
[0444] ESI-MS: m/z=638.2(M+H+Na.sup.+)
[0445] [.alpha.].sup.20.sub.D(C=1.025,
CHCl.sub.3)=-36.5.degree.
EXAMPLE 31
[0446] To a solution of 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(130 g) in N,N-dimethylformamide (400 ml) was added
1,3-bis(trimethylsilyl)urea (195 g), and the mixture was stirred at
room temperature for 30 minutes. To the solution was added
potassium iodide (44.4 g), and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture was added
tert-butyl
((3S)-3-hydroxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxo-
butyl)carbamate (106 g), and the whole mixture was stirred at
35.degree. C. for 22 hours. To the reaction mixture was added ethyl
acetate (1.7 L), and the mixture was washed successively with water
(1.6 L), 10% aqueous sodium trifluoroacetate solution (650
ml.times.3) and brine (650 ml), dried over magnesium sulfate and
filtered. The filtrate was concentrated to about 1 L in vacuo. The
concentrate was poured into diisopropyl ether (3 L), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the solid in methylene chloride (660 ml)
were added anisole (220 ml) and trifluoroacetic acid (660 ml).
[0447] The resulting solution was stirred at room temperature for 4
hours and poured into diisopropyl ether (7 L). The resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (156.2 g). The crude product was dissolved in water
(3.5 L). The solution was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 20% aqueous
2-propanol. The eluate was concentrated to about 1.5 L in vacuo,
and 2M aqueous sulfuric acid solution (33.18 ml) was added. The
mixture was lyophilized. The lyophilized product (40 g) was
dissolved in phosphate buffer (pH 7) and purified by preparative
HPLC utilizing ODS column. The eluate containing a desired product
was concentrated to about 30 ml in vacuo. The concentrate was
adjusted to about pH 3 with concentrated hydrochloric acid and
chromatographed on Diaion.RTM. HP-20 (Mitsubishi Chemical
Corporation) eluting with 10% aqueous 2-propanbl. The eluate was
concentrated to about 1 L in vacuo, and 2M aqueous sulfuric acid
solution was added (13.59 ml). The resulting solution was
lyophilized to give
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethox-
yimino)acetamido]-3-(3-amino-4-[((2S)-4-amino-2-hydroxybutanoyl)amino]-2-m-
ethyl-1-pyrazolio)methyl-3-cephem-4-carboxylic acid hydrogen
sulfate (20.82 g) as an amorphous solid.
[0448] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 1.9-2.4 (2H,
m), 3.20 (1H, d, J=17.6 Hz), 3.0-3.3 (2H, m), 3.45 (1H, d, J=17.6
Hz), 3.74 (3H, s), 4.47 (1H, dd, J=4, 6.3 Hz), 5.06 (1H, d, J=15.7
Hz), 5.25 (1H, d, J=4.8 Hz), 5.28 (1H, d, J=15.7 Hz), 5.87 (1H, d,
J=4.8 Hz), 8.07 (1H, s)
Preparation 55
[0449] To a suspension of
1-methyl-N.sup.5-trityl-1H-pyrazole-4,5-diamine (1.60 g) in ethanol
(50 ml) were added triethylamine (0.627 ml) and diethyl squarate
(0.858 ml), and the mixture was stirred at room temperature for 22
hours. To the reaction mixture were added ethyl acetate (200 ml)
and hexane (100 ml), and the solution was washed successively with
water, 5% aqueous citric acid solution and brine. The organic layer
was dried over anhydrous sodium sulfate, filtered and concentrated
in vacuo. The crystalline residue was washed with diethyl ether and
dried in vacuo to give
3-ethoxy-.4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-cyclobute-
ne-1,2-dione (1.45 g) as a solid.
[0450] .sup.1H-NMR (CDCl.sub.3) .delta. 1.42 (3H, br), 2.99 (3H,
s), 4.41 (1H, brs), 4.69 (2H, q, J=7.2 Hz), 6.40 (1H, br),
7.13-7.35 (16H, m)
Preparation 56
[0451] To a suspension of tert-butyl 2-aminoethylcarbamate (288 mg)
and
3-ethoxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-cyclobuten-
e-1,2-dione (718 mg) in ethanol (20 ml) was added triethylamine
(0.209 ml), and the mixture was stirred under reflux for 4 hours.
To the reaction mixture were added diethyl ether and hexane. The
crystalline precipitate was collected by filtration and dried in
vacuo to give tert-butyl
2-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3,4-dioxocyclobut-
-1-en-1-yl)aminolethylcarbamate (830 mg) as a solid.
[0452] .sup.1H-NMR (CDCl.sub.3) .delta. 1.40 (9H, s), 3.07-3.28
(5H, m), 3.38-3.67 (2H, m), 4.53-4.84 (1H, br), 4.84 (1H, br),
7.15-7.22 (6H, m), 7.23 (1H.sub., s), 7.22-7.34 (9H, m)
EXAMPLE 32
[0453] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(901 mg) in N,N-dimethylformamide (1.8 ml) was added
N-(trimethylsilyl)acetamide (720 mg), and the mixture was stirred
at room temperature for 1 hour. To the reaction mixture was added a
solution of tert-butyl
2-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3,4-dioxocyclobut-
-1-en-1-yl)amino]ethylcarbamate (682 mg) in N,N-dimethylformamide
(6.3 ml), and the whole mixture was stirred at 35-40.degree. C. for
7 hours. To the resulting reaction mixture was added ethyl acetate,
and the precipitate was filtered off. The filtrate was washed
successively with water and brine, dried over anhydrous sodium
sulfate and filtered. The filtrate was concentrated to about 5 ml
in vacuo. The concentrate was poured into diisopropyl ether (80
ml), and the resulting precipitate was collected by filtration and
dried in vacuo. To a solution of the resulting solid in methylene
chloride (2.6 ml) were added anisole (0.88 ml) and trifluoroacetic
acid (2.6 ml). The resulting solution was stirred at room
temperature for 3 hours and poured into diisopropyl ether (80 ml).
The resulting precipitate was collected by filtration and dried in
vacuo to give a crude product (580 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 10 ml in vacuo and
lyophilized to give
3-{[3-amino-4-((2-[(2-aminoethyl)amino]-3,4-dioxo-1-cyclobuten-1-yl}amino-
)-2-methyl-1-pyrazolio]methyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3--
yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate
(22 mg) as an amorphous solid.
[0454] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (3H, s), 1.54 (3H, s),
3.26-3.36 (1H, m), 3.27 (2H, t, J=5.7 Hz), 3.58-3.69 (1H, m), 3.74
(3H, s), 3.86-4.03 (2H, m), 4.93 (1H, d, J=14.5 Hz), 5.10 (1H, d,
J=14.5 Hz), 5.29 (1H, d, J=4.3 Hz), 5.83 (1H, d, J=4.3 Hz), 7.99
(1H, s)
Preparation 57
[0455] To a suspension-of tert-butyl 3-aminopropylcarbamate (366
mg) and
3-ethoxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl)amino}-3-cyclobuten-
e-1,2-dione (670 mg) in ethanol (30 ml) was added triethylamine
(0.195 ml), and the mixture was stirred under reflux for 3 hours.
To the reaction mixture were added diethyl ether (40 ml) and hexane
(10 ml). The crystalline precipitate was collected by filtration
and dried in vacuo to give tert-butyl
{3-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3,4-dioxo-1-cycl-
obuten-1-yl)amino]propyl)carbamate (788 mg) as a solid.
[0456] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 1.67 (2H,
quintet, J=5.5 Hz) 3.15 (2H, q, J=5.5 Hz), 3.17 (3H, s), 3.60 (2H,
q, J=5.5 Hz), 4.82 (1H, brs), 4.86 (1H, t, J=5.5 Hz), 5.44 (1H,
br), 5.86 (1H, br), 7.13-7.33 (15H, m), 7.17 (1H, s)
EXAMPLE 33
[0457] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(819 mg) in N,N-dimethylformamide (1.6 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 40 minutes. To the reaction mixture
was-added a solution of tert-butyl
(3-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3,4-dioxo-1-cycl-
obuten-1-yl)amino]propyl}carbamate (637 mg) in
N,N-dimethylformamide (3.2 ml), and the whole mixture was stirred
at 35-400.degree. C. for 3.5 hours. To the resulting reaction
mixture was added ethyl acetate (60 ml) and the precipitate was
filtered off. The filtrate was washed successively with water (50
ml.times.2) and brine (50 ml), dried over anhydrous sodium sulfate
and filtered. The filtrate was concentrated to about 8 ml in vacuo.
The concentrate was poured into diisopropyl ether (80 ml), and the
resulting precipitate was-collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(2.4,ml) were added anisole (0.80 ml) and trifluoroacetic acid (1.6
ml). The resulting solution was stirred at room temperature for 3
hours and poured into diisopropyl ether (80 ml). The resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (565 mg), which was purified by preparative HPLC
utilizing ODS column eluting with a mixture of acetonitrile and
phosphate buffer (pH 5.5). The eluate containing a desired product
was concentrated to about 20 ml in vacuo. The concentrate was
desalted by preparative HPLC utilizing ODS column, and the fraction
eluted with 8% acetonitrile/0.01 M hydrochloric acid was
concentrated to about 10 ml in vacuo and lyophilized to give
3-{[3-amino-4-({2-[(3-aminopropyl)amino]-3,4-dioxo-1-cyclobuten-1-yl}amin-
o)-2-methyl-1-pyrazolio]methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-
-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate
trihydrochloride (34 mg) as an amorphous solid.
[0458] .sup.1H-NMR (D.sub.2O) .delta. 1.62 (6H, s), 2.02 (2H,
quintet, J=7.3 Hz), 3.09 (2H, t, J=7.3 Hz), 3.32 (1H, d, J=17.5
Hz), 3.54-3.65 (1H, m), 3.67-3.78 (2H, m), 3.75 (3H, s), 4.93-5.23
(2H, m), 5.30 (1H, d, J=4.5 Hz), 5.86 (1H, d, J=4.5 Hz), 7.99 (1H,
s)
Preparation 58
[0459] To a solution of
1,1'-(1,2-dioxo-1,2-ethanediyl)bis-1H-imidazole (761 mg) in
N,N-dimethylformamide (8 ml) was added
1-methyl-N.sup.5-trityl-1H-pyrazole-4,5-diamine (709 mg) under
ice-cooling, and the mixture was stirred at room temperature for 30
minutes. To the reaction mixture was added a solution of tert-butyl
2-aminoethylcarbamate (1.28 g) in N,N-dimethylformamide (2 ml), and
the mixture was stirred at room temperature for 27 hours. To the
reaction mixture was added ethyl acetate (50 ml). After the
precipitate was filtered off, the filtrate was washed successively
with water, 5%. aqueous citric acid solution and brine. The organic
layer was dried over anhydrous sodium sulfate, filtered and
concentrated in vacuo. The crystalline residue was washed with a
mixed solvent of diethyl ether and ethyl acetate and dried in vacuo
to give tert-butyl
{2-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoacetyl)amin-
o]ethyl}carbamate (823 mg) as a solid.
[0460] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 2.97 (3H, s),
3.31 (2H, q, J=5.5 Hz), 3.43 (2H, q, J=5.5 Hz), 4.53 (1H, s), 4.84
(1H, brs), 7.10-7.30 (15H, m), 7.47 (1H, s), 7.67 (1H, brs), 8.20
(1H, brs)
EXAMPLE 34
[0461] To a solution of 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(618 mg) in N,N-dimethylformamide (1.5 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 40 minutes. To the solution was added
potassium iodide (232 mg), and the mixture was stirred at room
temperature for 35 minutes. To the reaction mixture was added a
solution of tert-butyl
{2-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoacetyl)amin-
o]ethyl}carbamate (626 mg) in N,N-dimethylformamide (3 ml), and the
whole mixture was stirred at 35-40.degree. C. for 24 hours. To the
resulting reaction mixture was added ethyl acetate (50 ml), and the
solution was washed successively with water (50 ml.times.2), 10%
aqueous sodium trifluoroacetate solution (50 ml.times.2) and brine
(50 ml), dried over anhydrous sodium sulfate and filtered. The
filtrate was concentrated to about 10 ml in vacuo. The concentrate
was poured into diisopropyl ether (60 ml), and the resulting
precipitate was collected by filtration and dried in vacuo. To a
solution of the solid in methylene chloride (2.9 ml) were added
anisole (0.95 ml) and trifluoroacetic acid (2.9 ml). The resulting
solution was stirred at room temperature for 4 hours and poured
into diisopropyl ether (60 ml). The resulting precipitate was
collected by filtration and dried in vacuo to give a crude product
(770 mg), which was purified by preparative HPLC utilizing ODS
column. The eluate containing a desired product was concentrated to
about 30 ml in vacuo. The concentrate was adjusted to about pH 3
with concentrated hydrochloric acid and chromatographed on
Diaion.RTM. HP-20 (Mitsubishi Chemical Corporation) eluting with
30% aqueous 2-propanol. The eluate was concentrated to about 10 ml
in vatcuo and lyophilized to give
3-([3-amino-4-({2-[(2-aminoethyl)amino]-2-oxoacetyl)amino)-.sup.2-methyl--
1-pyrazolio]methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-ca-
rboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate (31 mg)
as an amorphous solid.
[0462] .sup.1H-NMR (D.sub.2O) .delta. 1.52. (3H, s), 1.53 (3H, s),
3.20 (1H, d, J=18.0 Hz), 3.24 (2H, t, J=6.0 Hz), 3.45 (1H, d,
J=18.0 Hz), 3.66 (2H, t, J=6.0 Hz), 3.75 (3H, s), 5.02 (1H, d,
J=15.5 Hz), 5.21 (1H, d, J=15.5 Hz), 5.25 (1H, d, J=5.0 Hz), 5.85
(1H, d, J=5.0 Hz), 8.14 (1H, s)
Preparation 59
[0463] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (711 mg) and
tert-butyl 3-azetidinylcarbamate acetic acid salt (418 mg) in
methylene chloride (8 ml) was added N-ethyldiisopropylamine (0.62
ml), and the mixture was stirred under reflux for 16 hours. To the
reaction mixture was added methylene chloride, and the solution was
washed successively with 10% aqueous citric acid solution, 10%
aqueous sodium hydroxide solution and brine. The organic layer was
dried over anhydrous magnesium sulfate, filtered and concentrated
in vacuo. The residue was triturated with a mixed solvent of ethyl
acetate and hexane to give tert-butyl
[1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino]carbonyl)-3-azetidin-
yl]carbamate (735 mg) as a solid.
[0464] .sup.1H-NMR (CDCl.sub.3) .delta. 1.47 (9H, s), 2.92 (3H, s),
3.56 (2H, dd, J=7.5, 5.0 Hz), 4.02 (2H, dd, J=7.5, 7.5 Hz), 4.42
(1H, brs), 4.71 (1H, s), 4.74 (1H, s), 4.94 (1H, brs), 7.18-7.21
(7H, m), 7.25-7.32 (9H, m)
EXAMPLE 35
[0465] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(819 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (655 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added a solution of tert-butyl
[1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-azetidin-
yl]carbamate (553 mg) in N,N-dimethylformamide (3 ml), and the
whole mixture was stirred at room temperature for 3 hours, and then
stirred at 50.degree. C. for 1 hour. To the resulting reaction
mixture were added ethyl acetate (50 ml) and water (50 ml). The
aqueous layer was separated, and the organic layer was washed with
water and brine, dried over anhydrous magnesium sulfate and
filtered. The filtrate was concentrated to about 5 ml in vacuo. The
concentrate was poured into diisopropyl ether (80 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(2.1 ml) were added anisole (0.7 ml) and trifluoroacetic acid (2.1
ml). The resulting solution was stirred at room temperature for 4.5
hours and poured into diisopropyl ether (80 ml). The resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (521 mg), which was purified by preparative HPLC
utilizing ODS column eluting with a mixture of acetonitrile and
phosphate buffer (pH 5.5). The eluate containing a desired product
was concentrated to about 20 ml in vacuo. The concentrate was
desalted by preparative HPLC utilizing ODS column, and the fraction
eluted with 7% acetonitrile/0.01 M hydrochloric acid was
concentrated to about 10 ml in vacuo and lyophilized to give
3-[(3-amino-4-([(3-amino-1-azetidinyl)carbonyl]amino]-2-methyl-1-pyrazoli-
o)methyl]-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-me-
thylethoxyimino)acetamido]-3-cephem-4-carboxylate trihydrochloride
(22 mg) as an amorphous solid.
[0466] .sup.1H-NMR (D.sub.2O) .delta. 1.62 (3H, s), 1.63 (3H, s),
3.25 (1H, d, J=17.9 Hz), 3.50 (1H, d, J=17.9 Hz), 3.72 (3H, s),
4.14 (2H, dd, J=9.6, 4.4 Hz), 4.25 (1H, tt, J=7.8, 4.6 Hz), 4.46
(2H, dd, J=9.6, 7.8 Hz), 5.08 (1H, d, J=15.6 Hz), 5.24 (1H, d,
J=15.6 Hz), 5.27 (1H, d, J=4.6 Hz), 5.88 (1H, d, J=4.6 Hz), 7.91
(1H, s)
Preparation 60
[0467] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (2.18 g) and
tert-butyl 3-amino-1-azetidinecarboxylate (793 mg) in methylene
chloride (20 ml) was added N-ethyldiisopropylamine (1.07 ml), and
the mixture was stirred under reflux for 40 hours. To the reaction
mixture was added methylene chloride, and the solution was washed
successively with 10% aqueous citric acid solution, 10% aqueous
sodium hydroxide solution and brine. The organic layer was dried
over anhydrous magnesium sulfate, filtered and concentrated in
vacuo. The residue was purified by column chromatography on silica
gel eluting with 10% methanol/methylene chloride to give tert-butyl
3-[(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-az-
etidinecarboxylate (1.52 g) as a solid.
[0468] .sup.1H-NMR (CDCl.sub.3) .delta. 1.44 (9H, s), 3.03 (3H, s),
3.59 (2H, dd, J=9.2, 5.0 Hz), 4.17 (2H, dd, J=9.2, 7.8 Hz),
4.39-4.43 (3H, m), 4.64 (1H, brs), 7.18-7.21 (6H, m), 7.27 (1H, s)
7.29-7.32 (9H, m)
EXAMPLE 36
[0469] To a solution of 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(1.48 g) in N,N-dimethylformamide (3.0 ml) was added
N-(trimethylsilyl)acetamide (1.42 g), and the mixture was stirred
at room temperature for 30 minutes. To the solution was added
potassium iodide (504 mg) and the mixture was stirred at room
temperature for 30 minutes. To the reaction mixture was added a
solution of tert-butyl
3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-az-
etidinecarboxylate (1.20 g) in N,N-dimethylformamide (2.2 ml), and
the whole mixture was stirred at 50.degree. C. for 16 hours. To the
35 -resulting reaction mixture was added ethyl-acetate (200 ml),
and the solution was washed successively with water (50 ml), 10%
aqueous sodium trifluoroacetate solution (50 ml.times.2) and brine
(50 ml), dried over anhydrous sodium sulfate and filtered. The
filtrate was concentrated to about 10 ml in vacuo. The concentrate
was poured into diisopropyl ether (160 ml), and the resulting
precipitate was collected by filtration and dried in vacuo. To a
solution of the solid in methylene chloride (8.64 ml) were added
anisole (2.88 ml) and trifluoroacetic acid (8.64 ml). The resulting
solution was stirred at room temperature for 3 hours and poured
into diisopropyl ether (160 ml). The resulting precipitate was
collected by filtration and dried in vacuo to give a crude product
(2.22 g), which was purified by preparative HPLC utilizing ODS
column eluting with a mixture of acetonitrile and phosphate buffer
(pH 5.5). The eluate containing a desired product was concentrated
to about 20 ml in vacuo. The concentrate was desalted by
preparative HPLC utilizing ODS column, and the fraction eluted with
8% aqueous acetonitrile was concentrated to about 10 ml in vacuo
and lyophilized to give
3-[(3-amino-4-{[(3-azetidinylamino)carbonyl]amino}-2-methyl-1-pyrazolio)m-
ethyl]-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methy-
lethoxyimino)acetamido]-3-cephem-4-carboxylate (220 mg) as an
amorphous solid.
[0470] .sup.1H-NMR (D.sub.2O) .delta. 1.50 (3H, s), 1.51 (3H, s),
3.20 (1H, d, J=17.6 Hz), 3.47 (1H, d, J=17.6 Hz), 3.70 (3H, s),
4.18 (2H, dd, J=11.2, 7.6 Hz), 4.31 (2H, dd, J=11.2, 8.3 Hz), 4.68
(1H, tt, J=8.3, 7.6 Hz), 4.94 (1H, d, J=15.6 Hz), 5.15 (1H, d,
J=15.6 Hz), 5.23 (1H, d, J=4.8 Hz), 5.83 (1H, d, J=4.8 Hz), 7.87
(1H, s)
Preparation 61
[0471] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (786 mg) and
tert-butyl 3-pyrrolidinylcarbamate (373 mg) in methylene chloride
(6 ml) was added N-ethyldiisopropylamine (0.43 ml), and the mixture
was stirred under reflux for 10 hours. The reaction mixture was
washed successively with 10% aqueous citric acid solution, brine
and saturated aqueous sodium hydrogen carbonate solution. The
organic layer was dried over anhydrous magnesium sulfate, filtered
and concentrated in vacuo to give tert-butyl
[1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-pyrrolid-
inyl]carbamate (730 mg) as a solid.
[0472] .sup.1H-NMR (CDCl.sub.3) .delta. 1.48 (9H, s), 1.82-1.88
(1H, m), 2.12-2.18 (1H, m), 2.89 (3H, s), 2.89-3.03 (1H, m),
3.20-3.30 (2H, m), 3.38-3.43 (1H, m), 4.22 (1H, br), 4.69 (1H, br)
4.88 (1H, brs),. 4.96 (1H, brs), 7.18-7.27 (16H, m)
EXAMPLE 37
[0473] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(819 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (655 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added a solution of tert-butyl
[1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyrrolid-
inyl]carbamate (567 mg) in N,N-dimethylformamide (3.0 ml). The
whole mixture was stirred at room temperature for 3 hours. To the
resulting reaction mixture were added ethyl acetate (100 ml) and
water (50 ml). The aqueous layer was separated, and the organic
layer was washed successively with 10% aqueous sodium
trifluoroacetate solution, 10% aqueous sodium thiosulfate solution
and brine, dried over sodium sulfate and filtered. The filtrate was
concentrated to about 2.5 ml in vacuo. The concentrate was poured
into diisopropyl ether (80 ml), and the resulting precipitate was
collected by filtration and dried in vacuo. To a solution of the
resulting solid in methylene chloride (2.55 ml) were added anisole
(0.85 ml) and trifluoroacetic acid (2.55 ml), and the mixture was
stirred at room temperature for 3 hours. The reaction mixture was
poured into diisopropyl ether (80 ml), and the resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (608 mg), which was purified by preparative HPLC
utilizing ODS column eluting with a mixture of acetonitrile and
phosphate buffer (pH 5.5). The eluate containing a desired product
was concentrated to about 20 ml in vacuo. The concentrate was
desalted by preparative HPLC utilizing ODS column, and the fraction
eluted with 7% acetonitrile/0.01 M hydrochloric acid was
concentrated to about 10 ml in vacuo and lyophilized to give
3-[(3-amino-4-{[(3-amino-1-pyrrolidinyl)carbonyl]amino)-2-methyl-1-pyrazo-
lio)methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1--
methylethoxyimino)acetamido]-3-cephem-4-carboxylate
trihydrochloride (31 mg) as an amorphous solid.
[0474] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (3H, s), 1.61 (3H, s),
2.13-2.27 (1H, m), 2.39-2.54 (1H, m), 3.29 (1H, d, J=18.1 Hz), 3.51
(1H, d, J=18.1 Hz), 3.55-3.68 (3H, m), 3.73 (3H, s), 3.80 (1H, dd,
J=11.5, 6.0 Hz), 4.01-4.11 (1H, m), 5.20 (1H, d, J=16.0 Hz), 5.24
(1H, d, J=16.0 Hz), 5.28 (1H, d, J=4.8 Hz), 5.89 (1H, d, J=4.8 Hz),
7.91 (1H, s)
Preparation 62
[0475] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (711 mg) and
tert-butyl 3-amino-1-pyrrolidinecarboxylate (372 mg) in methylene
chloride (15 ml) was added N-ethyldiisopropylamine (0.51 ml), and
the mixture was stirred under reflux for 17 hours. The reaction
mixture was washed successively with 10% aqueous citric acid
solution, brine and saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
purified by column chromatography on silica gel eluting with 10%
methanol/methylene chloride to give tert-butyl
3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-py-
rrolidinecarboxylate (511 mg) as a solid.
[0476] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 1.66-1.74
(1H, m), 2.04-2.11 (1H, m), 2.9-7 (3H, s), 3.05-3.11 (1H, m),
3.30-3.43 (2H, m), 3.53-3.58 (1H, m), 4.16-4.23 (2H, m), 4.45 (1H,
brs), 4.74 (1H, br), 7.18-7.20 (6H, m), 7.28-7.30 (10H, m)
EXAMPLE 38
[0477] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(707 mg) in N,N-dimethylformamide (2.1 ml) was added
N-(trimethylsilyl)acetamide (566 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture-was
added a solution of tert-butyl
3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)amino]-1-py-
rrolidinecarboxylate (490 mg) in N,N-dimethylformamide (2.0 ml).
The whole mixture was stirred at room temperature for 3 hours. To
the resulting reaction mixture were added ethyl acetate (100 ml)
and water (50 ml). The aqueous layer was separated, and the organic
layer was washed successively with 10% aqueous sodium
trifluoroacetate solution, 10% aqueous sodium thiosulfate solution
and brine, dried over sodium sulfate and filtered. The filtrate was
concentrated to about 3 ml in vacuo. The concentrate was poured
into diisopropyl ether (80 ml), and the resulting precipitate was
collected by filtration and dried in vacuo. To a solution of the
resulting solid in methylene chloride (1.83 ml) were added anisole
(0.61 ml) and trifluoroacetic acid (1.83 ml), and the mixture was
stirred at room temperature for 5 hours. The reaction mixture was
poured into diisopropyl ether (8-0 ml), and the resulting
precipitate was collected by filtration and dried in vacuo to give
a crude product (440 mg), which was purified by preparative HPLC
utilizing ODS column. The eluate containing desired products was
concentrated to about 30 ml in vacuo. The concentrate was adjusted
to about pH 3 with concentrated hydrochloric acid and
chromatographed on Diaion.RTM. HP-20 (Mitsubishi Chemical
Corporation) eluting with 30% aqueous 2-propanol. The eluate was
concentrated to about 30 ml in vacuo and lyophilized to give
3-[(3-amino-2-methyl-4-{[(3-pyrrolidinylamino)carbonyl]amino)-1-pyrazolio-
)methyl]-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-met-
hylethoxyimino)acetamido]-3-cephem-4-carboxylate (18 mg) as an
amorphous solid.
[0478] .sup.1H-NMR (D.sub.2O) .delta. 1.54 (3H, s), 1.55 (3H, s),
2.00-2.10 (1H, m), 2.30-2.40 (1H, m), 3.23 (0.5H, d, J=17.9 Hz),
3.24 (0.5H, d, J=17.9 Hz), 3.27-3.34 (1H, m), 3.34-3.43 (1H, m),
3.45-3.57 (3H, m), 3.72 (3H, s), 4.36-4.46 (1H, m), 4.95 (0.5H, d,
J=15.1 Hz), 4.96 (0.5H, d, J=15.6 Hz), 5.17 (1H, d, J=15.6 Hz),
5.26 (1H, d, J=5.0 Hz), 5.85 (1H, d, J=5.0 Hz), 7.88 (1H, s)
Preparation 63
[0479] To a suspension of tert-butyl
{2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-eth-
yl}carbamate (10.8 g) in methanol (50 ml) was added 4M hydrogen
chloride solution in dioxane (50 ml). The mixture was stirred at
room temperature for 3 hours. The solvent was concentrated in
vacuo, and the residue was triturated with ethyl acetate and dried
in vacuo to give
N-(2-aminoethyl)-N'-(5-amino-1-methyl-1H-pyrazol-4-yl)urea
trihydrochloride (5.6 g) as a solid.
[0480] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.84-2.87 (2H, m), 3.30
(2H, brs), 3.71 (3H, s), 6.57 (1H, br), 7.91 (1H, s), 8.05 (4H,
br), 8.55 (1H, br)
Preparation 64
[0481] To a solution of
N-(2-aminoethyl)-N'-(5-amino-1-methyl-1H-pyrazol-4-yl)urea
trihydrochloride (3.1 g) and triethylamine (4.6 g) in chloroform
(100 ml) was added di-tert-butyl
({[(trifluoromethyl)sulfonyl]imino)-methylene)biscarbamate (5.9 g).
The mixture was stirred at room temperature for 90 minutes. The
reaction mixture was washed successively with 10% aqueous citric
acid solution, brine and saturated aqueous sodium hydrogen
carbonate solution. The organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. The residue
was triturated with ethyl acetate to give di-tert-butyl
((Z)-{[2-(([(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl)amino)-ethyl-
]amino}methylidene)biscarbamate (4.3 g) as a'solid.
[0482] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 1.48 (9H,
s), 3.18 (2H, q, J=6.0 Hz), 3.35 (2H, br), 3.49 (3H, s), 4.77 (1H,
brs), 6.05 (1H, br), 6.97 (1H, s), 7.19 (1H, brs), 8.36 (1H, t,
J=5.5 Hz), 11.49 (1H, brs)
Preparation 65
[0483] To a solution of di-tert-butyl
((Z)-{[2-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino)carbonyl)amino)-ethyl-
]amino}methylidene)biscarbamate (2.2 g) and triethylamine (0.6 g)
in chloroform (30 ml) was added trityl chloride (1.7 g), and the
mixture was stirred at room temperature for 14 hours. The reaction
mixture was washed successively with 10% aqueous citric acid
solution, brine and saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
triturated with ethyl acetate to give di-tert-butyl
[(Z)-((2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amin-
o]-ethyl}amino)methylidene]biscarbamate (1.9 g) as a solid.
[0484] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 1.47 (9H,
s), 2.72 (3H, s), 3.09-3.10 (2H, m), 3.31-3.34 (2H, m), 5.69 (1H,
s), 6.10 (1H, br), 6.77 (1H, brs), 7.02 (1H, s), 7.14-7.16 (6H, m),
7.22-7.27 (9H, m), 8.36 (1H, t, J=5.5 Hz), 11.51 (1H, brs)
EXAMPLE 39
[0485] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(820 mg) in N,N-dimethylformamide (1.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture were
added di-tert-butyl
[(Z)-({2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amin-
o]ethyl}amino)methylidene]-biscarbamate (820 mg) and
N,N-dimethylformamide (2.0 ml). The whole mixture was stirred at
room temperature for 3 hours. To the resulting reaction mixture
were added ethyl acetate (100 ml) and water (50 ml). The aqueous
layer was separated, and the organic layer was washed successively
with 10% aqueous sodium trifluoroacetate solution, 10% aqueous
sodium thiosulfate solution and brine, dried over sodium sulfate
and filtered. The filtrate was concentrated to about 5 ml in vacuo.
The concentrate was poured into diisopropyl ether (120 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(3.0 ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0
ml), and the mixture was stirred at room temperature for 4 hours.
The reaction mixture was poured into diisopropyl ether (100 ml),
and the resulting precipitate was collected by filtration and dried
in vacuo to give a crude product (740 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
3-([3-amino-4-({[(2-guanidinoethyl)amino]carbonyl}amino)-2-methyl-1-pyraz-
olio]methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-
-methylethoxyimino)acetamido]-3-cephem-4-carboxylate (70 mg) as an
amorphous solid.
[0486] .sup.1H-NMR (D.sub.2O) .delta. 1.55 (3H, s), 1.56 (3H, s),
3.24 (1H, d, J=17.6 Hz), 3.28-3.40 (4H, m), 3.52 (1H, d, J=17.6
Hz), 3.73 (3H, s), 4.97 (1H, d, J=15.4 Hz), 5.16 (1H, d, J=15.4
Hz), 5.27 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 7.87 (1H,
s)
Preparation 66
[0487] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (950 mg) and
tert-butyl (3S)-3-pyrrolidinylcarbamate (560 mg) in methylene
chloride (20 ml) was added N-ethyldiisopropylamine (390 mg), and
the mixture was stirred under reflux for 23 hours. The reaction
mixture was washed successively with 10% aqueous citric acid
solution, brine and saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
purified by column chromatography on silica gel eluting with 4%
methanol/chloroform to give tert-butyl
[(3S)-1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyr-
rolidinyl]carbamate (680 mg) as a solid.
[0488] .sup.1H-NMR (CDCl.sub.3) .delta. 1.48 (9H, s), 1.82-1.88
(1H, m), 2.12-2.18 (1H, m), 2.89 (3H, s), 2.89-3.03 (1H, m),
3.20-3.30 (2H, m), 3.38-3.43 (1H, m), 4.22 (1H, br), 4.69 (1H, br),
4.88 (1H, brs), 4.96 (1H, brs), 7.18-7.27 (16H, m)
EXAMPLE 40
[0489] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(820 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added tert-butyl
[(3S)-1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-pyr-
rolidinyl]carbamate (680 mg). The whole mixture was stirred at room
temperature for 3 hours. To the resulting reaction mixture were
added ethyl acetate (80 ml) and water (50 ml). The aqueous layer
was separated, and the organic layer was washed successively with
10% aqueous sodium trifluoroacetate solution, 10% aqueous sodium
thiosulfate Evolution and brine, dried over sodium sulfate and
filtered. The filtrate was concentrated to about 5 ml in vacuo. The
concentrate was poured into diisopropyl ether (120 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(3.0 ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0
ml), and the mixture was stirred at room temperature for 4 hours.
The reaction mixture was poured-into diisopropyl ether (100 ml),
and the resulting precipitate was collected by filtration and dried
in vacuo to give a crude product (690 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give
3-{[3-amino-4-({[(3S)-3-amino-1-pyrrolidinyl]carbonyl}amino)-2-methyl-1-p-
yrazolio]methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carbo-
xy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate (60 mg) as
an amorphous solid.
[0490] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (6H, s), 2.13-2.27 (1H,
m), 2.38-2.53 (1H, m), 3.20 (1H, d, J=17.4 Hz), 3.46 (1H, d, J=17.4
Hz), 3.54-3.67 (3H, m), 3.73 (3H, s), 3.79 (1H, dd, J=11.5, 6.0
Hz), 4.00-4.10 (1H, m), 4.97 (1H, d, J=15.4 Hz), 5.16 (1H, d,
J=15.4 Hz), 5.25 (1H, d, J=4.8 Hz), 5.83 (1H, d, J=4.8 Hz), 7.85
(1H, s)
Preparation 67
[0491] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (950 mg) and
tert-butyl (3R)-3-pyrrolidinylcarbamate (560 mg) in methylene
chloride (20 ml) was added N-ethyldiisopropylamine (390 mg), and
the mixture was stirred under reflux for 23 hours. The reaction
mixture was washed successively with 10% aqueous citric acid
solution, brine and saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
purified by column chromatography on silica gel eluting with 4%
methanol/chloroform to give tert-butyl
[(3R)-1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyr-
rolidinyl]carbamate (700 mg) as a solid.
[0492] .sup.1H-NMR (CDCl.sub.3) .delta. 1.48 (9H, s), 1.82-1.88
(1H, m), 2.12-2.18 (1H, m), 2.89 (3H, s), 2.89-3.03 (1H, m),
3.20-3.30 (2H, m), 3.38-3.43 (1H, m), 4.22 (1H, br), 4.69 (1H, br),
4.88 (1H, brs), 4.96 (1H, brs), 7.18-7.27. (16H, m)
EXAMPLE 41
[0493] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(820 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide. (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added tert-butyl
[(3R)-1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyr-
rolidinyl]carbamate (680 mg). The whole mixture was stirred at room
temperature for 3 hours. To the resulting reaction mixture were
added ethyl acetate (80 ml) and water (50 ml). The aqueous layer
was separated, and the organic layer was washed successively with
10% aqueous sodium trifluoroacetate solution, 10% aqueous sodium
thiosulfate solution and brine, dried over sodium sulfate and
filtered. The filtrate was concentrated to about 5 ml in vacuo. The
concentrate was poured into diisopropyl ether (120 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(3.0 ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0
ml), and the mixture was stirred at room temperature for 4 hours.
The reaction mixture was poured into diisopropyl ether (100 ml),
and the resulting precipitate was collected by filtration and dried
in vacuo to give a crude product (760 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30%
aqueous-2-propanol. The eluate was concentrated to about 30 ml in
vacuo and lyophilized to give
3-{[3-amino-4-({[(3R)-3-amino-1-pyrrolidinyl]carbonyl)amino}-2-methyl-1-p-
yrazolio]methyl}-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carbo-
xy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate (68 mg) as
an amorphous solid.
[0494] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (6H, s), 2.13-2.27 (1H,
m), 2.38-2.53 (1H, m), 3.20 (1H, d, J=17.6 Hz), 3.47 (1H, d, J=17.6
Hz), 3.56-3.66 (3H, m), 3.73 (3H, s), 3.79 (1H, dd, J=11.0, 6.0
Hz), 4.00-4.10 (1H, m), 4.96 (1H, d, J=15.1 Hz), 5.15 (1H, d,
J=15.1 Hz), 5.26 (1H, d, J=4.8 Hz), 5.83 (1H, d, J=4.8 Hz), 7.84
(1H, s)
Preparation 68
[0495] To a suspension of phenyl
(5-amino-1-methyl-1H-pyrazol-4-yl)carbamate (1.86 g) and
(3S)-1-benzyl-3-pyrrolidinamine (2.0 g) in chloroform (50 ml) was
added N-ethyldiisopropylamine (3.1 g), and the mixture was stirred
under reflux for 19 hours. The reaction mixture was concentrated in
vacuo to give crude
(S)-5-amino-4-[3-(1-benzyl-3-pyrrolidinyl)ureido]-1-methyl-1H-pyraz-
ole as a solid. A solution of the crude product in acetic acid was
treated with palladium black (3 ml) under a hydrogen atomosphere at
room temperature for 24 hours. After the catalyst was filtered off,
the filtrate was concentrated in vacuo, and the residue was
dissolved in saturated aqueous sodium hydrogen carbonate solution
(100 ml). To the solution was added a solution of di-tert-butyl
dicarbonate (5.0 g) in tetrahydrofuran (40 ml), and the mixture was
stirred at room temperature for hours. The reaction mixture was
extracted with chloroform. The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated in vacuo.
The residue was triturated with diethyl ether to give tert-butyl
(3S)-3-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}amino)-1-pyrro-
lidinecarboxylate (1.9 g) as a solid.
[0496] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.40 (9H, s), 1.70-1.76
(1H, m), 1.95-2.02 (1H, m), 3.01-3.05 (1H, m), 3.24-3.34 (2H, m),
3.38-3.45 (1H, m) 3.50 (3H, s), 4.06-4.11 (1H, m), 4.78 (2H, brs),
6.19 (1H, brs), 6.97 (1H, s), 7.09 (1H, brs)
Preparation 69
[0497] To a solution of tert-butyl
(3S)-3-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}amino)-1-pyrro-
lidinecarboxylate (1.8 g) and N-ethyldiisopropylamine (720 mg) in
chloroform (50 ml) was added trityl chloride (1.6 g), and the
mixture was stirred at room temperature for 28 hours. The reaction
mixture was washed successively with 10% aqueous citric acid
solution, brine and saturated aqueous sodium hydrogen carbonate
solution. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was
purified by column chromatography on silica gel eluting with 3%
methanol/chloroform to give tert-butyl
(3S)-3-[(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-
-1-pyrrolidinecarboxylate (1.7 g) as a solid.
[0498] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 1.66-1.74
(1H, m), 2.04-2.11 (1H, m), 2.97 (3H, s), 3.05-3.11 (1H, m),
3.30-3.43 (2H, m), 3.53-3.58 (1H, m), 4.16-4.23 (2H, m), 4.45 (1H,
brs), 4.74 (1H, br), 7.18-7.20 (6H, m), 7.28-7.30 (1H, m)
EXAMPLE 42
[0499] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(820 mg) in N,N-dimethylformamide (2.4 ml) was added
N-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added tert-butyl
(3S)-3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-
-1-pyrrolidinecarboxylate (680 mg). The whole mixture was stirred
at room temperature for 3 hours. To the resulting reaction mixture
were added ethyl acetate (80 ml) and water (50 ml). The aqueous
layer was separated, and the organic layer was washed successively
with 10% aqueous sodium trifluoroacetate solution, 10% aqueous
sodium thiosulfate solution and brine, dried over sodium sulfate
and filtered. The filtrate was concentrated to about 5 ml in vacuo.
The concentrate was poured into diisopropyl ether (120 ml), and the
resulting precipitate was collected by filtration and dried in
vacuo. To a solution of the resulting solid in methylene chloride
(3.0 ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0
ml), and the mixture was stirred at room temperature for 5 hours.
The reaction mixture was poured into diisopropyl ether (100 ml),
and the resulting precipitate was collected by filtration and dried
in vacuo to give a crude product (870 mg), which was purified by
preparative HPLC utilizing ODS column. The eluate containing a
desired product was concentrated to about 30 ml in vacuo. The
concentrate was adjusted to about pH 3 with concentrated
hydrochloric acid and chromatographed on Diaion.RTM. HP-20
(Mitsubishi Chemical Corporation) eluting with 30% aqueous
2-propanol. The eluate was concentrated to about 30 ml in vacuo and
lyophilized to give 3-{[3-amino-2-methyl-4-({[(3S)
-3-pyrrolidinylamino]carbonyl)-amino)-1-pyrazolio]methyl)-7.beta.-[(Z)-2--
(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)-acetamid-
o]-3-cephem-4-carboxylate (68 mg) as an amorphous solid.
[0500] .sup.1H-NMR (D.sub.2O) .delta. 1.52 (3H, s), 1.53 (3H, s),
2.00-2.09 (1H, m), 2.28-2.38 (1H, m), 3.22 (1H, d, J=17.4 Hz), 3.29
(1H, dd, J=12.4, 4.6 Hz), 3.34-3.42 (1H, m), 3.44-3.54 (3H, m),
3.71 (3H, s), 4.36-4.43 (1H, m), 4.95 (1H, d, J=15.6 Hz), 5.15 (1H,
d, J=15.6 Hz), 5.25 (1H, d, J=4.6 Hz), 5.84 (1H, d, J=4.6 Hz), 7.87
(1H, s)
Preparation 70
[0501] To a suspension of 4-[(tert-butoxycarbonyl)amino]butanoic
acid (2.13 g) in dichloromethane (40 ml) was added
1-hydroxybenzotriazole (HOBT) (1.41 g) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (WSCD
HCl) (3.65 g), and the mixture was stirred for 1 hour. To the
solution were added 1-methyl-1H-pyrazole-4,5-diamine sulfate (2 g)
and N,N-diisopropylethylamine (3.32 ml). The reaction mixture was
stirred for 18 hours. To the resulting solution were added brine
and saturated aqueous sodium hydrogen carbonate solution, and the
mixture was extracted with ethyl acetate. The aqueous layer was
extracted with tetrahydrofuran/ethyl acetate=1/1 twice. The extract
was dried over anhydrous magnesium sulfate, filtered and
concentrated in vacuo. To the residue was added pyridiny (40 ml),
and then added chlorotriphenylmethane (5.3 g). The mixture was
stirred at 65.degree. C. for 6 hours. The mixture was dissolved in
ethyl acetate. The solution was washed successively with water, 10%
aqueous citric acid solution, water and brine. The extract was
dried over anhydrous magnesium sulfate, filtered and concentrated
in vacuo. The residue was purified by column chromatography on
silica gel eluting with 60% ethyl acetate/dichloromethane to give
tert-butyl
(4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxobutyl)carbamate
(2.01 g).
[0502] .sup.1H-NMR (CDCl.sub.3) .delta. 1.44 (9H, s), 1.67 (2H, tt,
J=6.7, 6.7 Hz), 1.92 (2H, t, J=6.7 Hz), 2.90 (3H, s), 3.09 (2H, dt,
J=6.7, 6.7 Hz), 4.50 (1H, s), 4.71 (1H, t, J=6.7 Hz), 6.53 (1H, s),
7.0-7.35 (16H, m), 7.56 (1H, s)
EXAMPLE 43
[0503] To a solution of benzhydryl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate
(2 g) in N,N-dimethylformamide (6 ml) was added
N-(trimethylsilyl)acetamide (1.77 g), and the mixture was stirred
at room temperature for 30 minutes. To the reaction mixture was
added tert-butyl
(4-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-4-oxobutyl)carbamate
(1.98 g), and the whole mixture was stirred at 35.degree. C. for 30
hours. To the resulting reaction mixture was added ethyl acetate,
and the solution was washed successively with water, 10% aqueous
sodium trifluoroacetate solution and brine, dried over magnesium
sulfate and filtered. The filtrate was concentrated to about 25 ml
in vacuo. The concentrate was poured into diisopropyl ether (150
ml), and the resulting precipitate was collected by filtration and
dried in vacuo. To a solution of the solid in methylene chloride (5
ml) were added anisole (1.5 ml) and trifluoroacetic acid (5 ml).
The resulting solution was stirred at room temperature for 4 hours
and poured into diisopropyl ether. The resulting precipitate was
collected by filtration and dried in vacuo to give a crude product
(1.2 g). The crude product was dissolved in a mixture of phosphate
buffer (pH 6.86, 10 ml) and saturated aqueous sodium hydrogen
carbonate solution and purified by preparative HPLC utilizing ODS
column. The eluate containing a desired product was concentrated to
about 20 ml in vacuo. The concentrate was adjusted to about pH 3
with concentrated hydrochloric acid and chromatographed on
Diaion.RTM. HP-20 (Mitsubishi Chemical Corporation) eluting with
20% aqueous 2-propanol. The eluate was concentrated to about 30 ml
in vacuo, and 2M aqueous sulfuric acid solution (72 ml) was added.
The mixture was lyophilized to give
3-({3-amino-4-[(4-aminobutanoyl)amino]-2-methyl-1-pyrazolio}methyl)-7.bet-
a.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino-
)acetamido]-3-cephem-4-carboxylic acid hydrogen sulfate (113 mg) as
an amorphous solid.
[0504] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 2.01 (2H, tt,
J=7.6, 7.6 Hz) 2.58 (2H, t, J=7.6 Hz), 3.07 (2H, t, J=7.6 Hz), 3.23
(1H, d, J=18 Hz), 3.45 (1H, d, J=18 Hz), 3.72 (3H, s), 5.06 (1H, d,
J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.28 (1H, d, J=15.7 Hz), 5.87
(1H, d, J=4.8 Hz), 8.03 (1H, s)
Preparation 71
tert-Butyl
(5-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-5-oxopenty-
l)carbamate
[0505] The title compound was obtained from
5-[(tert-butoxycarbonyl)amino]pentanoic acid in the same manner as
in Preparation 70.
[0506] .sup.1H-NMR (CDCl.sub.3) .delta. 1.43 (9H, s), 1.2-1.6 (4H,
m), 1.90 (2H, t, J=7.0 Hz), 2.90 (3H, s), 3.09 (2H, dt, J=7.0, 7.0
Hz), 4.52 (1H, s), 4.61 (1H, t, J=7.0 Hz), 6.28 (1H, s), 7.0-7.35
(16H, m), 7.59 (1H, s)
EXAMPLE 44
3-({3-Amino-4-[(5-aminopentanoyl)amino]-2-methyl-1-pyrazolio)methyl)-7.bet-
a.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino-
)acetamido]-3-cephem-4-carboxylic acid hydrogen sulfate
[0507] The title compound was obtained from tert-butyl
(5-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-5-oxopentyl)carbamat-
e in the same manner as in Example 43.
[0508] .sup.1H-NMR (D.sub.2O) .delta. 1.61 (6H, s), 1.65-1.8 (4H,
m), 2.50 (2H, m)o, 3.02 (2H, m), 3.23 (1H, d, J=18 Hz) 3.45 (1H, d,
J=18 Hz), 3.72 (3H, s), 5.06 (1H, d, J=15.7 Hz), 5.25 (1H, d, J=4.8
Hz), 5.28 (1H, d, J=15.7 Hz), 5.87 (1H, d, J=4.8 Hz), 8.02 (1H,
s)
Preparation 72
[0509] To a solution of
1-methyl-N.sup.5-trityl-1H-pyrazole-4,5-diamine (4 g) in
dichloromethane (100 ml) was added tert-butyl
4-{[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl}-1-piperidinecarboxylate
(4.05 g), and the mixture was refluxed for 72 hours. The reaction
mixture was washed successively with water, 10% aqueous citric acid
solution, water and brine. The extract was dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo to give
tert-butyl
4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperidin-
ecarboxylate (1.806 g).
[0510] .sup.1H-NMR (CDCl.sub.3) .delta. 1.3-1.9 (14H, m), 1.5-1.8
(2H, m), 2.95 (3H, s), 4.10 (2H, m), 4.36 (1H, s), 6.53 (1H, s),
7.0-7.35 (16H, m), 7.68 (1H, s)
EXAMPLE 45
3-({3-Amino-2-methyl-4-[(4-piperidinylcarbonyl)amino]-1-pyrazolio)methyl)--
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-cephem-4-carboxylate
[0511] The title compound was obtained from tert-butyl
4-({([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-piperidi-
necarboxylate in the same manner as in Example 36.
[0512] .sup.1H-NMR (D.sub.2O) .delta. 1.57 (6H, s), 1.8-2.3 (4H,
m), 2.7-3.6 (7H, m), 3.72 (3H, s), 5.06 (1H, d, J=15.7 Hz), 5.25
(1H, d, J=4.8 Hz), 5.28 (1H, d, J=15.7 Hz), 5.87 (1H, d, J=4.8 Hz),
8.01 (AH, s)
Preparation 73
[0513] To a suspension of
3-[N-(tert-butoxycarbonyl)-N-methylaminolpropanoic acid (3.33 g) in
dichloromethane (33 ml) and tetrahydrofuran (33 ml) were added HOBT
(3.33 g) and WSC HCl (6.29 g), and the mixture was stirred for 1
hour. To the solution were added 1-methyl-1H-pyrazole-4,5-diamine
sulfate (3.45 g) and N,N-diisopropylethylamine (11.4 ml). The
reaction mixture was stirred at room temperature overnight. To the
resulting solution was added brine and extracted with
tetrahydrofuran/ethyl acetate=1/1. The extract was dried over
anhydrous magnesium sulfate, filtered and concentrated in vacuo to
give tert-butyl
N-{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropyl}-N-methylcarba-
mate as an oil (2.4 g). This product was used in the next step
without further purification.
Preparation 74
[0514] To a solution of tert-butyl
N-{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropyl)-N-methylcarba-
mate (4.88 g) in N,N-dimethylformamide (50 ml) were added trityl
chloride (6.86 g), triethylamine (6.86 ml) and
4-dimethylaminopyridine (80 mg) succesively. The mixture was
stirred at room temperature overnight. To the resulting mixture was
added ethyl acetate and washed with water (three times) and brine.
The organic layer was dried over anhydrous magnesium sulfate,
filtered and concentrated in vacuo. The residue was purified by
column chromatography on silica gel to give tert-butyl
N-methyl-N-(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxoprop-
yl)carbamate (4.20 g) as an amorphous solid.
[0515] IR (KBr) 1659, 1587, 1491, 1446, 1173, 1151, 762, 739, 708
cm.sup.-1
[0516] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.40 (9H, s), 2.12 (2H,
t, J=7.4 Hz) 2.74 (3H, s), 2.74 (3H, s), 3.24 (2H, t, J=7.4 Hz),
5.58 (1H, s), 7.13-7.40 (16H, m), 8.30 (1H, s)
EXAMPLE 46
3-[(3-Amino-2-methyl-4-{[3-(methylamino)propanoyl]amino}-1-pyrazolio)methy-
l]-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyleth-
oxyimino)acetamido]-3-cephem-4-carboxylate
[0517] The title compound was obtained from tert-butyl
N-methyl-N-(3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxoprop-
yl)carbamate in the same manner as in Example 32 as an amorphous
solid.
[0518] IR (KBr) 1770, 1664, 1599, 1531, 1400, 1360 cm.sup.-1
[0519] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 2.77 (3H, s),
2.92 (2H, t, J=6.5 Hz), 3.19 and 3.45 (2H, ABq, J=17.7 Hz), 3.74
(3H, s), 5.00 and 5.21. (2H, ABq, J=15.4 Hz), 5.25 (1H, d, J=4.8
Hz), 5.85 (1H, d, J=4.8 Hz), 8.02 (1H, s)
[0520] ESI-MS 666.3 (M+H.sup.+)
Preparation 75
tert-Butyl
3-{[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}-1-azetidi-
necarboxylate
[0521] The title compound was obtained from
1-(tert-butoxycarbonyl)-3-azetidinecarboxylic acid in the same
manner as in Preparation 73 as an oil. This product was used in the
next step without further purification.
Preparation 76
tert-Butyl
3-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-
-azetidinecarboxylate
[0522] The title compound was obtained from tert-butyl
3-{[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}-1-azetidinecarboxyl-
ate in the same manner as in Preparation 74 as an amorphous
solid.
[0523] IR (KBr) 3367, 3321, 1701, 1662, 1489, 1414, 1144, 766, 704
cm.sup.-1
[0524] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 2.75 (3H,
s), 2.97-3.05 (1H, m), 3.63-3.70 (2H, m)0, 3.82-3.90 (2H, m), 5.57
(1H, s), 7.10-7.33 (16H, m), 8.41 (1H, s)
[0525] ESI-MS 560.3 (M+Na.sup.+)
EXAMPLE 47
3-({3-Amino-4-[(3-azetidinylcarbonyl)amino]-2-methyl-1-pyrazolio}methyl)-7-
.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyi-
mino)acetamido]-3-cephem-4-carboxylate
[0526] The title compound was obtained from tert-butyl
3-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-azetidine-
carboxylate in the same manner as in Example 32 as an amorphous
solid.
[0527] IR (KBr) 1768, 1663, 1624, 1605, 1406, 1362 cm.sup.-1
[0528] .sup.1H-NMR (D.sub.2O) .delta. 1.53 *(3H, s), 1.53 (3H, s),
3.19 and 3.50 (2H, ABq, J=17.7 Hz), 3.82-3.98 (1H, m), 4.31-4.35
(4H, m), 4.49 and 5.20 (2H, ABq, J=15.3 Hz), 5.25 (1H, d, J=4.8
Hz), 5.85 (1H, d, J=4.8 Hz), 8.04 (1H, s)
[0529] ESI-MS 664.2 (M+H.sup.+)
Preparation 77
tert-Butyl
N-{2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethyl}-N-me-
thylcarbamate
[0530] The title compound was obtained from
[N-(tert-butoxycarbonyl)-N-(methyl)amino]acetic acid in the same
manner as in Preparation 73 as an oil. This product was used in the
next step without further purification.
Preparation 78
tert-Butyl
N-methyl-N-(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-
-2-oxoethyl)carbamate
[0531] The title compound was obtained from tert-butyl
N-(2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethyl)-N-methylcarbam-
ate in the same manner as in Preparation 74 as a white solid. The
NMR spectrum of this compound indicates the existence of its
rotamer.
[0532] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.32 and 1.39 (9H, s),
2.72 and 2.77 (3H, s), 3.52 and 3.61 (2H, brs), 5.61 (1H, s),
7.13-7.33 (16H, m), 8.20 and 8.30 (1H, brs)
[0533] ESI-MS 548;3 (M+Na.sup.+)
EXAMPLE 48
3-[(3-Amino-2-methyl-4-{[(methylamino)acetyl]amino}-1-pyrazolio)methyl]-71-
-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)a-
cetamido]-3-cephem-4-carboxylate
[0534] The title compound was obtained from tert-butyl
N-methyl-N-(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethy-
l)carbamate in the same manner as in Example 32 as an
amorphous-solid.
[0535] IR (KBr) 1770, 1657, 1601, 1400, 1362 cm.sup.-1
[0536] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 2.82 (3H, s),
3.18 and 3.45 (2H, ABq, J=17.7 Hz), 3.74 (3H, s), 4.08 (2H, s),
5.00 and 5.20 (2H, ABq, J=15.3 Hz), 5.25 (1H, d, J=4.8 Hz), 5.84
(1H, d, J=4.8 Hz), 8.05 (1H, s)
[0537] ESI-MS 652.2 (M+H.sup.+)
Preparation 79
N-(5-Amino-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol--
2-yl)acetamide
[0538] The title compound was obtained from
(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetic acid in the same
manner as in Preparation 73 as a solid.
[0539] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.55. (3H, s), 4.36 (2H,
s), 4.91 (2H, brs), 7.14 (1H, s), 7.85-8.02 (4H, m), 9.48 (1H,
s)
[0540] ESI-MS 322.2 (M+Na.sup.+)
Preparation 80
2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-[1-methyl-5-(tritylamino)-1H--
pyrazol-4-yl]acetamide
[0541] The title compound was obtained from
N-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-
-2-yl)acetamide in the same manner as in Preparation 74 as a
solid.
[0542] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.70 (3H, s), 4.12 (2H,
s), 5.41 (1H, s), 7.12-7.33 (16H, m), 7.85-7.95 (4H, m), 8.93 (1H,
s)
[0543] ESI-MS 564.3 (M+Na.sup.+)
Preparation 81
[0544] Hydrazine monohydrate (1.46 ml) was added to a solution of
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-[1-methyl-5-(tritylamino)-1H-
-pyrazol-4-yl]acetamide (5.42 g) in ethanol (108 ml) and
tetrahydrofuran (54 ml) at room temperature, and the mixture was
stirred at 70.degree. C. for 2 hours. The reaction mixture was
cooled to 0.degree. C., and the insoluble materials were removed-by
filtration. The filtrate was concentrated in vacuo. The residue was
triturated with diisopropyl ether, collected by filtration and
dried in vacuo to give
2-amino-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide (3.37
g) as a solid. This product was used in the next step without
further purification.
Preparation 82
[0545] To a solution of
2-amino-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide (2.47
g) in tetrahydrofuran (50 ml) were added di-tert-butyl
({[(trifluoromethyl)sulfonyl]imino}methylene)-biscarbamate (2.35 g)
and triethylamine (2.5 ml), and the mixture was stirred at room
temperature for 30 minutes. The reaction mixture was poured into a
mixture of ethyl acetate and water. The aqueous layer was
separated, and the organic layer was washed with brine, dried over
anhydrous magnesium sulfate and filtered. The filtrate was
concentrated in vacuo. The concentrate was purified by silica gel
column chromatography to give di-tert-butyl
{(E)-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethyl)ami-
no]methylidene}-biscarbamate (3.25 g) as an amorphous solid.
[0546] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 1.49 (9H,
s), 2.75 (3H, s), 3.79 (2H, d, J=4.7 Hz), 5.47 (1H, s), 7.12-7.33
(16H, m), 8.55 (1H, t, J=4.7 Hz), 8.61 (1H, s), 11.43 (1H, s)
[0547] ESI-MS 676.3 (M+Na.sup.+)
EXAMPLE 49
3-({3-Amino-4-[(guanidinoacetyl)amino]-2-methyl-1-pyrazolio}methyl)-7.beta-
.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)-
acetamido]-3-cephem-4-carboxylate
[0548] The title compound was obtained from di-tert-butyl
{(E)-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-.sup.4-yl]amino}-2-oxoethy-
l)amino]methylidene)biscarbamate in the same manner as in Example
32 as an amorphous solid.
[0549] IR (KBr) 1770, 1668, 1655, 1620, 1601, 1402, 1363
cm.sup.-1
[0550] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 3.20 and 3.48
(2H, ABq, J=17.6 Hz), 3.75 (3H, s), 4.21 (2H, s), 5.00 and 5.20
(2H, ABq, J=15.3 Hz), 5.26 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8
Hz), 8.02 (1H, s)
[0551] ESI-MS 678.2 (M-H.sup.+) (negative)
EXAMPLE 50
[0552] To a solution of
3-({3-amino-4-[(3-aminopropanoyl)amino]-2-methyl-1-pyrazolio)methyl)-7.be-
ta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimin-
o)acetamido]-3-cephem-4-carboxylate (652 mg) in water (30 ml) and
acetonitrile (3 ml) were added ethyl formimidate hydrochloride (658
mg) and potassium carbonate (1.106 g) under ice cooling. After
stirring at 5.degree. C. for 3 hours, 1N HCl was added to
neutralize the reaction mixture. The resulting solution was
purified by preparative HPLC eluting with a mixture of phosphate
buffer (pH 5.5) and acetonitrile, and the eluate was subjected to
column chromatography on Diaion.RTM. HP20 (Mitsubishi Chemical
Corporation) and lyophilized to give
3-({3-amino-4-[(3-guanidinopropanoyl)amino]-2-methyl-1-pyrazolio}methyl)--
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-cephem-4-carboxylate (23 mg) as an amorphous.
The NMR spectrum of this compound indicates the existence of its
rotamer. Only major isomer was described.
[0553] IR (KBr) 1770, 1714, 1668, 1653, 1456, 1400, 1360
cm.sup.-1
[0554] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 2.85 (2H, t,
J=6.4 Hz), 3.19 and 3.46 (2H, ABq, J=17.7 Hz), 3.65 (2H, t, J=6.4
Hz), 5.00 and 5.21 (2H, ABq, J=15.2 Hz), 5.26 (1H, d, J=4.8 Hz),
5.85 (1H, d, J=4.8 Hz), 7.80 (1H, s), 8.01 (1H, s)
[0555] ESI-MS 677.2 (M-H.sup.+) (negative)
Preparation 83
[0556] To a stirred solution of 1-methyl-1H-pyrazole-4,5-diamine
sulfate (2.1 g) and 3-ethoxy-3-oxopropanoic acid (1.32 g) in
dichloromethane (10 ml) and-tetrahydrofuran (10 ml) was added WSCD
HCl (3.83 g) and N,N-diisopropylethylamine (6.96 ml), and the
mixture was stirred overnight. The solvent was removed under
reduced pressure, and the crude residue which includes ethyl
3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropanoate was
used for the next reaction without further purification.
Preparation 84
[0557] The crude residue containing ethyl
3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropanoate was
dissolved in N,N-dimethylformamide (20 ml), and trityl chloride
(5.52 g) and triethylamine (4.14 ml) were added with stirring. The
mixture was stirred overnight and quenched with water (10 ml). The
whole mixture was extracted with ethyl acetate, and the extract was
washed with water and brine, dried over magnesium sulfate and
concentrated under reduced pressure to give a residual oil, which
was chromatographed on silica gel eluting with
dichloromethane-ethyl acetate (2:3) to give ethyl
3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoate
(1.23 g).
[0558] ESI-MS 491.2 [M+Na].sup.+(positive), 467.3 [M-HV.sup.-
(negative)
[0559] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.18 (3H, t, J=7.1 Hz),
2.75 (3H, s) 3.04 (2H, s), 4.07 (2H, q, J=7.1 Hz), 5.55 (1H, s),
7.1-7.4 (16H, m), 8.54 (1H, s)
Preparation 85
[0560] To a stirred solution of ethyl
3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropanoate
(1.3 g) in tetrahydrofuran (30 ml) was added 1N aqueous sodium
hydroxide solution (3.1 ml), and the mixture was stirred at room
temperature for 3 hours. Tetrahydrofuran was removed in vacuo and
the residue was made acidic with diluted citric acid. The resulting
precipitate was collected by filtration and dried under reduced
pressure to give
3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoic
acid (1.22 g).
[0561] ESI-MS 463.2 [M+Na].sup.+ (positive)
[0562] .sup.1H-NMR (DMSO-d.sub.6) .delta. 2.74 (3H, s), 2.95 (2H,
s), 5.56 (1H, s), 7.0-7.4 (16H, m), 8.54 (1H, s), 12.0-13.0 (1H,
brs)
Preparation 86
[0563] To a suspension of
3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoic
acid (600 mg) and tert-butyl (2-aminoethyl)carbamate (240 mg) in
tetrahydrofuran (12 ml) and dichloromethane (6 ml) was added WSCD
HCl (522 mg), and the whole mixture was stirred at room temperature
overnight. To the reaction mixture was added water (3 ml), and the
whole mixture was extracted with ethyl acetate. The extract was
washed with water and brine and dried over magnesium sulfate. The
evaporation of the solvent gave a crude residue, which was
triturated with diisopropyl ether-ethyl acetate (2:1) to give
tert-butyl
{2-[(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoyl)a-
mino]ethyl}carbamate (537 mg).
[0564] ESI-MS 604.9 [M+Na].sup.+ (positive)
[0565] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.74 (3H,
s), 2.85 (2H, s), 2.9-3.2 (4H, m), 5.61 (1H, s), 6.7-6.9 (1H, m),
7.0-7.4 (16H, m), 8.0-8.1 (1H, m), 8.63 (1H, s)
EXAMPLE 51
3-{[3-Amino-4-({3-[(2-aminoethyl)amino]-3-oxopropanoyl}amino)-2-methyl-1-p-
yrazolio]methyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carbo-
xy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate
[0566] The title compound was obtained from tert-butyl
(2-[(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoyl)a-
mino]ethyl}carbamate in the same manner as in Example 34.
[0567] ESI-MS 731.2 [M+Na].sup.+ (positive)
[0568] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 3.1-3.3 (2H,
m), 3.19 and 3.44 (2H, ABq, J=17.7 Hz), 3.54 (2H, s), 3.5-3.7 (2H,
m), 3.74 (3H, s), 5.00 and 5.22 (2H, ABq, J=15.5 Hz), 5.25 (1H, d,
J=4.7 Hz), 5.86 (1H, d, J=4.8 Hz), 8.05 (1H, s)
Preparation 87
[0569] To a stirred solution of 3-amino-2-hydroxypropanoic acid
(2.1 g) in tetrahydrofuran (30 ml) and water (30 ml) was added 1N
aqueous sodium hydroxide solution to make the solution basic
(pH=9). To the mixture was added di-tert-butyl dicarbonate (4.36
g), and the mixture was stirred at room temperature for 4 hours
keeping pH of the mixture between 8.5 and 9.0. The whole mixture
was washed with diethyl ether. The aquous layer was made acidic
(pH=2) with 10% aqueous potassium hydrogen sulfate, saturated with
sodium chloride and extracted with ethyl acetate. The extract was
dried over magnesium sulfate. The solvent was evaporated under
reduced pressure to give
3-[(tert-butoxycarbonyl)amino]-2-hydroxypropanoic acid (3.96
g).
[0570] ESI-MS 228.2 [M+Na].sup.+ (positive)
[0571] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 (9H, s), 3.0-3.8
(3H, m), 3.9-4.1 (1H, m), 6.5-6.8 (1H, m)
Preparation 88
[0572] To a solution of
3-[(tert-butoxycarbonyl)amino]-2-hydroxypropanoic acid (1.61 g) in
dichloromethane (8 ml) and tetrahydrofuran (8 ml) were added HOBT
(1.59 g) and WSCD HCl (3.01 g), and the mixture was stirred at room
temperature for 1 hour. The solution was cooled to 0.degree. C.,
and 1-methyl-1H-pyrazole-4,5-diamine sulfate and
N,N-diisopropylethylamine (4.1 ml) were added. The mixture was
stirred at room temperature for 8 hours. The solvent was removed
under reduced pressure to give crude tert-butyl
(3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-hydroxy-3-oxopropyl)carbam-
ate, which was used in the next reaction without further
purification.
Preparation 89
tert-Butyl
(2-hydroxy-3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}--
3-oxopropyl)carbamate
[0573] The title compound was obtained from tert-butyl
{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-hydroxy-3-oxopropyl]carbam-
ate in the same manner as in Preparation 84.
[0574] ESI-MS 564.3 [M+Na].sup.+ (positive)
[0575] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 2.7-2.9
(1H, m), 2.83 (3H, s), 3.1-3.4 (1H, m), 3.7-3.9 (1H, m), 5.79 (1H,
d, J=5.3 Hz), 5.98 (1H, s), 6.5-6.7 (1H, m), 7.1-7.4 (16H, m), 8.36
(1H, s)
EXAMPLE 52
3-((3-Amino-4-[(3-amino-2-hydroxypropanoyl)amino]-2-methyl-1-pyrazoliometh-
yl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylet-
hoxyimino)acetamido]-3-cephem-4-carboxylate
[0576] The title compound was obtained from tert-butyl
(2-hydroxy-3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropy-
l)carbamate in the same manner as in Example 32.
[0577] .sup.1H-NMR (D.sub.2O) .delta. 1.49 (6H, s), 3.1-3.6 (4H,
m), 3.76 (3H, s) 4.6-4.7 (1H, m), 5.02-and 5.21 (2H, ABq, J=15.4
Hz), 5.26 (1H, d, J=4.8 Hz), 5.86 (1H, d, J=4.8 Hz), 8.05 (1H.sub.,
s)
Preparation 90
[0578] To a suspension of 2-(4,5-diamino-1H-pyrazol-1-yl)ethanol
sulfate (5 g) in dichloromethane (50 ml) was added triethylamine
(6.38 ml) at 0.degree. C., and the mixture was stirred at 0.degree.
C. for 10 minutes. A mixture of acetic anhydride (2.16 ml) and
formic acid (1.74 ml) was stirred at 40.degree. C. for 30 minutes,
cooled to 0.degree. C. and added dropwise to the above solution at
0.degree. C. The whole mixture was stirred at 0.degree. C. for 2
hours. To the mixture was added brine, and the whole mixture was
extracted with tetrahydrofuran. The extract was dried over
magnesium sulfate and evaporated under reduced pressure to give
crude [5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]formamide, which
was used in the next reaction without further purification.
Preparation 91
[1-(2-Hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]formamide
[0579] The title compound was obtained from
[5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]formamide in the same
manner as in Preparation 84. The NMR spectrum of this compound
indicates the existence of its rotamer.
[0580] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.10 (2H, t, J=6.2 Hz),
3.3-3.5 and 3.4-3.6 (2H, m), 4.89 and 5.06 (1H, t, J=5.1 Hz), 5.77
and 6.07 (1H, s), 7.1-7.4 (16H, m), 7.58 and 8.07 (1H, s), 7.58
(1H, s)
Preparation 92
[0581] To a stirred solution of
[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]formamide (2 g)
in N,N-dimethylformamide (30 ml) was added sodium hydride (213 mg,
60% oil suspension) under a nitrogen stream at 0.degree. C., and
the whole mixture was stirred at 0.degree. C. for 20 minutes. A
solution of tert-butyl (3-bromopropyl)carbamate (1.27 g) in
N,N-dimethylformamide (10 ml) and sodium iodide (799 mg) were added
to the above solution, and the mixture was stirred overnight. 10%
Aqueous potassium hydrogen sulfate solution (5 ml) was added, and
the whole mixture was extracted with ethyl acetate. The extract was
washed with water and brine and dried over magnesium sulfate.
Evaporation of the solvent under reduced pressure gave an oil,
which was chromatographed on silica gel eluting with
dichloromethane-ethyl acetate (2:1) to give tert-butyl
(3-{N-formyl-N-[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}-
propyl)carbamate (1 g). The NMR spectrum of this compound indicates
the existence of its rotamer.
[0582] ESI-MS 592.3 [M+Na].sup.+ (positive)
[0583] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.37 and 1.38 (9H, s),
2.7-3.5 (10H, m) 4.80 and 4.88 (1H, t, J=5.0 Hz), 5.52 & 6.06
(1H, s), 6.5-6.9 (1H, m), 7.0-7.4 (16H, m), 7.52 (1H, s)
EXAMPLE 53
3-({3-Amino-4-[N-(3-aminopropyl)-N-formylamino]-2-(2-hydroxyethyl)-1-pyraz-
olio)methyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-
-methylethoxyimino)acetamido]-3-cephem-4-carboxylate
[0584] The title compound was obtained from tert-butyl
(3-{N-formyl-N-[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}-
propyl)carbamate in the same manner as in Example 32.
[0585] ESI-MS 694.2 [M-H].sup.- (negative)
[0586] .sup.1H-NMR (D.sub.2O) .delta. 1.53 (6H, s), 1.7-2.1 (2H,
m), 2.9-3.1 (2H, m), 3.1-3.8 (4H, m), 3.8-4.0 (2H, m), 4.3-4.6 (2H,
m), 4.8-5.2 (2H, m), 5.29 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.7
Hz), 8.0-8.3 (2H, m)
EXAMPLE 54
[0587] To a stirred suspension of
3-({3-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-(2-hydroxyethyl)-1-pyra-
zolio}methyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy--
1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate (100 mg) in
methanol (1.4 ml) was added concentrated hydrochloric acid (0.125
ml) at room temperature, and the mixture was stirred for 6.5 hours.
To the above solution was added sodium hydrogen carbonate (109 mg),
and the mixture was purified by preparative HPLC (ODS column;
acetonitrile:phosphate buffer (pH 7)=5:95). The eluate containing a
desired product was evaporated to remove acetonitrile, made acidic
with diluted hydrochloric acid and chromatographed on Diaion.RTM.
HP20 (Mitsubishi Chemical Corporation) eluting with 20% aqueous
2-propanol. The eluate was concentrated under reduced pressure and
lyophilized to give
3-({3-amino-4-[(3-aminopropyl)amino]-2-(2-hydroxyethyl)-1-pyrazolio}methy-
l)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyleth-
oxyimino)acetamido]-3-cephem-4-carboxylate (18 mg).
[0588] ESI-MS 666.2 [M-H].sup.- (negative)
[0589] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.53 (6H, s), 1.96 (2H,
tt, J=7.5 Hz), 3.0-3.2 (4H, m), 3.13 and 3.43 (2H, ABq, J=17.6 Hz),
3.87 (2H, t, J=4.8 Hz), 4.2-4.4 (2H, m), 4.87 and 5.03 (2H, ABq,
J=15.2 Hz), 5.24 (1H, d, J=4.8 Hz), 5.83 (1H, d, J=4.8 Hz), 7.64
(1H, s)
Preparation 93
[0590] To a stirred solution of
N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]-2-(tritylamino)acetamide
(2 g) in N,N-dimethylformamide (20 ml) was added sodium hydride
(245 mg, 60% oil suspension) at 0.degree. C., and the mixture was
stirred for 30 minutes with warming to room temperature. The
mixture was cooled to 0.degree. C., and methyl iodide (1.3 g) was
added. The whole mixture was stirred at room temperature overnight.
Water (5 ml) was added, and the whole mixture was extracted with
ethyl acetate. The organic layer was washed with water and brine
and dried over magnesium sulfate. Evaporation of the solvent under
reduced pressure gave
N-methyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]-2-(tritylamino)acet-
amide (2.05 g).
[0591] ESI-MS 690.3 [M+Na].sup.+ (positive)
[0592] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.99 (3H, s), 2.3-2.8
(3H, m), 2.52 (3H, s), 5.44 (1H, s), 6.85 (1H, s), 6.9-7.5 (30H,
m)
Preparation 94
[0593] Lithium aluminum-hydride (455 mg) was added slowly to
tetrahydrofuran (40 ml) at 0.degree. C. and the mixture was stirred
for 20 minutes.
N-Methyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-.sup.4-yl]-2-(tritylamino-
)acetamide (2 g) was added to the mixture at 0.degree. C., and the
whole mixture was stirred for 2 hours with warming to room
temperature and refluxed for 2 hours. Sodium fluoride (2.51 g) and
water (862 mg) were added to the mixture, and the whole mixture was
stirred at room temperature for 30 minutes. The precipitate was
filtered off, and the filtrate was concentrated under reduced
pressure to give crude residue, which was chromatographed (silica
gel; ethyl acetate:dichloromethane=1:10) to give N
4,1-dimethyl-N.sup.5-trityl-N.sup.4-[2-(tritylamino)ethyl]-1H-pyrazole-4,-
5-diamine (740 mg).
[0594] ESI-MS 676.2 [M+Na].sup.+ (positive)
[0595] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.7-2.0 (2H, m), 1.98
(3H, s), 2.2-2.4 (1H, m), 2.6-2.8 (2H, m), 2.81 (3H, s), 5.24 (1H,
s), 7.00 (1H, s), 7.0-7.5 (30H, m)
EXAMPLE 55
3-({3-Amino-4-[N-(2-aminoethyl)-N-methylamino]-2-methyl-1-pyrazolio)methyl-
)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyletho-
xyimino)acetamido]-3-cephem-4-carboxylate
[0596] The title compound was obtained from N.sup.4,
1-dimethyl-N.sup.5-trityl-N.sup.4-[2-(tritylamino)ethyl]-1H-pyrazole-4,5--
diamine in the same manner as in Example 32.
[0597] ESI-MS 636.2 [M-H].sup.- (negative)
[0598] .sup.1H-NMR (D.sub.2O) .delta. 1.60 (6H, s), 2.60 (3H, s),
3.0-3.2 (4H, m) 3.19 and 3.39 (2H, ABq, J=17.7 Hz), 3.67 (3H, s),
4.87 and 5.20 (2H, ABq, J=15.8 Hz), 5.22 (1H, d, J=4.9 Hz), 5.85
(1H, d, J=4.7 Hz), 7.90 (1H, s)
Preparation 95
[0599] To a solution of
[1-(2-fluoroethyl)-1H-pyrazol-5-yl]formamide (15.7 g) in methanol
(78 ml) was added concentrated hydrochloric acid (21 ml) at room
temperature. The reaction mixture was stirred for 3.5 hours and
evaporated in vacuo. The residue was dissolved in ethyl acetate and
washed with aqueous sodium hydrogen carbonate solution. The organic
layer was dried over magnesium sulfate and concentrated in vacuo to
give 1-(2-fluoroethyl)-1H-pyrazol-5-amine (12 g).
[0600] .sup.1H-NMR (DMSO-d.sub.6) .delta. 4.15 (2H, dt, J=25.2, 5.1
Hz), 4.66 (2H, dt, J=47.2, 5.1 Hz), 5.1 (2H, brs), -5.27 (1H, d,
J=1.7 Hz), 7.06 (1H, d, J=1.7 Hz)
Preparation 96
[0601] To a solution of 1-(2-fluoroethyl)-1H-pyrazol-5-amine (12 g)
in ethanol (30 ml) were added concentrated hydrochloric acid (70
mg) and isoamyl nitrite (10.9 g). The reaction mixture was stirred
at 25-38.degree. C. for 2 hours. Diisopropyl ether and hexane were
added to the reaction mixture, and the resulting oil was purified
by column chromatography on silica gel (ethyl
acetate:hexane=1:2.fwdarw.1:1.fwdarw.2:1.fwdarw.1:0) to give
1-(2-fluoroethyl)-4-nitroso-1H-pyrazol-5-amine (4.8 g).
[0602] .sup.1H-NMR (DMSO-d.sub.6) .delta. 4.10-4.90 (4H, m), 7.09
and 8.59 (1H, s), 8.20 and 8.26 (1H, brs)
Preparation 97
[0603] To a solution of
1-(2-fluoroethyl)-4-nitroso-1H-pyrazol-5-amine (4.8 g) in water (30
ml) and methanol (30 ml) were added sulfuric acid (2.98 g) and 10%
palladium on carbon (2.5 g), and the mixture was hydrogenated under
balloon pressure for 7.5 hours. The reaction mixture was filtered
through a bed of Celite, and the filtrate was concentrated in
vacuo. 2-Propanol was added to the residue, and the precipitate was
collected by filtration to give
1-(2-fluoroethyl)-1H-pyrazole-4,5-diamine sulfate (7 g).
[0604] .sup.1H-NMR (D.sub.2O) .delta. 4.25-4.95 (4H, m), 7.66 (1H,
s)
Preparation 98
[0605] To a suspension of 1-(2-fluoroethyl)-1H-pyrazole-4,5-diamine
sulfate (3 g) in tetrahydrofuran (30 ml) were added tert-butyl
(3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl)carbamate (3.9 g)
and N,N-diisoporpylethylamine (3.5 g) under ice-cooling. The
reaction mixture was stirred at room temperature for 2 hours. An
aqueous sodium hydrogen carbonate solution and sodium chloride were
added, and the mixture was extracted with ethyl
acetate-tetrahydrofuran (three times). The organic layer was dried
over magnesium sulfate and concentrated in vacuo. The residue was
purified by column chromatography on silica gel (ethyl
acetate.fwdarw.ethyl acetate:ethanol=8:1) to give tert-butyl
(3-{[5-amino-1-(2-fluoroethyl)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbama-
te (2.3 g).
[0606] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.38 (9H, s), 2.36 (2H,
t, J=7.1 Hz) 3.10-3.27 (2H, m), 4.16 (2H, dt, J=25.5, 5.0 Hz),4.67
(2H, dt, J=47.2, 5.0 Hz), 5.27 (2H, brs), 6.75-6.90 (1H, m), 7.23
(1H.sub., s), 9.08 (1H, brs)
Preparation 99
[0607] To a solution of tert-butyl
(3-{[5-amino-1-(2-fluoroethyl)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbama-
te (2.3 g) in N,N-dimethylformamide (12 ml) were added
triethylamine (1.48 g), 4-dimethylaminopyridine (35.6 mg) and
trityl chloride (2.2 g) at room temperature. The reaction mixture
was stirred for 2 hours, and water was added. The mixture was
extracted with ethyl acetate, and the organic layer was washed with
water and aqueous sodium chloride solution. The organic layer was
dried over magnesium sulfate and concentrated in vacuo.
Acetonitrile was added, and the precipitate was collected by
filtration to give tert-butyl
(3-([1-(2-fluoroethy1)-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropyl-
)carbamate (2 g).
[0608] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.39 (9H, s), 2.05 (2H,
t, J=7.2 Hz) 3.00-3.08 (2H, m), 3.23 (2H, dt, J=25.3, 5.1 Hz), 4.41
(2H, dt, J=47.1, 5.1 Hz)
EXAMPLE 56
3-({3-Amino-4-[(3-aminopropionyl)amino]-2-(2-fluoroethyl)-1-pyrazolio}meth-
yl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylet-
hoxyimino)acetamido]-3-cephem-4-carboxylate
[0609] The title compound was obtained from tert-butyl
(3-{[1-(2-fluoroethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropyl-
)carbamate in the same manner as in Example 38.
[0610] .sup.1H-NMR (D.sub.2O) .delta. 2.89 (2H, t, J=6.5 Hz), 3.22
(1H, d, J=9.2 Hz), 3.34 (1H, t, J=6.5 Hz), 3.50 (1H, d, J=9.2 Hz),
4.55-4.95 (4H, m), 5.08 (2H, brs), 5.26 (1H, d, J=4.9 Hz), 5.84
(1H, d, J=4.9 Hz), 8.-09(1H, s)
Preparation 100
1-Methyl-7-nitroso-1H-imidazo[1,2-b]pyrazole
[0611] The title compound was obtained from
1-methyl-1H-imidazo[1,2-b]pyrazole in the same manner as in
Preparation 96.
[0612] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.93 (1H, s), 7.48 (1H,
m), 7.92 (1H, m), 9.03 (1H, s)
Preparation 101
1-Methyl-1H-imidazo[1,2-b]pyrazol-7-amine sulfate
[0613] The title compound was obtained from
1-methyl-7-nitroso-1H-imidazo[1,2-b]pyrazole in the same manner as
in Preparation 97.
[0614] .sup.1H-NMR (DMSO-d.sub.6) .delta. 3.73 (3H, s), 7.24 (1H,
m), 7.62 (2H, m)
Preparation 102
Di-tert-butyl
((Z)-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]methylidene)biscarbam-
ate
[0615] The title compound was obtained from
1-methyl-1H-imidazo[1,2-b]pyrazol-.sup.7-amine sulfate in the same
manner as in Preparation 64.
[0616] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.34 (9H, s), 1.52 (9H,
s), 3.61 (3H, s), 7.14 (1H, m), 7.42 (1H, m), 7.52 (1H, m)
EXAMPLE 57
7.beta.-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxy-
imino)acetamido]-3-([7-guanidino-1-methyl-5-(1H-imidazo[1,2-b]pyrazolio)]m-
ethyl)-3-cephem-4-carboxylate
[0617] The title compound was obtained from di-tert-butyl
{(Z)-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]methylidene)biscarbam-
ate in the same manner as in Example 43.
[0618] .sup.1H-NMR (D.sub.2O) .delta. 1.51 (6H, s), 3.40 (2H, m),
3.85 (3H, s), 5.15-5.30 (3H, m), 5.83 (1H, d, J=4.8 Hz) 7.49 (1H,
d, J=2.2 Hz), 8.02 (1H, d, J=2.2 Hz), 8.27 (1H, d, J=1.0 Hz)
[0619] IR (KBr) 3400, 3392, 1770, 1672, 1606, 1531 cm.sup.-1
Preparation 103
tert-Butyl
{3-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]-3-oxopropyl)-
carbamate
[0620] The title compound was obtained from
1-methyl-1H-imidazo[1,2-b]pyrazol-7-amine sulfate and
3-[(tert-butoxycarbonyl)amino]propanoic acid in the same manner as
in Preparation 70.
[0621] .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.43 (9H, s), 2.61 (2H,
m), 3.49 (2H, m), 3.65 (3H, s), 7.22 (1H, m), 7.26 (1H, m), 7.44
(1H, m)
EXAMPLE 58
3-({7-[(3-Aminopropanoyl)amino]-1-methyl-5-(1H-imidazo[1,2-b]pyrazolio))me-
thyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-cephem-4-carboxylate
[0622] The title compound was obtained from tert-butyl
{3-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]-3-oxopropyl)carbamate
in the same manner as in Example 43.
[0623] .sup.1H-NMR (D.sub.2O) .delta. 1.50 (6H, s), 2.97 (2H, d,
J=6.5 Hz), 3.36 (2H, d, J=6.5 Hz), 3.4 (2H, m), 3.81 (3H, s),
5.15-5.30 (3H, m), 5.82 (1H, d, J=4.8 Hz), 7.44 (1H, d, J=2.2 Hz),
7.98 (1H, d, J=2.2 Hz), 8.11 (1H, d, J=1.0 Hz)
[0624] IR (KBr) 3401, 1770, 1666, 1606, 1525 cm.sup.-1
Preparation 104
[0625] To a suspension of phenyl
[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (4.6 g) in
N,N-dimethylformamide (32 ml) were added triethylamine (1.08 g) and
tert-butyl 1-piperazinecarboxylate (1.99 g). The reaction mixture
was stirred for 3 hours and poured into water. The mixture was
extracted with ethyl acetate, and the organic layer was
concentrated in vacuo. The residue was purified by column
chromatography on silica gel (ethyl acetate.fwdarw.ethyl
acetate:ethanol=20:1) to give tert-butyl
4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperazin-
ecarboxylate (4.7 g).
[0626] .sup.1H-NMR (CDCl.sub.3) .delta. 1.46 (9H, s), 2.90 (3H, s),
3.05-3.25 (4H, m), 3.30-3.45 (4H, m), 4.76 (1H, brs), 5.34 (1H,
brs), 7.10-7.30 (16H, m)
EXAMPLE 59
[0627] To a solution of 4-methoxybenzyl
7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-
-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate
(2 g) in N,N-dimethylformamide (6 ml) was added
1,3-bis(trimethylsilyl)urea (3 g), and the reaction mixture was
stirred for 30 minutes. Potassium iodide (680 mg) was added to this
solution, and the mixture was stirred for 30 minutes tert-Butyl
4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperazin-
ecarboxylate (2 g) was added to this solution. The reaction mixture
was stirred at 25.degree. C. for 23 hours and poured into a mixture
of ethyl acetate-water-20% aqueous sodium chloride solution. The
organic layer was washed with a mixture of 10% aqueous sodium
thiosulfate solution and 20% aqueous sodium chloride solution. The
organic layer was washed successively with 10% aqueous sodium
trifluoroacetate solution twice and 20% aqueous sodium chloride
solution. The organic layer was concentrated in vacuo to a volume
of approximately 10 ml. The concentrate was added to diisopropyl
ether, and the suspension was stirred for 1 hour. The resulting
solid was collected by filtration and dried.
[0628] The solid was dissolved in dichloromethane (6 ml). To this
solution was added anisole (2 ml) and trifluoroacetic acid (6 ml).
The reaction mixture was stirred for 4 hours and poured into
diisopropyl ether. The resulting solid was collected by filtration
and dried. This solid was purified by preparative HPLC utilizing
ODS column. The eluate containing a desired product was
concentrated in vacuo. The concentrate was adjusted to about pH 1
with concentrated hydrochloric acid and chromatographed on
Diaion.RTM. HP-20 (Mitsubishi Chemical Corporation) eluting with
20% aqueous 2-propanol. The eluate was concentrated in vacuo, and
2M sulfuric acid was added. The mixture was lyophilized to give
3-({3-amino-2-methyl-4-[(1-piperazinylcarbonyl)amino]-1-pyrazolio)me-
thyl)-7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methyl-
ethoxyimino)acetamido]-3-cephem-4-carboxylic acid hydrogen sulfate
(679 mg).
[0629] .sup.1H-NMR (D.sub.2O) .delta. 1.60 (6H, s), 3.20 (2H, d,
J=17.7 Hz), 3.25-3.45 (4H, m), 3.45 (1H, d, J=17.7 Hz) 3.72 (3H,
m), 3.75-3.85 (4H, m), 5.00 (1H, d, J=15.7 Hz), 5.24 (1H, d, J=15.7
Hz), 5.25 (1H, d, J=4.8 Hz), 5.86(1H, d, J=4.8 Hz), 7.89 (1H,
s)
[0630] This application is based on application No. 2002952355
filed in Australia on Oct. 30, 2002, and application No. 2003904813
filed in Australia on Sep. 4, 2003, the content of which is
incorporated hereinto by reference.
* * * * *